DE69015207D1 - Liposomenmikroreservoirzusammensetzung und -verfahren. - Google Patents

Liposomenmikroreservoirzusammensetzung und -verfahren.

Info

Publication number: DE69015207D1
Authority: DE; Germany
Prior art keywords: tumor; entrapped; liposomes; compound; composition
Prior art date: 1989-10-20
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Revoked

Application number

DE69015207T

Other languages

English (en)

Other versions

DE69015207T2 (de

Inventor

Frank Martin

Martin Woodle

Carl Redemann

Ramachandran Radhakrishnan

Annie Yau-Young

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Liposome Technology Inc

Original Assignee

Liposome Technology Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1989-10-20

Filing date

1990-10-19

Publication date

1995-01-26

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23685679&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69015207(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

US case filed in California Northern District Court litigation https://portal.unifiedpatents.com/litigation/California%20Northern%20District%20Court/case/3%3A02-cv-05524 Source: District Court Jurisdiction: California Northern District Court "Unified Patents Litigation Data" by Unified Patents is licensed under a Creative Commons Attribution 4.0 International License.

1990-10-19 Application filed by Liposome Technology Inc filed Critical Liposome Technology Inc

1995-01-26 Application granted granted Critical

1995-01-26 Publication of DE69015207D1 publication Critical patent/DE69015207D1/de

1995-05-04 Publication of DE69015207T2 publication Critical patent/DE69015207T2/de

2010-10-20 Anticipated expiration legal-status Critical

Status Revoked legal-status Critical Current

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/5537—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom the heteroring containing the structure -C(=O)-N-C(=O)- (both carbon atoms belong to the heteroring)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents

DE69015207T 1989-10-20 1990-10-19 Liposomenmikroreservoirzusammensetzung und -verfahren. Revoked DE69015207T2 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US07/425,224 US5013556A (en)	1989-10-20	1989-10-20	Liposomes with enhanced circulation time
PCT/US1990/006034 WO1991005545A1 (en)	1989-10-20	1990-10-19	Liposome microreservoir composition and method

Publications (2)

Publication Number	Publication Date
DE69015207D1 true DE69015207D1 (de)	1995-01-26
DE69015207T2 DE69015207T2 (de)	1995-05-04

Family

ID=23685679

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
DE19675048C Active DE19675048I2 (de)	1989-10-20	1990-10-19	Methode und zusammensetzung zur behandlung solider tumoren.
DE69019366T Expired - Lifetime DE69019366T2 (de)	1989-10-20	1990-10-19	Methode und zusammensetzung zur behandlung solider tumoren.
DE69015207T Revoked DE69015207T2 (de)	1989-10-20	1990-10-19	Liposomenmikroreservoirzusammensetzung und -verfahren.

Family Applications Before (2)

Application Number	Title	Priority Date	Filing Date
DE19675048C Active DE19675048I2 (de)	1989-10-20	1990-10-19	Methode und zusammensetzung zur behandlung solider tumoren.
DE69019366T Expired - Lifetime DE69019366T2 (de)	1989-10-20	1990-10-19	Methode und zusammensetzung zur behandlung solider tumoren.

Country Status (18)

Country	Link
US (2)	US5013556A (de)
EP (2)	EP0496835B1 (de)
JP (4)	JP2667051B2 (de)
KR (2)	KR0134982B1 (de)
AT (2)	ATE122229T1 (de)
AU (2)	AU642679B2 (de)
CA (2)	CA2067133C (de)
DE (3)	DE19675048I2 (de)
DK (1)	DK0496835T3 (de)
ES (1)	ES2071976T3 (de)
FI (2)	FI105151B (de)
GR (1)	GR3017060T3 (de)
HK (1)	HK14097A (de)
IL (2)	IL96069A (de)
LU (1)	LU88854I2 (de)
NL (1)	NL960031I2 (de)
NO (3)	NO921213L (de)
WO (2)	WO1991005545A1 (de)

Families Citing this family (1598)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5456663A (en) *	1984-05-25	1995-10-10	Lemelson; Jerome H.	Drugs and methods for treating diseases
US5882330A (en) *	1984-05-25	1999-03-16	Lemelson; Jerome H.	Drugs and methods for treating diseases
US5925375A (en) *	1987-05-22	1999-07-20	The Liposome Company, Inc.	Therapeutic use of multilamellar liposomal prostaglandin formulations
JPH0720857B2 (ja) *	1988-08-11	1995-03-08	テルモ株式会社	リポソームおよびその製法
GB8824593D0 (en) *	1988-10-20	1988-11-23	Royal Free Hosp School Med	Liposomes
US6132763A (en) *	1988-10-20	2000-10-17	Polymasc Pharmaceuticals Plc	Liposomes
US5153000A (en) *	1988-11-22	1992-10-06	Kao Corporation	Phosphate, liposome comprising the phosphate as membrane constituent, and cosmetic and liposome preparation comprising the liposome
US5013556A (en) *	1989-10-20	1991-05-07	Liposome Technology, Inc.	Liposomes with enhanced circulation time
US20010051183A1 (en) *	1989-10-20	2001-12-13	Alza Corporation	Liposomes with enhanced circulation time and method of treatment
US5843473A (en) *	1989-10-20	1998-12-01	Sequus Pharmaceuticals, Inc.	Method of treatment of infected tissues
US5527528A (en) *	1989-10-20	1996-06-18	Sequus Pharmaceuticals, Inc.	Solid-tumor treatment method
US5356633A (en) *	1989-10-20	1994-10-18	Liposome Technology, Inc.	Method of treatment of inflamed tissues
US5620689A (en) *	1989-10-20	1997-04-15	Sequus Pharmaceuuticals, Inc.	Liposomes for treatment of B-cell and T-cell disorders
US5542935A (en) *	1989-12-22	1996-08-06	Imarx Pharmaceutical Corp.	Therapeutic delivery systems related applications
US5585112A (en) *	1989-12-22	1996-12-17	Imarx Pharmaceutical Corp.	Method of preparing gas and gaseous precursor-filled microspheres
US5922304A (en)	1989-12-22	1999-07-13	Imarx Pharmaceutical Corp.	Gaseous precursor filled microspheres as magnetic resonance imaging contrast agents
US5441746A (en) *	1989-12-22	1995-08-15	Molecular Bioquest, Inc.	Electromagnetic wave absorbing, surface modified magnetic particles for use in medical applications, and their method of production
US5656211A (en) *	1989-12-22	1997-08-12	Imarx Pharmaceutical Corp.	Apparatus and method for making gas-filled vesicles of optimal size
US5733572A (en) *	1989-12-22	1998-03-31	Imarx Pharmaceutical Corp.	Gas and gaseous precursor filled microspheres as topical and subcutaneous delivery vehicles
US6146657A (en)	1989-12-22	2000-11-14	Imarx Pharmaceutical Corp.	Gas-filled lipid spheres for use in diagnostic and therapeutic applications
US5352435A (en) *	1989-12-22	1994-10-04	Unger Evan C	Ionophore containing liposomes for ultrasound imaging
US6551576B1 (en)	1989-12-22	2003-04-22	Bristol-Myers Squibb Medical Imaging, Inc.	Container with multi-phase composition for use in diagnostic and therapeutic applications
US5469854A (en) *	1989-12-22	1995-11-28	Imarx Pharmaceutical Corp.	Methods of preparing gas-filled liposomes
US5776429A (en) *	1989-12-22	1998-07-07	Imarx Pharmaceutical Corp.	Method of preparing gas-filled microspheres using a lyophilized lipids
US6001335A (en) *	1989-12-22	1999-12-14	Imarx Pharmaceutical Corp.	Contrasting agents for ultrasonic imaging and methods for preparing the same
US5580575A (en) *	1989-12-22	1996-12-03	Imarx Pharmaceutical Corp.	Therapeutic drug delivery systems
US5773024A (en) *	1989-12-22	1998-06-30	Imarx Pharmaceutical Corp.	Container with multi-phase composition for use in diagnostic and therapeutic applications
US5305757A (en) *	1989-12-22	1994-04-26	Unger Evan C	Gas filled liposomes and their use as ultrasonic contrast agents
US6088613A (en) *	1989-12-22	2000-07-11	Imarx Pharmaceutical Corp.	Method of magnetic resonance focused surgical and therapeutic ultrasound
US5705187A (en) *	1989-12-22	1998-01-06	Imarx Pharmaceutical Corp.	Compositions of lipids and stabilizing materials
US5882678A (en) *	1990-01-12	1999-03-16	The Liposome Co, Inc.	Interdigitation-fusion liposomes containing arachidonic acid metabolites
US5162361A (en) *	1990-04-10	1992-11-10	The United States Of America As Represented By The Secretary, Department Of Health And Human Services	Method of treating diseases associated with elevated levels of interleukin 1
US6465188B1 (en) *	1990-06-11	2002-10-15	Gilead Sciences, Inc.	Nucleic acid ligand complexes
US20060084797A1 (en) *	1990-06-11	2006-04-20	Gilead Sciences, Inc.	High affinity TGFbeta nucleic acid ligands and inhibitors
US20030113369A1 (en) *	1991-01-16	2003-06-19	Martin Francis J.	Liposomes with enhanced circulation time and method of treatment
US5205290A (en)	1991-04-05	1993-04-27	Unger Evan C	Low density microspheres and their use as contrast agents for computed tomography
US5874062A (en) *	1991-04-05	1999-02-23	Imarx Pharmaceutical Corp.	Methods of computed tomography using perfluorocarbon gaseous filled microspheres as contrast agents
JP3220180B2 (ja) *	1991-05-23	2001-10-22	三菱化学株式会社	薬剤含有タンパク質結合リポソーム
GB9111611D0 (en) *	1991-05-30	1991-07-24	Sandoz Ltd	Liposomes
AU682308C (en)	1992-04-03	2006-08-17	Regents Of The University Of California, The	Self-assembling polynucleotide delivery system
ZA933926B (en) *	1992-06-17	1994-01-03	Amgen Inc	Polyoxymethylene-oxyethylene copolymers in conjuction with blomolecules
JP3337075B2 (ja) *	1992-08-05	2002-10-21	名糖産業株式会社	小粒子径水溶性カルボキシ多糖−磁性酸化鉄複合体
NL9201722A (nl) *	1992-10-05	1994-05-02	Stichting Tech Wetenschapp	Farmaceutische samenstelling voor de plaatsgebonden afgifte van een stolsel oplossend eiwit en werkwijze voor de bereiding daarvan.
DE4236237A1 (de) *	1992-10-27	1994-04-28	Behringwerke Ag	Prodrugs, ihre Herstellung und Verwendung als Arzneimittel
US6764693B1 (en) *	1992-12-11	2004-07-20	Amaox, Ltd.	Free radical quenching composition and a method to increase intracellular and/or extracellular antioxidants
JP3351476B2 (ja) *	1993-01-22	2002-11-25	三菱化学株式会社	リン脂質誘導体及びそれを含有するリポソーム
US5395619A (en) *	1993-03-03	1995-03-07	Liposome Technology, Inc.	Lipid-polymer conjugates and liposomes
AU6368394A (en) *	1993-03-23	1994-10-11	Liposome Technology, Inc.	Polymer-polypeptide composition and method
US6326353B1 (en) *	1993-03-23	2001-12-04	Sequus Pharmaceuticals, Inc.	Enhanced circulation effector composition and method
US6180134B1 (en)	1993-03-23	2001-01-30	Sequus Pharmaceuticals, Inc.	Enhanced ciruclation effector composition and method
WO1994026251A1 (en) *	1993-05-07	1994-11-24	Sequus Pharmaceuticals, Inc.	Subcutaneous liposome delivery method
US20050181976A1 (en) *	1993-05-10	2005-08-18	Ekwuribe Nnochiri N.	Amphiphilic oligomers
US6191105B1 (en)	1993-05-10	2001-02-20	Protein Delivery, Inc.	Hydrophilic and lipophilic balanced microemulsion formulations of free-form and/or conjugation-stabilized therapeutic agents such as insulin
US5359030A (en) *	1993-05-10	1994-10-25	Protein Delivery, Inc.	Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
US5681811A (en) *	1993-05-10	1997-10-28	Protein Delivery, Inc.	Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same
JPH08510748A (ja) *	1993-05-21	1996-11-12	ザリポソームカンパニー、インコーポレーテッド	リポソームが誘発する生理的副作用の低減
US5514670A (en) *	1993-08-13	1996-05-07	Pharmos Corporation	Submicron emulsions for delivery of peptides
US5744155A (en) *	1993-08-13	1998-04-28	Friedman; Doron	Bioadhesive emulsion preparations for enhanced drug delivery
AU680702B2 (en) *	1993-10-25	1997-08-07	Transave, Inc.	Liposomal defensins
US5415869A (en) *	1993-11-12	1995-05-16	The Research Foundation Of State University Of New York	Taxol formulation
US5468499A (en) *	1993-11-15	1995-11-21	Ohio State University	Liposomes containing the salt of phosphoramide mustard and related compounds
US7083572B2 (en) *	1993-11-30	2006-08-01	Bristol-Myers Squibb Medical Imaging, Inc.	Therapeutic delivery systems
EP0741580A4 (de) *	1993-12-14	2001-07-11	Univ Johns Hopkins Med	Die kontrollierte freisetzung von pharmazeutisch aktiven substanzen in der immuntherapie
US6773719B2 (en) *	1994-03-04	2004-08-10	Esperion Luv Development, Inc.	Liposomal compositions, and methods of using liposomal compositions to treat dislipidemias
US6312719B1 (en) *	1994-03-04	2001-11-06	The University Of British Columbia	Liposome compositions and methods for the treatment of atherosclerosis
US20010055581A1 (en) *	1994-03-18	2001-12-27	Lawrence Tamarkin	Composition and method for delivery of biologically-active factors
US5736121A (en) *	1994-05-23	1998-04-07	Imarx Pharmaceutical Corp.	Stabilized homogenous suspensions as computed tomography contrast agents
DE4423131A1 (de) *	1994-07-01	1996-01-04	Bayer Ag	Neue hIL-4-Mutantenproteine als Antagonisten oder partielle Agonisten des humanen Interleukin 4
US5626862A (en)	1994-08-02	1997-05-06	Massachusetts Institute Of Technology	Controlled local delivery of chemotherapeutic agents for treating solid tumors
US5512294A (en) *	1994-08-05	1996-04-30	Li; King C.	Targeted polymerized liposome contrast agents
US6132764A (en)	1994-08-05	2000-10-17	Targesome, Inc.	Targeted polymerized liposome diagnostic and treatment agents
US6124439A (en) *	1994-08-17	2000-09-26	The Rockefeller University	OB polypeptide antibodies and method of making
US6309853B1 (en)	1994-08-17	2001-10-30	The Rockfeller University	Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US6471956B1 (en)	1994-08-17	2002-10-29	The Rockefeller University	Ob polypeptides, modified forms and compositions thereto
US6350730B1 (en)	1994-08-17	2002-02-26	The Rockefeller University	OB polypeptides and modified forms as modulators of body weight
US6048837A (en) *	1994-08-17	2000-04-11	The Rockefeller University	OB polypeptides as modulators of body weight
US6124448A (en) *	1994-08-17	2000-09-26	The Rockfeller University	Nucleic acid primers and probes for the mammalian OB gene
US6001968A (en)	1994-08-17	1999-12-14	The Rockefeller University	OB polypeptides, modified forms and compositions
DE69527206T2 (de) *	1994-09-30	2003-02-27	Inex Pharmaceuticals Corp	Mittel zum einbringen polyanionischer materialien in zellen
US5820873A (en) *	1994-09-30	1998-10-13	The University Of British Columbia	Polyethylene glycol modified ceramide lipids and liposome uses thereof
US5885613A (en) *	1994-09-30	1999-03-23	The University Of British Columbia	Bilayer stabilizing components and their use in forming programmable fusogenic liposomes
JPH10507450A (ja) *	1994-10-14	1998-07-21	ザリポソームカンパニー、インコーポレーテッド	エーテル脂質リポソームおよびそれらの治療用の使用
CN1080575C (zh) *	1994-10-14	2002-03-13	蛋白质传送股份有限公司	结合稳定的多肽组合物、其治疗、诊断制剂及其制备和使用方法
US6214388B1 (en) *	1994-11-09	2001-04-10	The Regents Of The University Of California	Immunoliposomes that optimize internalization into target cells
US6743779B1 (en)	1994-11-29	2004-06-01	Imarx Pharmaceutical Corp.	Methods for delivering compounds into a cell
US5827531A (en) *	1994-12-02	1998-10-27	The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration	Microcapsules and methods for making
US5795587A (en)	1995-01-23	1998-08-18	University Of Pittsburgh	Stable lipid-comprising drug delivery complexes and methods for their production
US6008202A (en) *	1995-01-23	1999-12-28	University Of Pittsburgh	Stable lipid-comprising drug delivery complexes and methods for their production
US5830430A (en) *	1995-02-21	1998-11-03	Imarx Pharmaceutical Corp.	Cationic lipids and the use thereof
IL112834A (en) *	1995-03-01	2000-12-06	Yeda Res & Dev	Pharmaceutical compositions for controlled release of soluble receptors
US5658588A (en) *	1995-03-31	1997-08-19	University Of Cincinnati	Fibrinogen-coated liposomes
GB9509016D0 (en) *	1995-05-03	1995-06-21	Royal Free Hosp School Med	Tissue entrapment
US8071737B2 (en) *	1995-05-04	2011-12-06	Glead Sciences, Inc.	Nucleic acid ligand complexes
US6420549B1 (en)	1995-06-06	2002-07-16	Isis Pharmaceuticals, Inc.	Oligonucleotide analogs having modified dimers
US5997898A (en) *	1995-06-06	1999-12-07	Imarx Pharmaceutical Corp.	Stabilized compositions of fluorinated amphiphiles for methods of therapeutic delivery
US6673364B1 (en)	1995-06-07	2004-01-06	The University Of British Columbia	Liposome having an exchangeable component
US6521211B1 (en)	1995-06-07	2003-02-18	Bristol-Myers Squibb Medical Imaging, Inc.	Methods of imaging and treatment with targeted compositions
US7422902B1 (en)	1995-06-07	2008-09-09	The University Of British Columbia	Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
US5981501A (en) *	1995-06-07	1999-11-09	Inex Pharmaceuticals Corp.	Methods for encapsulating plasmids in lipid bilayers
JP4335310B2 (ja) *	1995-06-07	2009-09-30	ザユニバーシティオブブリティッシュコロンビア	疎水性脂質−核酸複合中間体を通して調製される脂質−核酸粒子、及び遺伝子移送のための使用
US6231834B1 (en)	1995-06-07	2001-05-15	Imarx Pharmaceutical Corp.	Methods for ultrasound imaging involving the use of a contrast agent and multiple images and processing of same
US6139819A (en)	1995-06-07	2000-10-31	Imarx Pharmaceutical Corp.	Targeted contrast agents for diagnostic and therapeutic use
US6033645A (en) *	1996-06-19	2000-03-07	Unger; Evan C.	Methods for diagnostic imaging by regulating the administration rate of a contrast agent
NZ313264A (en) *	1995-08-01	1999-11-29	Novartis Ag	Liposomal oligonucleotide compositions
US6051600A (en) *	1995-09-12	2000-04-18	Mayhew; Eric	Liposomal hydrolysis-promoting hydrophobic taxane derivatives
US6107332A (en)	1995-09-12	2000-08-22	The Liposome Company, Inc.	Hydrolysis-promoting hydrophobic taxane derivatives
US5834025A (en)	1995-09-29	1998-11-10	Nanosystems L.L.C.	Reduction of intravenously administered nanoparticulate-formulation-induced adverse physiological reactions
US5858397A (en) *	1995-10-11	1999-01-12	University Of British Columbia	Liposomal formulations of mitoxantrone
CN1119145C (zh) *	1995-10-11	2003-08-27	埃斯佩里安Luv发展公司	脂质体组合物及其使用方法
US20030040467A1 (en) *	1998-06-15	2003-02-27	Mary Ann Pelleymounter	Ig/ob fusions and uses thereof.
US6936439B2 (en) *	1995-11-22	2005-08-30	Amgen Inc.	OB fusion protein compositions and methods
US5626654A (en)	1995-12-05	1997-05-06	Xerox Corporation	Ink compositions containing liposomes
US5817856A (en) *	1995-12-11	1998-10-06	Yissum Research Development Company Of The Hebrew University Of Jerusalem	Radiation-protective phospholipid and method
US7002027B1 (en)	1996-01-08	2006-02-21	Canji, Inc.	Compositions and methods for therapeutic use
US6392069B2 (en)	1996-01-08	2002-05-21	Canji, Inc.	Compositions for enhancing delivery of nucleic acids to cells
IL125073A0 (en)	1996-01-08	1999-01-26	Genentech Inc	Wsx receptor and ligands
US20040014709A1 (en) *	1996-01-08	2004-01-22	Canji, Inc.	Methods and compositions for interferon therapy
US5789244A (en) *	1996-01-08	1998-08-04	Canji, Inc.	Compositions and methods for the treatment of cancer using recombinant viral vector delivery systems
US6096336A (en) *	1996-01-30	2000-08-01	The Stehlin Foundation For Cancer Research	Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs
US5908624A (en) *	1996-06-27	1999-06-01	Albany Medical College	Antigenic modulation of cells
USRE39042E1 (en) *	1996-02-16	2006-03-28	The Liposome Company, Inc.	Etherlipid-containing multiple lipid liposomes
US5965159A (en) *	1996-02-16	1999-10-12	The Liposome Company, Inc.	Etherlipid-containing multiple lipid liposomes
US6007839A (en) *	1996-02-16	1999-12-28	The Liposome Company, Inc.	Preparation of pharmaceutical compositions containing etherlipid-containing multiple lipid liposomes
US5942246A (en) *	1996-02-16	1999-08-24	The Liposome Company, Inc.	Etherlipid containing multiple lipid liposomes
US6667053B1 (en)	1996-02-16	2003-12-23	Elan Pharmaceuticals, Inc.	D and L etherlipid stereoisomers and liposomes
AU733212B2 (en)	1996-03-28	2001-05-10	Board Of Trustees Of The University Of Illinois, The	Material and methods for making improved liposome compositions
WO1997040679A1 (en)	1996-05-01	1997-11-06	Imarx Pharmaceutical Corp.	Methods for delivering compounds into a cell
US20070275921A1 (en) *	1996-06-06	2007-11-29	Isis Pharmaceuticals, Inc.	Oligomeric Compounds That Facilitate Risc Loading
US5898031A (en)	1996-06-06	1999-04-27	Isis Pharmaceuticals, Inc.	Oligoribonucleotides for cleaving RNA
US7812149B2 (en)	1996-06-06	2010-10-12	Isis Pharmaceuticals, Inc.	2′-Fluoro substituted oligomeric compounds and compositions for use in gene modulations
US9096636B2 (en)	1996-06-06	2015-08-04	Isis Pharmaceuticals, Inc.	Chimeric oligomeric compounds and their use in gene modulation
US20050042647A1 (en) *	1996-06-06	2005-02-24	Baker Brenda F.	Phosphorous-linked oligomeric compounds and their use in gene modulation
WO2005121368A1 (en) *	2004-06-03	2005-12-22	Isis Pharmaceuticals, Inc.	Chimeric gapped oligomeric compositions
US5919480A (en)	1996-06-24	1999-07-06	Yissum Research Development Company Of The Hebrew University Of Jerusalem	Liposomal influenza vaccine composition and method
US8007784B1 (en)	1996-06-27	2011-08-30	Albany Medical College	Antigenic modulation of cells
US7368129B1 (en)	1996-08-14	2008-05-06	Nutrimed Biotech	Amphiphilic materials and liposome formulations thereof
US6284267B1 (en)	1996-08-14	2001-09-04	Nutrimed Biotech	Amphiphilic materials and liposome formulations thereof
US6159462A (en) *	1996-08-16	2000-12-12	Genentech, Inc.	Uses of Wnt polypeptides
US5851984A (en) *	1996-08-16	1998-12-22	Genentech, Inc.	Method of enhancing proliferation or differentiation of hematopoietic stem cells using Wnt polypeptides
WO1998007409A1 (en) *	1996-08-23	1998-02-26	Sequus Pharmaceuticals, Inc.	Liposomes containing a cisplatin compound
DK0941066T3 (da) *	1996-08-26	2004-02-23	Transgene Sa	Kationisk lipid-nukleinsyre-komplekser
US6414139B1 (en)	1996-09-03	2002-07-02	Imarx Therapeutics, Inc.	Silicon amphiphilic compounds and the use thereof
EP0977597B1 (de) *	1996-09-11	2003-01-15	Imarx Pharmaceutical Corp.	Verbesserte verfahren zur diagnostischen bilderzeugung unter verwendung eines kontrastmittels und eines vasodilators
US5846517A (en) *	1996-09-11	1998-12-08	Imarx Pharmaceutical Corp.	Methods for diagnostic imaging using a renal contrast agent and a vasodilator
US6224903B1 (en)	1996-10-11	2001-05-01	Sequus Pharmaceuticals, Inc.	Polymer-lipid conjugate for fusion of target membranes
TW520297B (en) *	1996-10-11	2003-02-11	Sequus Pharm Inc	Fusogenic liposome composition and method
EP0932390A1 (de) *	1996-10-11	1999-08-04	Sequus Pharmaceuticals, Inc.	Therapeutische liposomenzusammensetzung und verfahren
US6056973A (en) *	1996-10-11	2000-05-02	Sequus Pharmaceuticals, Inc.	Therapeutic liposome composition and method of preparation
EP0964690B1 (de) *	1996-10-15	2003-07-09	The Liposome Company, Inc.	Peptid-lipid konjugate, liposomen und liposomale arzneimittelverabreichung
US6339069B1 (en) *	1996-10-15	2002-01-15	Elan Pharmaceuticalstechnologies, Inc.	Peptide-lipid conjugates, liposomes and lipsomal drug delivery
US6331289B1 (en)	1996-10-28	2001-12-18	Nycomed Imaging As	Targeted diagnostic/therapeutic agents having more than one different vectors
US6261537B1 (en)	1996-10-28	2001-07-17	Nycomed Imaging As	Diagnostic/therapeutic agents having microbubbles coupled to one or more vectors
US6264917B1 (en) *	1996-10-28	2001-07-24	Nycomed Imaging As	Targeted ultrasound contrast agents
US20070036722A1 (en) *	1996-10-28	2007-02-15	Pal Rongved	Separation processes
US5827533A (en) *	1997-02-06	1998-10-27	Duke University	Liposomes containing active agents aggregated with lipid surfactants
AU6161898A (en) *	1997-02-14	1998-09-08	Regents Of The University Of California, The	Lamellar gels and methods for making and regulating
US6090800A (en)	1997-05-06	2000-07-18	Imarx Pharmaceutical Corp.	Lipid soluble steroid prodrugs
US6143276A (en) *	1997-03-21	2000-11-07	Imarx Pharmaceutical Corp.	Methods for delivering bioactive agents to regions of elevated temperatures
US6537246B1 (en)	1997-06-18	2003-03-25	Imarx Therapeutics, Inc.	Oxygen delivery agents and uses for the same
US6120751A (en)	1997-03-21	2000-09-19	Imarx Pharmaceutical Corp.	Charged lipids and uses for the same
EP0973818B1 (de)	1997-04-03	2004-10-13	Guilford Pharmaceuticals Inc.	Bioabbaubare terephthalat polyester-polyphosphat polymere, zusammensetzungen, gegenstände und verfahren für ihre herstellung und verwendung
TR199903123T2 (xx)	1997-04-07	2000-05-22	Genentech, Inc.	Anti-Vegf antikorlar�.
AU740738B2 (en)	1997-04-07	2001-11-15	Genentech Inc.	Humanized antibodies and methods for forming humanized antibodies
WO1998044910A1 (en)	1997-04-09	1998-10-15	Philipp Lang	NEW TECHNIQUE TO MONITOR DRUG DELIVERY NONINVASIVELY $i(IN VIVO)
US6416740B1 (en)	1997-05-13	2002-07-09	Bristol-Myers Squibb Medical Imaging, Inc.	Acoustically active drug delivery systems
US20020039594A1 (en) *	1997-05-13	2002-04-04	Evan C. Unger	Solid porous matrices and methods of making and using the same
WO1998051278A2 (en) *	1997-05-14	1998-11-19	Inex Pharmaceuticals Corporation	High efficiency encapsulation of charged therapeutic agents in lipid vesicles
DE19724796A1 (de) *	1997-06-06	1998-12-10	Max Delbrueck Centrum	Mittel zur Antitumortherapie
US6663899B2 (en)	1997-06-13	2003-12-16	Genentech, Inc.	Controlled release microencapsulated NGF formulation
US6113947A (en) *	1997-06-13	2000-09-05	Genentech, Inc.	Controlled release microencapsulated NGF formulation
US6217886B1 (en)	1997-07-14	2001-04-17	The Board Of Trustees Of The University Of Illinois	Materials and methods for making improved micelle compositions
US6548047B1 (en)	1997-09-15	2003-04-15	Bristol-Myers Squibb Medical Imaging, Inc.	Thermal preactivation of gaseous precursor filled compositions
EP1014946B1 (de) *	1997-09-18	2010-04-07	Pacira Pharmaceuticals, Inc.	Retardierte freisetzung liposmaler anesthetischer zusammensetzungen.
US6734171B1 (en)	1997-10-10	2004-05-11	Inex Pharmaceuticals Corp.	Methods for encapsulating nucleic acids in lipid bilayers
US6083923A (en) *	1997-10-31	2000-07-04	Isis Pharmaceuticals Inc.	Liposomal oligonucleotide compositions for modulating RAS gene expression
US7229841B2 (en) *	2001-04-30	2007-06-12	Cytimmune Sciences, Inc.	Colloidal metal compositions and methods
JP4575592B2 (ja)	1997-11-14	2010-11-04	パシラファーマシューティカルズインコーポレーテッド	多小胞リポソームの製造
DE69840105D1 (de)	1997-11-21	2008-11-20	Genentech Inc	Plättchen-spezifische antigene und deren pharmazeutische verwendung
US7192589B2 (en)	1998-09-16	2007-03-20	Genentech, Inc.	Treatment of inflammatory disorders with STIgMA immunoadhesins
US6787132B1 (en) *	1997-12-04	2004-09-07	Yissum Research Development Company Of The Hebrew University Of Jerusalem	Combined chemo-immunotherapy with liposomal drugs and cytokines
WO1999027908A1 (en) *	1997-12-04	1999-06-10	Yissum Research Development Company Of The Hebrew University Of Jerusalem	Combined chemo-immunotherapy with liposomal drugs and cytokines
EP1947119A3 (de)	1997-12-12	2012-12-19	Genentech, Inc.	Krebsbehandlung mit Antikörpern gegen ERBB2 und einem chemotherapeutischen Mittel
US6123923A (en)	1997-12-18	2000-09-26	Imarx Pharmaceutical Corp.	Optoacoustic contrast agents and methods for their use
US20010003580A1 (en)	1998-01-14	2001-06-14	Poh K. Hui	Preparation of a lipid blend and a phospholipid suspension containing the lipid blend
DE69920405T2 (de)	1998-02-04	2006-01-05	Genentech, Inc., South San Francisco	Verwendung des heregulins als epithelzellenwachstumsfaktor
WO1999039738A1 (en) *	1998-02-09	1999-08-12	Bracco Research S.A.	Targeted delivery of biologically active media
US6312685B1 (en)	1998-03-13	2001-11-06	Timothy C. Fisher	Red blood cells covalently bound with two different polyethylene glycol derivatives
US6942859B2 (en)	1998-03-13	2005-09-13	University Of Southern California	Red blood cells covalently bound with polymers
IL138488A0 (en)	1998-03-17	2001-10-31	Genentech Inc	Polypeptides homologous to vegf and bmp1
IL138572A0 (en) *	1998-03-25	2001-10-31	Biosource Genetics Corp	Benzoate derivatives and pharmaceutical compositions containing the same
US6433012B1 (en) *	1998-03-25	2002-08-13	Large Scale Biology Corp.	Method for inhibiting inflammatory disease
US6858706B2 (en)	1998-04-07	2005-02-22	St. Jude Children's Research Hospital	Polypeptide comprising the amino acid of an N-terminal choline binding protein a truncate, vaccine derived therefrom and uses thereof
PT1079805E (pt) *	1998-04-27	2005-03-31	Opperbas Holding Bv	Composicao farmaceutica compreendendo factor viii e lipossomas neutros
US6986902B1 (en) *	1998-04-28	2006-01-17	Inex Pharmaceuticals Corporation	Polyanionic polymers which enhance fusogenicity
US6331407B1 (en)	1998-05-06	2001-12-18	St. Jude Children's Research Hospital	Antibiotics and methods of using the same
US6448224B1 (en)	1998-05-06	2002-09-10	St. Jude Children's Research Hospital	Antibiotics and methods of using the same
US6169078B1 (en) *	1998-05-12	2001-01-02	University Of Florida	Materials and methods for the intracellular delivery of substances
EP3112468A1 (de)	1998-05-15	2017-01-04	Genentech, Inc.	Il-17-homologe polypeptide und therapeutische verwendung davon
ES2292242T5 (es)	1998-05-15	2011-05-04	Genentech, Inc.	Utilizaciones terapéuticas de polipéptidos homólogos de il-17.
EP1865061A3 (de)	1998-05-15	2007-12-19	Genentech, Inc.	IL-17-homologe Polypeptide und ihre therapeutische Verwendung
PT1086138E (pt)	1998-06-12	2010-01-04	Genentech Inc	Anticorpos monoclonais, anticorpos de reacção cruzada e método para produzir os mesmos
US6726925B1 (en) *	1998-06-18	2004-04-27	Duke University	Temperature-sensitive liposomal formulation
US6200598B1 (en) *	1998-06-18	2001-03-13	Duke University	Temperature-sensitive liposomal formulation
US20040229363A1 (en) *	1998-06-24	2004-11-18	Ed Nolan	High efficiency transfection based on low electric field strength, long pulse length
US20040247662A1 (en) *	1998-06-25	2004-12-09	Dow Steven W.	Systemic immune activation method using nucleic acid-lipid complexes
US6693086B1 (en) *	1998-06-25	2004-02-17	National Jewish Medical And Research Center	Systemic immune activation method using nucleic acid-lipid complexes
US20030022854A1 (en)	1998-06-25	2003-01-30	Dow Steven W.	Vaccines using nucleic acid-lipid complexes
JP2002520120A (ja)	1998-07-17	2002-07-09	スカイファーマインコーポレーテッド	封入物質の制御放出のための生分解性組成物
US20020172678A1 (en)	2000-06-23	2002-11-21	Napoleone Ferrara	EG-VEGF nucleic acids and polypeptides and methods of use
US6703381B1 (en) *	1998-08-14	2004-03-09	Nobex Corporation	Methods for delivery therapeutic compounds across the blood-brain barrier
EP1121102B1 (de) *	1998-09-16	2003-04-23	Alza Corporation	In liposomen eingeschlossene topoisomerase inhibitoren
US6077709A (en)	1998-09-29	2000-06-20	Isis Pharmaceuticals Inc.	Antisense modulation of Survivin expression
US6153212A (en) *	1998-10-02	2000-11-28	Guilford Pharmaceuticals Inc.	Biodegradable terephthalate polyester-poly (phosphonate) compositions, articles, and methods of using the same
US6419709B1 (en)	1998-10-02	2002-07-16	Guilford Pharmaceuticals, Inc.	Biodegradable terephthalate polyester-poly(Phosphite) compositions, articles, and methods of using the same
US6660843B1 (en) *	1998-10-23	2003-12-09	Amgen Inc.	Modified peptides as therapeutic agents
KR100719202B1 (ko)	1998-10-23	2007-05-16	키린-암젠 인코포레이티드	ＭＰｌ 수용체에 결합하는 화합물 및 이를 함유하는 제약학적 조성물
SI1135498T1 (sl)	1998-11-18	2008-06-30	Genentech Inc	Variante protitelesa z viĹˇjo vezavno afiniteto vprimerjavi z izvirnimi protitelesi
CA2350599A1 (en) *	1998-11-20	2000-06-02	Genentech, Inc.	Method of inhibiting angiogenesis
US6773911B1 (en) *	1998-11-23	2004-08-10	Amgen Canada Inc.	Apoptosis-inducing factor
CA2450402A1 (en)	1998-12-22	2000-06-29	Genentech, Inc.	Methods and compositions for inhibiting cancer cell growth comprising pro224
IL143596A0 (en)	1998-12-22	2002-04-21	Genentech Inc	Vascular endothelial cell growth factor antagonists and uses thereof
US6350464B1 (en) *	1999-01-11	2002-02-26	Guilford Pharmaceuticals, Inc.	Methods for treating ovarian cancer, poly (phosphoester) compositions, and biodegradable articles for same
US6818227B1 (en) *	1999-02-08	2004-11-16	Alza Corporation	Liposome composition and method for administration of a radiosensitizer
US6537585B1 (en)	1999-03-26	2003-03-25	Guilford Pharmaceuticals, Inc.	Methods and compositions for treating solid tumors
US6379698B1 (en)	1999-04-06	2002-04-30	Isis Pharmaceuticals, Inc.	Fusogenic lipids and vesicles
US7098192B2 (en)	1999-04-08	2006-08-29	Isis Pharmaceuticals, Inc.	Antisense oligonucleotide modulation of STAT3 expression
US7112337B2 (en)	1999-04-23	2006-09-26	Alza Corporation	Liposome composition for delivery of nucleic acid
CN1172670C (zh) *	1999-04-29	2004-10-27	阿尔萨公司	用于改善药物保留的脂质体组合物
CA2270600A1 (en)	1999-05-03	2000-11-03	Infectio Recherche Inc.	Method and formulations for the treatment of diseases, particularly those caused by human immunodeficiency virus and leishmania
EP1649870A3 (de)	1999-05-07	2006-05-03	Genentech, Inc.	Behandlung von Autoimmunkrankheiten mit Antagonisten die Oberflächenmarker von B Zellen binden
WO2000067760A1 (fr) *	1999-05-11	2000-11-16	Sankyo Company, Limited	Preparation de liposomes a base de medicaments antitumoraux liposolubles
US20040229779A1 (en) *	1999-05-14	2004-11-18	Ramesh Kekuda	Therapeutic polypeptides, nucleic acids encoding same, and methods of use
US6974684B2 (en) *	2001-08-08	2005-12-13	Curagen Corporation	Therapeutic polypeptides, nucleic acids encoding same, and methods of use
US20040023874A1 (en) *	2002-03-15	2004-02-05	Burgess Catherine E.	Therapeutic polypeptides, nucleic acids encoding same, and methods of use
US20040067490A1 (en) *	2001-09-07	2004-04-08	Mei Zhong	Therapeutic polypeptides, nucleic acids encoding same, and methods of use
AU5152700A (en)	1999-06-15	2001-01-02	Genentech Inc.	Secreted and transmembrane polypeptides and nucleic acids encoding the same
US7169889B1 (en)	1999-06-19	2007-01-30	Biocon Limited	Insulin prodrugs hydrolyzable in vivo to yield peglylated insulin
US6309633B1 (en)	1999-06-19	2001-10-30	Nobex Corporation	Amphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same
WO2001000173A1 (fr) *	1999-06-24	2001-01-04	Kyowa Hakko Kogyo Co., Ltd.	Methode de regulation de la fuite de medicaments encapsules dans des liposomes
CN100340575C (zh)	1999-06-25	2007-10-03	杰南技术公司	人源化抗ErbB2抗体及其在制备药物中的应用
US6352996B1 (en)	1999-08-03	2002-03-05	The Stehlin Foundation For Cancer Research	Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs
GB9918670D0 (en)	1999-08-06	1999-10-13	Celltech Therapeutics Ltd	Biological product
DK1210115T3 (da)	1999-08-27	2009-11-30	Genentech Inc	Doseringer til behandling med anti-ErB2-antistoffer
NZ523206A (en) *	1999-08-31	2004-12-24	Genentech Inc	Antibodies that bind to tumor gene sequences
DE60034871T2 (de) *	1999-09-03	2008-01-17	Amgen Inc., Thousand Oaks	Verfahren und zusammensetzungen zur prevention oder behandlung von krebs und von krebs assoziertem knochenverlust
AU7868400A (en) *	1999-10-08	2001-04-23	Alza Corporation	Neutral-cationic lipid for nucleic acid and drug delivery
IT1315253B1 (it) *	1999-10-22	2003-02-03	Novuspharma Spa	Preparazione liposomiale di 6,9-bis-(2-amminoetil)ammino\|benzog\|isochinolin-5,10-dione dimaleato
US7067111B1 (en) *	1999-10-25	2006-06-27	Board Of Regents, University Of Texas System	Ethylenedicysteine (EC)-drug conjugates, compositions and methods for tissue specific disease imaging
US6511676B1 (en)	1999-11-05	2003-01-28	Teni Boulikas	Therapy for human cancers using cisplatin and other drugs or genes encapsulated into liposomes
AU784634B2 (en)	1999-11-30	2006-05-18	Mayo Foundation For Medical Education And Research	B7-H1, a novel immunoregulatory molecule
CA2496312A1 (en)	1999-12-01	2001-06-07	Kevin P. Baker	Colon tumour marker pro4799 polypeptides and nucleic acids encoding the same
US6593308B2 (en)	1999-12-03	2003-07-15	The Regents Of The University Of California	Targeted drug delivery with a hyaluronan ligand
US20030147944A1 (en) *	1999-12-10	2003-08-07	Mayer Lawrence D	Lipid carrier compositions with protected surface reactive functions
DK1897945T3 (da)	1999-12-23	2012-05-07	Genentech Inc	IL-17 homologe polypeptider og terapeutiske anvendelser deraf.
US20040009229A1 (en) *	2000-01-05	2004-01-15	Unger Evan Charles	Stabilized nanoparticle formulations of camptotheca derivatives
JP2003520210A (ja) *	2000-01-05	2003-07-02	イマレックスセラピューティクス，インコーポレイテッド	低い水溶性を有する薬物の送達のための薬学的処方物
AU785055B2 (en) *	2000-01-13	2006-09-07	Genentech Inc.	Novel stra6 polypeptides
US6261840B1 (en)	2000-01-18	2001-07-17	Isis Pharmaceuticals, Inc.	Antisense modulation of PTP1B expression
US20020055479A1 (en)	2000-01-18	2002-05-09	Cowsert Lex M.	Antisense modulation of PTP1B expression
MXPA02007320A (es) *	2000-01-28	2004-07-30	Alza Corp	Liposomas conteniendo un compuesto atrapado en solucion supersaturada.
US20030176385A1 (en) *	2000-02-15	2003-09-18	Jingfang Ju	Antisense modulation of protein expression
JP4922824B2 (ja) *	2000-04-03	2012-04-25	参天製薬株式会社	送達性物質およびそれを利用した薬物デリバリーシステム
LT2857516T (lt)	2000-04-11	2017-09-11	Genentech, Inc.	Multivalentiniai antikūnai ir jų panaudojimas
WO2001076555A2 (en) *	2000-04-12	2001-10-18	Liplasome Pharma A/S	Lipid-based drug delivery systems for topical application
DK1290013T3 (da)	2000-04-21	2006-06-26	Amgen Inc	Apo-A1/All-peptidderivater
US6667300B2 (en)	2000-04-25	2003-12-23	Icos Corporation	Inhibitors of human phosphatidylinositol 3-kinase delta
US7030219B2 (en) *	2000-04-28	2006-04-18	Johns Hopkins University	B7-DC, Dendritic cell co-stimulatory molecules
US6677136B2 (en)	2000-05-03	2004-01-13	Amgen Inc.	Glucagon antagonists
AU2001258106A1 (en) *	2000-05-11	2001-11-20	Celator Technologies Inc.	Lipid carrier compositions for improved drug retention
US6680172B1 (en)	2000-05-16	2004-01-20	Regents Of The University Of Michigan	Treatments and markers for cancers of the central nervous system
KR100784120B1 (ko)	2000-06-02	2007-12-12	보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템	에틸렌디시스테인(ｅｃ)-약물 접합체
AU6531101A (en)	2000-06-02	2001-12-17	Genentech Inc	Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20030072794A1 (en) *	2000-06-09	2003-04-17	Teni Boulikas	Encapsulation of plasmid DNA (lipogenes™) and therapeutic agents with nuclear localization signal/fusogenic peptide conjugates into targeted liposome complexes
CA2411102A1 (en)	2000-06-20	2001-12-27	Idec Pharmaceutical Corporation	Cold anti-cd20 antibody/radiolabeled anti-cd22 antibody combination
CA2648048A1 (en)	2000-06-23	2002-01-03	Genentech, Inc.	Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
EP2275549A1 (de)	2000-06-23	2011-01-19	Genentech, Inc.	Zusammensetzungen und Verfahren zur Diagnose und Behandlung von Erkrankungen in Verbindung mit Angiogenese
US20040023259A1 (en) *	2000-07-26	2004-02-05	Luca Rastelli	Therapeutic polypeptides, nucleic acids encoding same, and methods of use
EP2014298A3 (de)	2000-08-24	2009-10-07	Genentech, Inc.	Interleukin-22-Polypeptide, Nukleinsäuren zu deren Codierung und Verfahren zur Behandlung von Bauchspeicheldrüsenerkrankungen
EP1944317A3 (de)	2000-09-01	2008-09-17	Genentech, Inc.	Sekretierte und Transmembran-Polypeptide sowie Nukleinsäure zu deren Kodierung
US20030133972A1 (en) *	2000-10-11	2003-07-17	Targesome, Inc.	Targeted multivalent macromolecules
US7045283B2 (en)	2000-10-18	2006-05-16	The Regents Of The University Of California	Methods of high-throughput screening for internalizing antibodies
JP4198990B2 (ja)	2000-10-18	2008-12-17	ザブリガムアンドウィメンズホスピタルインコーポレイテッド	造血細胞のｅ−セレクチン／ｌ−セレクチンリガンドポリペプチドおよびその使用法
EP1341497A4 (de) *	2000-11-02	2005-10-19	Smithkline Beecham Corp	Rezeptor-antagonisten-lipid-konjugate und diese enthaltende abgabeträger
DE10056136A1 (de) *	2000-11-07	2002-05-16	Nemod New Modalities	Verwendung von Schwangerschaftsproteinen, Liposomen, nativen Muzin-Fragmenten und Mimikry-Verbindungen zur Behandlung und Prophylaxe von entzündlichen Erkrankungen, zur Verhinderung der Metastasierung und zur Prophylaxe von Tumorerkrankungen
WO2002061036A2 (en) *	2000-11-30	2002-08-08	The Research Foundation Of State University Of New York	Method of complexing a protein by the use of a dispersed system and proteins thereof
US7625584B2 (en) *	2000-11-30	2009-12-01	The Research Foundation Of State University Of New York	Method of complexing a protein by the use of a dispersed system and proteins thereof
US8110218B2 (en) *	2000-11-30	2012-02-07	The Research Foundation Of State University Of New York	Compositions and methods for less immunogenic protein-lipid complexes
AU2002239607A1 (en) *	2000-11-30	2002-06-11	Baxter Healthcare Corporation	Ahf associated dispersion system and method for preparation
US20060014674A1 (en) *	2000-12-18	2006-01-19	Dennis Keith	Methods for preparing purified lipopeptides
WO2002059145A1 (en) *	2000-12-18	2002-08-01	Cubist Pharmaceuticals, Inc.	Methods for preparing purified lipopeptides
ES2691680T3 (es) *	2000-12-18	2018-11-28	Cubist Pharmaceuticals Llc	Daptomicina en forma cristalina y su preparación
US20040077604A1 (en) *	2001-12-19	2004-04-22	Lenard Lichtenberger	Method and compositions employing formulations of lecithin oils and nsaids for protecting the gastrointestinal tract and providingenhanced therapeutic activity
US6964849B2 (en)	2001-01-11	2005-11-15	Curagen Corporation	Proteins and nucleic acids encoding same
US20040043928A1 (en) *	2001-08-02	2004-03-04	Ramesh Kekuda	Therapeutic polypeptides, nucleic acids encoding same, and methods of use
US20020159996A1 (en)	2001-01-31	2002-10-31	Kandasamy Hariharan	Use of CD23 antagonists for the treatment of neoplastic disorders
AR035779A1 (es)	2001-02-06	2004-07-14	Genetics Inst Llc	Polipeptidos de fusion derivados de glicoproteina ib alfa de plaqueta y metodos de uso de los mismos
US6867183B2 (en) *	2001-02-15	2005-03-15	Nobex Corporation	Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
US7060675B2 (en) *	2001-02-15	2006-06-13	Nobex Corporation	Methods of treating diabetes mellitus
US7087726B2 (en)	2001-02-22	2006-08-08	Genentech, Inc.	Anti-interferon-α antibodies
CA2439953A1 (en) *	2001-03-08	2002-09-19	Mark D. Bednarski	Stabilized therapeutic and imaging agents
JP2004525138A (ja) *	2001-03-26	2004-08-19	アルザ・コーポレーシヨン	治療剤の改良された細胞内送達のためのリポソーム組成物
US20040126900A1 (en) *	2001-04-13	2004-07-01	Barry Stephen E	High affinity peptide- containing nanoparticles
WO2002088318A2 (en) *	2001-04-30	2002-11-07	Targeted Genetics Corporation	Lipid-comprising drug delivery complexes and methods for their production
US20030077829A1 (en) *	2001-04-30	2003-04-24	Protiva Biotherapeutics Inc..	Lipid-based formulations
GB0111279D0 (en) *	2001-05-10	2001-06-27	Nycomed Imaging As	Radiolabelled liposomes
BR0209546A (pt)	2001-05-11	2004-06-29	Amgen Inc	Composição de matéria, dna, vetor de expressão, célula hospedeira, e, métodos para tratar uma doença autoimune mediada pelas células b, lúpus, um câncer mediado pelas células b, e linfoma de células b
US20050261214A1 (en) *	2001-05-15	2005-11-24	Serge Braun	Complexes for transferring substances of interest into a cell
US20020197253A1 (en) *	2001-05-22	2002-12-26	Cheek Dennis J.	Compositions and methods for promoting or inhibiting NDPK
EP1395274A2 (de) *	2001-05-22	2004-03-10	Duke University	Zusammensetzungen und verfahren zur metastasenhemmung
AU2002308722B2 (en)	2001-05-30	2007-05-17	Genentech, Inc.	Anti-NGF antibodies for the treatment of various disorders
CA2447990C (en) *	2001-05-31	2012-01-31	Skyepharma Inc.	Encapsulation of nanosuspensions in liposomes and microspheres
US6858580B2 (en) *	2001-06-04	2005-02-22	Nobex Corporation	Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6828297B2 (en)	2001-06-04	2004-12-07	Nobex Corporation	Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6828305B2 (en) *	2001-06-04	2004-12-07	Nobex Corporation	Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6713452B2 (en)	2001-06-04	2004-03-30	Nobex Corporation	Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US7713932B2 (en)	2001-06-04	2010-05-11	Biocon Limited	Calcitonin drug-oligomer conjugates, and uses thereof
US6835802B2 (en) *	2001-06-04	2004-12-28	Nobex Corporation	Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties
US20070160576A1 (en)	2001-06-05	2007-07-12	Genentech, Inc.	IL-17A/F heterologous polypeptides and therapeutic uses thereof
AU2002312410A1 (en) *	2001-06-08	2002-12-23	Target Protein Technologies, Inc.	Tissue-specific endothelial membrane proteins
MXPA03011985A (es)	2001-06-20	2004-03-26	Genentech Inc	Composiciones y metodos para el diagnostico y tratamiento de tumores.
US20050107595A1 (en) *	2001-06-20	2005-05-19	Genentech, Inc.	Compositions and methods for the diagnosis and treatment of tumor
US7803915B2 (en) *	2001-06-20	2010-09-28	Genentech, Inc.	Antibody compositions for the diagnosis and treatment of tumor
CA2451643C (en)	2001-06-21	2012-11-13	Isis Pharmaceuticals, Inc.	Antisense modulation of superoxide dismutase 1, soluble expression
CN1827766B (zh)	2001-06-28	2010-08-25	徐荣祥	体外细胞的培养方法
US20030087274A1 (en) *	2001-07-05	2003-05-08	Anderson David W.	Therapeutic polypeptides, nucleic acids encoding same, and methods of use
US20040029790A1 (en) *	2001-07-05	2004-02-12	Meera Patturajan	Novel human proteins, polynucleotides encoding them and methods of using the same
WO2003007914A2 (en) *	2001-07-19	2003-01-30	Guilford Pharmaceuticals, Inc.	Biocompatible polymer containing composition for treatment of prostate cancers
US20030134892A1 (en) *	2001-07-19	2003-07-17	Wenbin Dang	Compositions for treatment of head and neck cancers, and methods of making and using the same
US6964950B2 (en)	2001-07-25	2005-11-15	Isis Pharmaceuticals, Inc.	Antisense modulation of C-reactive protein expression
US7425545B2 (en)	2001-07-25	2008-09-16	Isis Pharmaceuticals, Inc.	Modulation of C-reactive protein expression
IL160016A0 (en) *	2001-07-29	2004-06-20	Yissum Res Dev Co	Osteogenic growth oligopeptides as stimulants of hematopoiesis
US20030096772A1 (en)	2001-07-30	2003-05-22	Crooke Rosanne M.	Antisense modulation of acyl CoA cholesterol acyltransferase-2 expression
US7407943B2 (en)	2001-08-01	2008-08-05	Isis Pharmaceuticals, Inc.	Antisense modulation of apolipoprotein B expression
US20040030096A1 (en) *	2001-08-02	2004-02-12	Linda Gorman	Novel human proteins, polynucleotides encoding them and methods of using the same
US7227014B2 (en)	2001-08-07	2007-06-05	Isis Pharmaceuticals, Inc.	Antisense modulation of apolipoprotein (a) expression
AU2002323266B2 (en) *	2001-08-20	2008-04-24	Transave, Inc.	Method for treating lung cancers
CA2459161A1 (en)	2001-08-31	2003-03-13	The Rockefeller University	Phosphodiesterase activity and regulation of phosphodiesterase 1b-mediated signaling in brain
US20040235068A1 (en) *	2001-09-05	2004-11-25	Levinson Arthur D.	Methods for the identification of polypeptide antigens associated with disorders involving aberrant cell proliferation and compositions useful for the treatment of such disorders
US7166571B2 (en) *	2001-09-07	2007-01-23	Biocon Limited	Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US7312192B2 (en) *	2001-09-07	2007-12-25	Biocon Limited	Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US7196059B2 (en) *	2001-09-07	2007-03-27	Biocon Limited	Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
US6913903B2 (en)	2001-09-07	2005-07-05	Nobex Corporation	Methods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US7547673B2 (en) *	2001-09-13	2009-06-16	The Johns Hopkins University	Therapeutics for cancer using 3-bromopyruvate and other selective inhibitors of ATP production
ES2390531T3 (es)	2001-09-18	2012-11-13	Genentech, Inc.	Composiciones y procedimientos para el diagnósitco y tratamiento de tumor
US7981863B2 (en)	2001-09-19	2011-07-19	Neuronova Ab	Treatment of Parkinson's disease with PDGF
EP1438021A2 (de) *	2001-09-28	2004-07-21	Esperion Therapeutics Inc.	Verfahren und gerät zur extrusion von vesikeln bei hohem druck
DE10148065A1 (de) *	2001-09-28	2003-04-17	Max Planck Gesellschaft	(Ester)-Lysolecithine in Liposomen
US6750019B2 (en)	2001-10-09	2004-06-15	Isis Pharmaceuticals, Inc.	Antisense modulation of insulin-like growth factor binding protein 5 expression
US20030199442A1 (en) *	2001-10-09	2003-10-23	Alsobrook John P.	Therapeutic polypeptides, nucleic acids encoding same, and methods of use
NZ585001A (en)	2001-10-09	2011-08-26	Isis Pharmaceuticals Inc	Antisense modulation of insulin-like growth factor binding protein 5 expression
US7332474B2 (en) *	2001-10-11	2008-02-19	Amgen Inc.	Peptides and related compounds having thrombopoietic activity
AU2002368202B2 (en)	2001-11-02	2008-06-05	Insert Therapeutics, Inc	Methods and compositions for therapeutic use of RNA interference
AU2002340662B2 (en) *	2001-11-07	2008-07-03	Tekmira Pharmaceuticals Corporation	Mucosal adjuvants comprising an oligonucleotide and a cationic lipid
US20040219201A1 (en) *	2001-12-06	2004-11-04	Yechezkel Barenholz	Tempamine compositions and methods of use
US6965025B2 (en)	2001-12-10	2005-11-15	Isis Pharmaceuticals, Inc.	Antisense modulation of connective tissue growth factor expression
EP2067472A1 (de)	2002-01-02	2009-06-10	Genentech, Inc.	Zusammensetzungen und Verfahren zur Behandlung und Diagnose von Tumoren
AU2003206397B2 (en)	2002-01-04	2008-07-17	The Rockefeller University	Compositions and methods for prevention and treatment of amyloid-beta peptide-related disorders
US20040052928A1 (en) *	2002-09-06	2004-03-18	Ehud Gazit	Peptides and methods using same for diagnosing and treating amyloid-associated diseases
US7781396B2 (en) *	2002-01-31	2010-08-24	Tel Aviv University Future Technology Development L.P.	Peptides directed for diagnosis and treatment of amyloid-associated disease
KR100965026B1 (ko) *	2002-02-13	2010-06-21	이뮤놀로지 래보러토리스 인코포레이티드	미생물 감염증을 치료하기 위한 조성물 및 방법
EP1575480A4 (de)	2002-02-22	2008-08-06	Genentech Inc	Zusammensetzungen und verfahren zur behandlung von immunbedingten erkrankungen
US20100311954A1 (en) *	2002-03-01	2010-12-09	Xencor, Inc.	Optimized Proteins that Target Ep-CAM
US20090042291A1 (en) *	2002-03-01	2009-02-12	Xencor, Inc.	Optimized Fc variants
US20040132101A1 (en)	2002-09-27	2004-07-08	Xencor	Optimized Fc variants and methods for their generation
US20030180712A1 (en)	2002-03-20	2003-09-25	Biostratum Ab	Inhibition of the beta3 subunit of L-type Ca2+ channels
US20040009216A1 (en) *	2002-04-05	2004-01-15	Rodrigueza Wendi V.	Compositions and methods for dosing liposomes of certain sizes to treat or prevent disease
NZ535925A (en)	2002-04-16	2008-06-30	Genentech Inc	An isolated antibody that binds to a particular polypeptide
JP2005532793A (ja) *	2002-04-22	2005-11-04	レコファーマアーベー	微生物付着を阻害するための融合ポリペプチドおよび方法
US20040009944A1 (en) *	2002-05-10	2004-01-15	Inex Pharmaceuticals Corporation	Methylated immunostimulatory oligonucleotides and methods of using the same
US7199107B2 (en)	2002-05-23	2007-04-03	Isis Pharmaceuticals, Inc.	Antisense modulation of kinesin-like 1 expression
EP2305710A3 (de)	2002-06-03	2013-05-29	Genentech, Inc.	Synthetische Antikörperphagenbibliotheken
US7601688B2 (en) *	2002-06-13	2009-10-13	Biocon Limited	Methods of reducing hypoglycemic episodes in the treatment of diabetes mellitus
JP4722481B2 (ja)	2002-06-28	2011-07-13	プロティババイオセラピューティクスリミテッド	リポソーム製造方法および装置
ATE492295T1 (de) *	2002-07-02	2011-01-15	Univ Texas	Radioaktiv markierte verbindungen und liposome und ihre herstellungs- und anwendungsverfahren
US20040247661A1 (en) *	2002-07-03	2004-12-09	Dov Michaeli	Liposomal vaccine
JP2005535663A (ja) *	2002-07-03	2005-11-24	アフトンコーポレーション	リポソームワクチン
US20050169979A1 (en) *	2002-07-03	2005-08-04	Dov Michaeli	Liposomal vaccine
WO2004004649A2 (en)	2002-07-08	2004-01-15	Genentech, Inc.	Compositions and methods for the treatment of immune related diseases
US7622118B2 (en) *	2002-07-15	2009-11-24	Board Of Regents, The University Of Texas System	Cancer treatment methods using selected antibodies to aminophospholipids
US7572448B2 (en) *	2002-07-15	2009-08-11	Board Of Regents, The University Of Texas System	Combined cancer treatment methods using selected antibodies to aminophospholipids
US7625563B2 (en) *	2002-07-15	2009-12-01	Board Of Regents, The University Of Texas System	Cancer treatment methods using selected immunoconjugates for binding to aminophospholipids
JP5069843B2 (ja)	2002-07-15	2012-11-07	ジェネンテック，インコーポレイテッド	抗ＥｒｂＢ２抗体を用いる処置に応答性である腫瘍を同定するための方法
US7615223B2 (en) *	2002-07-15	2009-11-10	Board Of Regents, The University Of Texas System	Selected immunoconjugates for binding to aminophospholipids
DK2283868T3 (en) *	2002-07-15	2016-04-25	Univ Texas	PEPTIDES BINDING TO PHOSPHATIDYLETHANOLAMINE AND ITS USE IN TREATING VIRUS INFECTIONS AND CANCER
US7714109B2 (en) *	2002-07-15	2010-05-11	Board Of Regents, The University Of Texas System	Combinations and kits for cancer treatment using selected antibodies to aminophospholipids
US7678386B2 (en) *	2002-07-15	2010-03-16	Board Of Regents The University Of Texas	Liposomes coated with selected antibodies that bind to aminophospholipids
EP1546184A4 (de) *	2002-07-16	2006-08-23	Univ South Florida	Humanes immunosuppressives protein
US20040161423A1 (en) *	2002-07-18	2004-08-19	Sanjeev Kumar (Mendiratta)	Polymer modified anti-angiogenic serpins
US9186322B2 (en) *	2002-08-02	2015-11-17	Insmed Incorporated	Platinum aggregates and process for producing the same
BRPI0313191A2 (pt) *	2002-08-02	2016-11-08	Transave Inc	composição e processo para produzir um agregado de platina e formulação farmacêutica
EP2371389A3 (de)	2002-08-14	2012-04-18	MacroGenics, Inc.	FC-Gamma-RIIB-spezifische Antikörper und Verwendungsverfahren davon
EP1393720A1 (de) *	2002-08-27	2004-03-03	Universiteit Utrecht	Vesikel enthaltend Corticosteroide zur Behandlung von Krebs
WO2004019866A2 (en)	2002-08-28	2004-03-11	Immunex Corporation	Compositions and methods for treating cardiovascular disease
US20070231379A1 (en) *	2002-08-29	2007-10-04	Slater James L	Liposome-entrapped topoisomerase inhibitors
AR036316A1 (es) *	2002-08-29	2004-08-25	Monte Verde S A	Una composicion farmaceutica de liposomas de tamano pequeno y metodo de preparacion
US20080214437A1 (en) *	2002-09-06	2008-09-04	Mohapatra Shyam S	Methods and compositions for reducing activity of the atrial natriuretic peptide receptor and for treatment of diseases
AU2003268531A1 (en)	2002-09-06	2004-03-29	University Of South Florida	Materials and methods for treatment of allergic diseases
EP1539228B1 (de)	2002-09-11	2010-12-29	Genentech, Inc.	Neue zusammensetzung und verfahren zur behandlung von immunerkrankungen
AU2003276874B2 (en)	2002-09-11	2009-09-03	Genentech, Inc.	Novel compositions and methods for the treatment of immune related diseases
US20050196382A1 (en) *	2002-09-13	2005-09-08	Replicor, Inc.	Antiviral oligonucleotides targeting viral families
JP2005538186A (ja) *	2002-09-13	2005-12-15	レプリコールインコーポレーティッド	非配列相補性の抗ウイルス性オリゴヌクレオチド
US20070010434A1 (en)	2002-09-16	2007-01-11	Genetech, Inc.	Novel compositions and methods for the treatment of immune related diseases
US6919426B2 (en)	2002-09-19	2005-07-19	Amgen Inc.	Peptides and related molecules that modulate nerve growth factor activity
EP2500438A3 (de)	2002-09-25	2012-11-28	Genentech, Inc.	Neue Zusammensetzungen und Verfahren zur Behandlung von Psoriasis
EP1549767A4 (de)	2002-09-26	2006-06-07	Amgen Inc	Modulation der expression von forkhead-box o1a
BRPI0314814C1 (pt)	2002-09-27	2021-07-27	Xencor Inc	anticorpo compreendendo uma variante de fc
US20040062748A1 (en) *	2002-09-30	2004-04-01	Mountain View Pharmaceuticals, Inc.	Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
US8129330B2 (en) *	2002-09-30	2012-03-06	Mountain View Pharmaceuticals, Inc.	Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
US7432351B1 (en)	2002-10-04	2008-10-07	Mayo Foundation For Medical Education And Research	B7-H1 variants
AU2003284010A1 (en) *	2002-10-04	2004-05-04	Rinat Neuroscience Corp.	Methods for treating cardiac arrhythmia and preventing death due to cardiac arrhythmia using ngf antagonists
WO2005000194A2 (en)	2002-10-08	2005-01-06	Rinat Neuroscience Corp.	Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist antibody and compositions containing the same
UA80447C2 (en) *	2002-10-08	2007-09-25		Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic
DE60335957D1 (de) *	2002-10-08	2011-03-17	Rinat Neuroscience Corp	Verfahren zur behandlung von postoperativen schmerzen durch verabreichung eines antikörpers gegen nervenwachstumsfaktor und diesen enthaltende zusammensetzungen
BR0315157A (pt) *	2002-10-09	2005-08-09	Rinat Neuroscience Corp	Métodos de tratar doença de alzheimer empregando-se anticorpos direcionados contra peptìdeo beta amilóide e composições deste
JP2006515318A (ja) *	2002-10-29	2006-05-25	ファルマシア・コーポレーション	特異的に発現する癌関連遺伝子、それによってコードされるポリペプチドおよびその使用方法
EP2322201A3 (de)	2002-10-29	2011-07-27	Genentech, Inc.	Gestaltungen und Methoden für die behandlung von Immune verwandte Krankheiten
EP1578765A4 (de)	2002-11-05	2008-04-23	Isis Pharmaceuticals Inc	Oligomere verbindungen,die zuckerersatzstoffe enthalten, und zusammensetzung zur verwendung in dergenmodulation
EP1560839A4 (de)	2002-11-05	2008-04-23	Isis Pharmaceuticals Inc	Chimäre oligomere verbindungen und derenverwendung in der genmodulation
CA2503748A1 (en)	2002-11-08	2004-05-27	Genentech, Inc.	Compositions and methods for the treatment of natural killer cell related diseases
US20040093198A1 (en) *	2002-11-08	2004-05-13	Carbon Design Systems	Hardware simulation with access restrictions
AU2003285200A1 (en) *	2002-11-09	2004-06-03	Nobex Corporation	Modified carbamate-containing prodrugs and methods of synthesizing same
DK2336318T3 (da)	2002-11-13	2013-07-15	Genzyme Corp	Antisense-modulering af apolipoprotein b-ekspression
EP1569695B1 (de)	2002-11-13	2013-05-15	Genzyme Corporation	Antisense-modulation von apolipoprotein-b-expression
US20050158375A1 (en) *	2002-11-15	2005-07-21	Toshikiro Kimura	Pharmaceutical composition containing liposomes for treating cancer
US7144999B2 (en)	2002-11-23	2006-12-05	Isis Pharmaceuticals, Inc.	Modulation of hypoxia-inducible factor 1 alpha expression
JP2011516026A (ja)	2002-11-26	2011-05-26	ジェネンテック・インコーポレーテッド	免疫関連疾患の治療のための組成物と方法
US7648962B2 (en) *	2002-11-26	2010-01-19	Biocon Limited	Natriuretic compounds, conjugates, and uses thereof
DE60331584D1 (de)	2002-11-26	2010-04-15	Biocon Ltd	Modifizierte natriuretic verbindungen, konjugate und ihre verwendungen
US7491699B2 (en) *	2002-12-09	2009-02-17	Ramot At Tel Aviv University Ltd.	Peptide nanostructures and methods of generating and using the same
CA2510780A1 (en) *	2002-12-19	2004-07-08	Alza Corporation	Method of treating angiogenic tissue growth
US9498530B2 (en)	2002-12-24	2016-11-22	Rinat Neuroscience Corp.	Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same
US7569364B2 (en)	2002-12-24	2009-08-04	Pfizer Inc.	Anti-NGF antibodies and methods using same
CA2921578C (en) *	2002-12-24	2017-02-14	Rinat Neuroscience Corp.	Anti-ngf antibodies and methods using same
US8980310B2 (en) *	2002-12-31	2015-03-17	Bharat Serums and Vaccines, Ltd.	Non-pegylated long-circulating liposomes
EA008930B1 (ru)	2002-12-31	2007-08-31	Зайдус Би-Эс-Ви Рисерч Энд Дивелопмент Прайвит Лимитид	Непэгилированные, длительно циркулирующие липосомы
ATE426575T1 (de) *	2003-01-07	2009-04-15	Univ Ramot	Peptidenanostrukturen die fremdmaterial enthalten,und verfahren zur herstellung derselben
JPWO2004063216A1 (ja) *	2003-01-10	2006-06-15	アステラス製薬株式会社	血中滞留および癌組織特異的薬物送達のためのコンジュゲート
US7169892B2 (en)	2003-01-10	2007-01-30	Astellas Pharma Inc.	Lipid-peptide-polymer conjugates for long blood circulation and tumor specific drug delivery systems
CA2515484C (en)	2003-02-11	2011-09-20	Antisense Therapeutics Ltd	Modulation of insulin like growth factor i receptor expression
BRPI0407375A (pt)	2003-02-19	2006-02-07	Rinat Neuroscience Corp	Métodos para tratar dor por meio da administração de um antagonista do fator de crescimento neural e u nsaid e composições contendo os mesmos
US7803781B2 (en)	2003-02-28	2010-09-28	Isis Pharmaceuticals, Inc.	Modulation of growth hormone receptor expression and insulin-like growth factor expression
US7968115B2 (en)	2004-03-05	2011-06-28	Board Of Regents, The University Of Texas System	Liposomal curcumin for treatment of cancer
US20040185559A1 (en)	2003-03-21	2004-09-23	Isis Pharmaceuticals Inc.	Modulation of diacylglycerol acyltransferase 1 expression
US20060198882A1 (en) *	2003-03-21	2006-09-07	Yechezkel Barenholz	Stable liposomes or micelles comprising a sphinolipid and a peg-lipopolymer
CA2520864A1 (en)	2003-03-31	2004-10-21	Alza Corporation	Lipid particles having asymmetric lipid coating and method of preparing same
ES2349779T5 (es)	2003-04-04	2013-11-26	Genentech, Inc.	Formulaciones de anticuerpos y de proteínas a concentración elevada
UA99933C2 (ru)	2003-04-09	2012-10-25	Дженентек, Инк.	Лечение аутоиммунных заболеваний у пациента с неадекватным ответом на ингибитор tnf-альфа
DE602004013769D1 (de) *	2003-04-15	2008-06-26	Opperbas Holding Bv	Pharmazeutische zusammensetzung, enthaltend proteine und/oder polypeptide sowie kolloidpartikel
US20060246104A1 (en) *	2003-04-16	2006-11-02	Massia Stephen P	Stable rgd peptidomimetic composition
US7598227B2 (en)	2003-04-16	2009-10-06	Isis Pharmaceuticals Inc.	Modulation of apolipoprotein C-III expression
AU2004231740A1 (en) *	2003-04-17	2004-11-04	The Trustees Of Columbia University In The City Ofnew York	Desmoglein 4 is a novel gene involved in hair growth
US7399853B2 (en)	2003-04-28	2008-07-15	Isis Pharmaceuticals	Modulation of glucagon receptor expression
EP2204193A3 (de)	2003-05-12	2010-08-18	Affymax, Inc.	Spacer-Bestandteile für Poly(ethylenglykol)-modifizierte Verbindungen auf Peptidbasis
MXPA05012315A (es)	2003-05-12	2006-04-18	Affymax Inc	Compuestos poli(etilenglicol) modificados novedosos y usos de los mismos.
CA2526080A1 (en) *	2003-05-30	2005-01-06	Genentech, Inc.	Polypeptides that bind an anti-tissue factor antibody and uses thereof
RU2005136988A (ru)	2003-05-30	2006-06-10	Дженентек, Инк. (Us)	Лечение антителами против vegf
WO2005002507A2 (en)	2003-06-03	2005-01-13	Isis Pharmaceuticals, Inc.	Modulation of survivin expression
EP1628624A2 (de) *	2003-06-04	2006-03-01	CANJI, Inc.	Verfahren und zusammensetzungen für die interferon-therapie
EP1636593B9 (de)	2003-06-06	2009-12-16	Genentech, Inc.	Modulation der wechselwirkung zwischen hgf-beta-kette und c-met
RU2403262C2 (ru)	2003-06-11	2010-11-10	Уайт	Выделенный полипептид ib альфа гликопротеина тромбоцитов человека, слитый белок, молекула днк (варианты), экспрессирующий вектор (варианты), клетка (варианты), способ экспрессии полипептида, способ экспрессии слитого белка, фармацевтическая композиция (варианты), способ ингибирования прикрепления клетки крови к биологической ткани в биологической системе, способ ингибирования прикрепления белка к биологической ткани в биологической системе и способ лечения нарушения
EP1649061B1 (de)	2003-07-03	2010-08-25	University Of Medicine And Dentistry Of New Jersey	Gene als diagnostische werkzeuge für autismus
US7939058B2 (en) *	2003-07-03	2011-05-10	University Of Southern California	Uses of IL-12 in hematopoiesis
KR100835786B1 (ko)	2003-07-08	2008-06-09	제넨테크, 인크.	Ｉｌ-１７ａ／ｆ 이종 폴리펩티드 및 그의 치료 용도
AU2004257373B2 (en) *	2003-07-16	2011-03-24	Arbutus Biopharma Corporation	Lipid encapsulated interfering RNA
CN100431525C (zh) *	2003-07-17	2008-11-12	台湾东洋药品工业股份有限公司	脂质体悬浮液制造方法及含该法所制脂质体悬浮液的产物
KR20090077984A (ko) *	2003-07-31	2009-07-16	더 보드 오브 리전츠 오브 더 유니버시티 오브 텍사스 시스템	인지질과 소염성 약제의 멸균 제제
CA2533701A1 (en)	2003-07-31	2005-02-17	Isis Pharmaceuticals, Inc.	Oligomeric compounds and compositions for use in modulation of small non-coding rnas
WO2005019258A2 (en)	2003-08-11	2005-03-03	Genentech, Inc.	Compositions and methods for the treatment of immune related diseases
WO2005016348A1 (en) *	2003-08-14	2005-02-24	Icos Corporation	Method of inhibiting immune responses stimulated by an endogenous factor
US20050054614A1 (en) *	2003-08-14	2005-03-10	Diacovo Thomas G.	Methods of inhibiting leukocyte accumulation
US7825235B2 (en)	2003-08-18	2010-11-02	Isis Pharmaceuticals, Inc.	Modulation of diacylglycerol acyltransferase 2 expression
US8986731B2 (en) *	2003-08-26	2015-03-24	Biolitec Pharma Marketing Ltd	Pegylated liposomal formulations of hydrophobic photosensitizers for photodynamic therapy
WO2005037911A2 (en) *	2003-08-26	2005-04-28	Smithkline Beecham Corporation	Heterofunctional copolymers of glycerol and polyethylene glycol, their conjugates and compositions
US8846079B1 (en)	2004-12-01	2014-09-30	Vgsk Technologies, Inc.	Sterically stabilized carrier for aerosol therapeutics, compositions and methods for treating the respiratory tract of a mammal
US11324698B2 (en)	2003-08-28	2022-05-10	Vgsk Technologies, Inc.	Sterically stabilized carrier for aerosol therapeutics, compositions and methods for treating the respiratory tract of a mammal
US20060115523A1 (en) *	2004-12-01	2006-06-01	Konduri Kameswari S	Sterically stabilized liposome and triamcinolone composition for treating the respiratory tract of a mammal
US7696359B2 (en) *	2003-09-03	2010-04-13	Kyowa Hakko Kirin Co., Ltd.	Compound modified with glycerol derivative
US20050233435A1 (en) *	2003-09-04	2005-10-20	Nyu Medical Center	Plasmodium axenic liver stages as a noninfectious whole organism malaria vaccine
US20070123480A1 (en) *	2003-09-11	2007-05-31	Replicor Inc.	Oligonucleotides targeting prion diseases
JP4842821B2 (ja) *	2003-09-15	2011-12-21	プロチババイオセラピューティクスインコーポレイティッド	ポリエチレングリコール修飾脂質化合物およびその使用
EP2182063A3 (de)	2003-09-18	2012-07-18	Isis Pharmaceuticals, Inc.	Modulierung von EIF4E-Expression
WO2005027901A1 (en) *	2003-09-25	2005-03-31	Tel Aviv University Future Technology Development L.P.	Compositions and methods using same for treating amyloid-associated diseases
US8101720B2 (en) *	2004-10-21	2012-01-24	Xencor, Inc.	Immunoglobulin insertions, deletions and substitutions
US7625707B2 (en) *	2003-10-02	2009-12-01	Ramot At Tel Aviv University Ltd.	Antibacterial agents and methods of identifying and utilizing same
EP1678194B1 (de)	2003-10-10	2013-06-26	Alchemia Oncology Pty Limited	Modulation der synthese und des abbaus von hyaluronan bei der behandlung von krankheiten
CA2542099A1 (en) *	2003-10-11	2005-04-21	Inex Pharmaceuticals Corporation	Methods and compositions for enhancing innate immunity and antibody dependent cellular cytotoxicity
TW200517114A (en)	2003-10-15	2005-06-01	Combinatorx Inc	Methods and reagents for the treatment of immunoinflammatory disorders
WO2005041870A2 (en) *	2003-10-24	2005-05-12	Ader Enterprises, Inc.	Composition and method for the treatment of eye disease
JP2007533647A (ja) *	2003-10-24	2007-11-22	アルザ・コーポレーシヨン	脂質粒子の調製
WO2005040163A1 (en) *	2003-10-28	2005-05-06	Dr. Reddy's Laboratories Ltd	Heterocyclic compounds that block the effects of advanced glycation end products (age)
US20050191653A1 (en)	2003-11-03	2005-09-01	Freier Susan M.	Modulation of SGLT2 expression
US20050129753A1 (en) *	2003-11-14	2005-06-16	Gabizon Alberto A.	Method for drug loading in liposomes
EP1686959B1 (de) *	2003-11-14	2009-06-24	HET NEDERLANDS KANKER INSTITUUT (The Netherlands Cancer Institute)	Pharmazeutische formulierungen mit kurzketten-sphingolipiden und ihre verwendung
JP4901478B2 (ja)	2003-11-17	2012-03-21	ジェネンテック，インコーポレイテッド	造血系起源の腫瘍の治療のための組成物と方法
CN1914226B (zh) *	2003-11-25	2012-02-01	达纳-法伯癌症研究院有限公司	SARS-CoV抗体及其使用方法
EP1701979A2 (de) *	2003-12-03	2006-09-20	Xencor, Inc.	Optimierte antikörper gegen den rezeptor des epidermalen wachstumsfaktors
US9050378B2 (en) *	2003-12-10	2015-06-09	Board Of Regents, The University Of Texas System	N2S2 chelate-targeting ligand conjugates
US7312320B2 (en)	2003-12-10	2007-12-25	Novimmune Sa	Neutralizing antibodies and methods of use thereof
JP2008507252A (ja)	2003-12-11	2008-03-13	ジェネンテック・インコーポレーテッド	Ｃ−ｍｅｔ二量体化及び活性化を阻害するための方法と組成物
AU2004308482A1 (en)	2003-12-23	2005-07-14	Rinat Neuroscience Corp.	Agonist anti-trkC antibodies and methods using same
PT2311873T (pt)	2004-01-07	2018-11-20	Novartis Vaccines & Diagnostics Inc	Anticorpo monoclonal específico para m-csf e respetivos usos
KR20060103957A (ko) *	2004-01-15	2006-10-04	알자 코포레이션	치료제 전달용의 리포솜 조성물
EP1711606A2 (de)	2004-01-20	2006-10-18	Isis Pharmaceuticals, Inc.	Modulation der expression des glucocorticoidrezeptors
US7468431B2 (en)	2004-01-22	2008-12-23	Isis Pharmaceuticals, Inc.	Modulation of eIF4E-BP2 expression
US20050181035A1 (en) *	2004-02-17	2005-08-18	Dow Steven W.	Systemic immune activation method using non CpG nucleic acids
EP1727556A2 (de) *	2004-02-17	2006-12-06	University Of South Florida	Material und methoden zur behandlung von entzündlichen erkrankungen und zellproliferationsstörungen
DE602005018325D1 (de)	2004-02-19	2010-01-28	Genentech Inc	Antikörper mit korrigierten cdr
US8784881B2 (en)	2004-03-05	2014-07-22	Board Of Regents, The University Of Texas System	Liposomal curcumin for treatment of diseases
US8569474B2 (en)	2004-03-09	2013-10-29	Isis Pharmaceuticals, Inc.	Double stranded constructs comprising one or more short strands hybridized to a longer strand
EP1735009A4 (de)	2004-03-12	2011-03-30	Alnylam Pharmaceuticals Inc	Irna mittel targeting vegf
EP1579850A3 (de) *	2004-03-15	2009-12-16	Nipro Corporation	Pharmazeutische Zubereitung mit Lipsomen zur Behandlung von Krebs
EP2700720A3 (de)	2004-03-15	2015-01-28	Isis Pharmaceuticals, Inc.	Zusammensetzungen und Verfahren zur Optimierung der Spaltung von RNA durch RNase H
AU2005223654A1 (en) *	2004-03-18	2005-09-29	Transave, Inc.	Administration of cisplatin by inhalation
US20070065522A1 (en) *	2004-03-18	2007-03-22	Transave, Inc.	Administration of high potency platinum compound formulations by inhalation
WO2005092388A1 (ja) *	2004-03-26	2005-10-06	Terumo Kabushiki Kaisha	リポソーム製剤
CA2561221C (en) *	2004-03-26	2016-09-20	Curis, Inc.	Rna interference modulators of hedgehog signaling and uses thereof
US20050244869A1 (en) *	2004-04-05	2005-11-03	Brown-Driver Vickie L	Modulation of transthyretin expression
US7794713B2 (en)	2004-04-07	2010-09-14	Lpath, Inc.	Compositions and methods for the treatment and prevention of hyperproliferative diseases
HUE037549T2 (hu)	2004-04-07	2018-09-28	Rinat Neuroscience Corp	Eljárások csontrákfájdalom kezelésére idegi növekedési faktor antagonista antitest beadásával
JP2007532680A (ja) *	2004-04-16	2007-11-15	ジェネンテック・インコーポレーテッド	疾患の治療方法
US20150017671A1 (en)	2004-04-16	2015-01-15	Yaping Shou	Methods for detecting lp-pla2 activity and inhibition of lp-pla2 activity
WO2005107712A1 (en)	2004-05-03	2005-11-17	Hermes Biosciences, Inc.	Liposomes useful for drug delivery
US8658203B2 (en) *	2004-05-03	2014-02-25	Merrimack Pharmaceuticals, Inc.	Liposomes useful for drug delivery to the brain
AU2005245875C1 (en)	2004-05-13	2017-08-31	Icos Corporation	Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta
AU2005251691A1 (en) *	2004-05-17	2005-12-22	Tekmira Pharmaceuticals Corporation	Liposomal formulations comprising dihydrosphingomyelin and methods of use thereof
AU2005250369A1 (en) *	2004-05-18	2005-12-15	Genentech, Inc.	M13 virus major coat protein variants for C-terminal and BI-terminal display of a heterologous protein
US20050260260A1 (en) *	2004-05-19	2005-11-24	Edward Kisak	Liposome compositions for the delivery of macromolecules
CN101001633A (zh) *	2004-05-21	2007-07-18	特兰萨夫公司	肺病和肺病前期病症的治疗
JP2008500338A (ja) *	2004-05-25	2008-01-10	イコス・コーポレイション	造血細胞の異常増殖を治療及び／又は予防する方法
EP1749000A4 (de) *	2004-05-25	2009-12-30	Metabolex Inc	Bicyclische substituierte triazole als ppar-modulatoren und verfahren zu deren herstellung
AU2005247473A1 (en) *	2004-05-25	2005-12-08	Metabolex, Inc.	Substituted triazoles as modulators of PPAR and methods of their preparation
EP1758452B1 (de) *	2004-05-28	2017-01-25	Human Biomolecular Research Institute	Metabolisch stabile analgetika und schmerzstillende mittel
US20090048192A1 (en) *	2004-06-03	2009-02-19	Isis Pharmaceuticals, Inc.	Double Strand Compositions Comprising Differentially Modified Strands for Use in Gene Modulation
AU2005252662B2 (en) *	2004-06-03	2011-08-18	Isis Pharmaceuticals, Inc.	Double strand compositions comprising differentially modified strands for use in gene modulation
US8394947B2 (en)	2004-06-03	2013-03-12	Isis Pharmaceuticals, Inc.	Positionally modified siRNA constructs
BRPI0510915A (pt)	2004-06-04	2007-11-13	Genentech Inc	método para o tratamento da esclerose múltipla e artigo manufaturado
EP1781593B1 (de)	2004-06-07	2011-12-14	Protiva Biotherapeutics Inc.	Kationische lipide und verwendungsverfahren
JP4796062B2 (ja)	2004-06-07	2011-10-19	プロチババイオセラピューティクスインコーポレイティッド	脂質封入干渉ｒｎａ
EP1771435A4 (de) *	2004-06-19	2008-02-13	Human Biomolecular Res Inst	Modulatoren von neurotransmittern des zentralen nervensystems
EP2453024B1 (de)	2004-06-21	2017-12-06	The Board of Trustees of The Leland Stanford Junior University	Differenziell exprimierte Gene und Leitungsbahnen bei bipolarer Störung und/oder schwerer depressiver Erkrankung
WO2006014253A2 (en) *	2004-07-02	2006-02-09	Genentech, Inc.	Factor viia variants
EP1773857A4 (de)	2004-07-02	2009-05-13	Protiva Biotherapeutics Inc	Das immunsystem stimulierende sirna-moleküle und anwendungen davon
US8143380B2 (en) *	2004-07-08	2012-03-27	Amgen Inc.	Therapeutic peptides
US20090156471A1 (en) *	2004-07-15	2009-06-18	Ramot At Tel Aviv University Ltd.	Use of anti-amyloid agents for treating and typing pathogen infections
BRPI0510674A (pt)	2004-07-15	2007-12-26	Xencor Inc	variantes fc otimizadas
US20060051405A1 (en) *	2004-07-19	2006-03-09	Protiva Biotherapeutics, Inc.	Compositions for the delivery of therapeutic agents and uses thereof
EP1773878B1 (de) *	2004-07-19	2015-03-04	Biocon Limited	Insulinoligomerkonjugate, formulierungen und anwendungen davon
EP1771474B1 (de)	2004-07-20	2010-01-27	Genentech, Inc.	Angiopoietin-like 4 protein hemmer kombinationen und deren verwendung
MX2007001064A (es)	2004-07-26	2007-04-12	Genentech Inc	Metodos y composiciones para modular la activacion del factor de crecimiento de hepatocitos.
AP2007003890A0 (en) *	2004-07-30	2007-02-28	Rinat Neuroscience Corp	Antibodies directed against amy-loid-beta peptide and methods using same
US8568637B2 (en) *	2004-08-02	2013-10-29	Ramot At Tel-Aviv University Ltd.	Method of forming a fiber made of peptide nanostructures
US9132116B2 (en) *	2004-08-02	2015-09-15	Willowcroft Pharm Inc.	Mast cell stabilizers to prevent or treat laminitis
JP4934036B2 (ja)	2004-08-17	2012-05-16	タイコヘルスケアグループリミテッドパートナーシップ	抗癒着着バリア
JP2006056807A (ja) *	2004-08-18	2006-03-02	Konica Minolta Medical & Graphic Inc	光線力学療法製剤
US7732479B2 (en)	2004-08-19	2010-06-08	Tel Aviv University Future Technology Development L.P.	Compositions for treating amyloid associated diseases
JP4715133B2 (ja) *	2004-08-26	2011-07-06	コニカミノルタエムジー株式会社	抗腫瘍リポソーム製剤およびその製造方法
JP2006069929A (ja) *	2004-08-31	2006-03-16	Konica Minolta Medical & Graphic Inc	真菌症治療製剤およびその製造方法
US7786086B2 (en)	2004-09-08	2010-08-31	Ramot At Tel-Aviv University Ltd.	Peptide nanostructures containing end-capping modified peptides and methods of generating and using the same
US7884086B2 (en)	2004-09-08	2011-02-08	Isis Pharmaceuticals, Inc.	Conjugates for use in hepatocyte free uptake assays
CN101048138B (zh) *	2004-09-09	2010-12-08	耶路撒冷希伯来大学伊萨姆研发公司	脂质体糖皮质激素用于治疗炎性状态的用途
JP2008512444A (ja) *	2004-09-09	2008-04-24	イッスム・リサーチ・ディベロップメント・カンパニー・オブ・ザ・ヘブルー・ユニバーシティ・オブ・エルサレム	神経変性状態の治療のための、両親媒性弱塩基様テンパミンを含むリポソーム製剤
US6998028B1 (en) *	2004-09-24	2006-02-14	Superpower, Inc.	Methods for forming superconducting conductors
AU2005289685B2 (en)	2004-09-24	2009-07-16	Amgen Inc.	Modified Fc molecules
WO2006039400A2 (en)	2004-09-29	2006-04-13	Mount Sinai School Of Medicine Of New York University	Fsh and fsh receptor modulator compositions and methods for inhibiting osteoclastic bone resorption and bone loss in osteoporosis
CA2580271A1 (en)	2004-10-05	2006-04-20	Genentech, Inc.	Method for treating vasculitis
US9315862B2 (en) *	2004-10-05	2016-04-19	California Institute Of Technology	Aptamer regulated nucleic acids and uses thereof
HUE039237T2 (hu)	2004-10-06	2018-12-28	Mayo Found Medical Education & Res	B7-H1 és PD-1 vesesejt karcinoma kezelésében
EP1809246B1 (de) *	2004-10-08	2008-07-16	Alza Corporation	Verfahren zur einführung eines lipid-verknüpften teils in eine vorgeformte lipidanordnung mit mikrowellen
TW200612993A (en) *	2004-10-08	2006-05-01	Alza Corp	Lipopolymer conjugates
JO3000B1 (ar)	2004-10-20	2016-09-05	Genentech Inc	مركبات أجسام مضادة .
CA2582452C (en) *	2004-10-26	2010-09-07	Erard Gilles	Pegylated liposomal doxorubicin in combination with ecteinascidin 743
CA2584583A1 (en) *	2004-10-28	2006-05-11	Alza Corporation	Lyophilized liposome formulations and method
BRPI0517238B1 (pt)	2004-10-29	2021-11-09	Pharma Mar, S.A.	Composições que compreendem ecteinascidina e um dissacarídeo, método para produzir um frasco que contém a referida composição e para preparar uma solução para infusão intravenosa e uso da referida solução
WO2006052767A2 (en)	2004-11-05	2006-05-18	Inex Pharmaceuticals Corporation	Compositions and methods for stabilizing liposomal camptothecin formulations
TW200618820A (en) *	2004-11-05	2006-06-16	Alza Corp	Liposome formulations of boronic acid compounds
CA2584673A1 (en) *	2004-11-08	2006-05-26	Transave, Inc.	Methods of treating cancer with lipid-based platinum compound formulations administered intraperitoneally
WO2006060148A2 (en) *	2004-11-11	2006-06-08	Affymax, Inc.	Novel peptides that bind to the erythropoietin receptor
US20080058274A1 (en) *	2004-11-15	2008-03-06	Yechezkel Barenholz	Combination Therapy
US20060134189A1 (en) *	2004-11-17	2006-06-22	Protiva Biotherapeutics, Inc	siRNA silencing of apolipoprotein B
US20070298094A1 (en) *	2004-11-18	2007-12-27	Terumo Kabushiki Kaisha	Medicinal Composition, Preparation and Combined Preparation
JP2008523157A (ja) *	2004-12-14	2008-07-03	アルナイラムファーマシューティカルズインコーポレイテッド	ＭＬＬ−ＡＦ４のＲＮＡｉ調節およびその使用方法
EP2230517A1 (de)	2005-01-07	2010-09-22	Diadexus, Inc.	OVR110-Antikörperzusammensetzungen und Verwendungsverfahren dafür
US20080207505A1 (en) *	2005-01-12	2008-08-28	James Kenneth D	Bna Conjugates and Methods of Use
CN102580084B (zh)	2005-01-21	2016-11-23	健泰科生物技术公司	Her抗体的固定剂量给药
JP5221126B2 (ja) *	2005-01-28	2013-06-26	協和発酵キリン株式会社	水溶性物質で表面修飾された微粒子の製造方法
EP1853289A4 (de)	2005-01-31	2008-04-09	Vaxinnate Corp	Neuartige polypeptid-liganden für den toll-artigen rezeptor 2
US8029783B2 (en) *	2005-02-02	2011-10-04	Genentech, Inc.	DR5 antibodies and articles of manufacture containing same
EP1855694B1 (de)	2005-02-09	2020-12-02	Sarepta Therapeutics, Inc.	Antisense-zusammensetzung zur behandlung von muskelatrophie
KR101289537B1 (ko)	2005-02-15	2013-07-31	듀크 유니버시티	항-ｃｄ19 항체 및 종양학에서 이의 용도
US20060263357A1 (en)	2005-05-05	2006-11-23	Tedder Thomas F	Anti-CD19 antibody therapy for autoimmune disease
EP1885356A2 (de) *	2005-02-17	2008-02-13	Icos Corporation	Phophoinositid-3-kinaseinhibitoren zur hemmung der leukozytenakkumulation
WO2006088245A1 (ja) *	2005-02-18	2006-08-24	The University Of Tokushima	ポリオキシアルキレン鎖含有脂質誘導体及び該誘導体を含有する脂質膜構造体
WO2006089141A2 (en)	2005-02-18	2006-08-24	Dana-Farber Cancer Institute	Antibodies against cxcr4 and methods of use thereof
CN103251946A (zh)	2005-02-23	2013-08-21	健泰科生物技术公司	使用her二聚化抑制剂在癌症患者中延长病情进展前时间或存活
TW200714289A (en) *	2005-02-28	2007-04-16	Genentech Inc	Treatment of bone disorders
US20060204505A1 (en) *	2005-03-08	2006-09-14	Sliwkowski Mark X	Methods for identifying tumors responsive to treatment with HER dimerization inhibitors (HDIs)
CN101175769A (zh)	2005-03-10	2008-05-07	健泰科生物技术公司	用于调控血管完整性的方法和组合物
JP2006248978A (ja) *	2005-03-10	2006-09-21	Mebiopharm Co Ltd	新規なリポソーム製剤
US20070065359A1 (en) *	2005-03-14	2007-03-22	Shiladitya Sengupta	Nanocells for diagnosis and treatment of diseases and disorders
WO2006102426A2 (en)	2005-03-21	2006-09-28	Metabolex, Inc.	Methods for avoiding edema in the treatment of metabolic, inflammatory, and cardiovascular disorders
CN1840193B (zh) *	2005-03-29	2010-05-12	中国科学院生物物理研究所	聚乙二醇化磷脂包载的蒽环类抗肿瘤抗生素的纳米胶束制剂
PL1866414T3 (pl)	2005-03-31	2012-10-31	Calando Pharmaceuticals Inc	Inhibitory podjednostki 2 reduktazy rybonukleotydowej i ich zastosowania
MY148086A (en)	2005-04-29	2013-02-28	Rinat Neuroscience Corp	Antibodies directed against amyloid-beta peptide and methods using same
US7531637B2 (en)	2005-05-06	2009-05-12	Zymogenetics, Inc.	IL-31 monoclonal antibodies
EP3805245A1 (de)	2005-05-17	2021-04-14	University of Connecticut	Zusammensetzungen und verfahren zur immunomodulation in einem organismus
US7550433B2 (en)	2005-06-03	2009-06-23	Affymax, Inc.	Erythropoietin receptor peptide formulations and uses
US7919461B2 (en) *	2005-06-03	2011-04-05	Affymax, Inc.	Erythropoietin receptor peptide formulations and uses
US8324159B2 (en) *	2005-06-03	2012-12-04	Affymax, Inc.	Erythropoietin receptor peptide formulations and uses
WO2006132788A2 (en)	2005-06-06	2006-12-14	Genentech, Inc.	Transgenic models for different genes and their use for gene characterization
TW200726485A (en) *	2005-07-01	2007-07-16	Alza Corp	Liposomal delivery vehicle for hydrophobic drugs
WO2007008943A2 (en)	2005-07-08	2007-01-18	Xencor, Inc.	Optimized anti-ep-cam antibodies
JP4997239B2 (ja)	2005-07-22	2012-08-08	ワイズ・エー・シー株式会社	抗ｃｄ２６抗体およびその使用方法
EP1913028B1 (de) *	2005-07-28	2015-03-04	Novartis AG	Anwendung von antikörpern gegen m-csf
JP5457671B2 (ja) *	2005-07-28	2014-04-02	ノバルティスアーゲー	Ｍ−ｃｓｆ特異的モノクローナル抗体およびその使用
US8591457B2 (en)	2005-08-10	2013-11-26	Alza Corporation	Method for making a needle-free jet injection drug delivery device
US8008453B2 (en)	2005-08-12	2011-08-30	Amgen Inc.	Modified Fc molecules
AU2006280321A1 (en)	2005-08-15	2007-02-22	Genentech, Inc.	Gene disruptions, compositions and methods relating thereto
US20070054873A1 (en) *	2005-08-26	2007-03-08	Protiva Biotherapeutics, Inc.	Glucocorticoid modulation of nucleic acid-mediated immune stimulation
US7700567B2 (en)	2005-09-29	2010-04-20	Supergen, Inc.	Oligonucleotide analogues incorporating 5-aza-cytosine therein
US10004828B2 (en) *	2005-10-11	2018-06-26	Romat at Tel-Aviv University Ltd.	Self-assembled Fmoc-ff hydrogels
US7875602B2 (en) *	2005-10-21	2011-01-25	Sutter West Bay Hospitals	Camptothecin derivatives as chemoradiosensitizing agents
TW200732350A (en)	2005-10-21	2007-09-01	Amgen Inc	Methods for generating monovalent IgG
ES2618785T3 (es)	2005-10-31	2017-06-22	Oncomed Pharmaceuticals, Inc.	Composiciones y métodos para tratar el cáncer basados en receptores FZD humanos
GB0522082D0 (en)	2005-10-31	2005-12-07	Pharma Mar Sa	Formulations
BRPI0618214A2 (pt)	2005-11-01	2011-08-23	Alnylam Pharmaceuticals Inc	inibição de rnai de replicação do influenza vìrus
EP2395012B8 (de) *	2005-11-02	2018-06-06	Arbutus Biopharma Corporation	Modifizierte siRNA-Moleküle und Verwendungen davon
US7879212B2 (en) *	2005-11-03	2011-02-01	Ramot At Tel-Aviv University Ltd.	Peptide nanostructure-coated electrodes
DE102005053066A1 (de)	2005-11-04	2007-05-10	Basf Ag	Verwendung von Copolymeren als Solubilisatoren für in Wasser schwerlöslichen Verbindungen
WO2007056236A2 (en) *	2005-11-08	2007-05-18	Transave, Inc.	Methods of treating cancer with lipid-based platinum compound formulations administered intravenously
US9107824B2 (en)	2005-11-08	2015-08-18	Insmed Incorporated	Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally
US20070190180A1 (en) *	2005-11-08	2007-08-16	Pilkiewicz Frank G	Methods of treating cancer with high potency lipid-based platinum compound formulations administered intravenously
US20070190182A1 (en) *	2005-11-08	2007-08-16	Pilkiewicz Frank G	Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally
WO2007059064A2 (en)	2005-11-12	2007-05-24	The Board Of Trustees Of The Leland Stanford Junior University	Fgf2-related methods for diagnosing and treating depression
TW200736277A (en)	2005-11-14	2007-10-01	Amgen Inc	RANKL antibody-PTH/PTHrP chimeric molecules
MY153249A (en)	2005-11-14	2015-01-29	Rinat Neuroscience Corp	Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
MY149159A (en)	2005-11-15	2013-07-31	Hoffmann La Roche	Method for treating joint damage
WO2007056858A1 (en)	2005-11-18	2007-05-24	Glenmark Pharmaceuticals S.A.	Anti-alpha2 integrin antibodies and their uses
JP2009516710A (ja)	2005-11-21	2009-04-23	アイシスファーマシューティカルズ，インコーポレーテッド	ｅＩＦ４Ｅ−ＢＰ２の発現のモジュレート
AU2006335053A1 (en)	2005-11-21	2007-07-19	Genentech, Inc.	Novel gene disruptions, compositions and methods relating thereto
US20070122350A1 (en) *	2005-11-30	2007-05-31	Transave, Inc.	Safe and effective methods of administering therapeutic agents
CN105859886A (zh)	2005-12-02	2016-08-17	健泰科生物技术公司	牵涉与il-22和il-22r结合的抗体的组合物和方法
EP1979379B1 (de)	2005-12-02	2013-09-18	Dana-Farber Cancer Institute	Carboanhydrase ix (g250)-antikörper und verfahren zur verwendung davon
US20090155345A1 (en) *	2005-12-08	2009-06-18	Ben Gurion University Of The Negev Research And Development Authority	Methods for affecting liposome composition ultrasound irradiation
CN101325976A (zh) *	2005-12-09	2008-12-17	巴斯夫欧洲公司	聚乙烯基内酰胺-聚氧化烯嵌段共聚物作为微水溶性化合物的加溶剂的用途
US9149543B2 (en)	2005-12-15	2015-10-06	The Trustees Of The University Of Pennsylvania	Methods and models for rapid, widespread delivery of genetic material to the CNS using non-viral, cationic lipid-mediated vectors
US20090246208A1 (en) *	2006-01-05	2009-10-01	Novartis Ag	Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis
WO2007082144A2 (en) *	2006-01-05	2007-07-19	Mayo Foundation For Medical Education And Research	B7-h1 and survivin in cancer
WO2007082154A2 (en) *	2006-01-05	2007-07-19	Mayo Foundation For Medical Education And Research	B7-h1 and b7-h4 in cancer
EP2264061A1 (de)	2006-01-26	2010-12-22	Recopharma AB	Zusammensetzung und verfahren zur Bekämpfung von viralen Infektionen
PT2161038E (pt)	2006-01-26	2014-03-10	Isis Pharmaceuticals Inc	Composições e suas utilizações dirigidas à huntingtina
US7829097B2 (en) *	2006-02-06	2010-11-09	University Of Pittsburgh - Of The Commonwealth System Of Higher Education	Use of HMGB1 for protection against ischemia reperfusion injury
WO2007114979A2 (en)	2006-02-17	2007-10-11	Genentech, Inc.	Gene disruptons, compositions and methods relating thereto
EP2540741A1 (de)	2006-03-06	2013-01-02	Aeres Biomedical Limited	Humanisierte Anti-CD22-Antikörper und ihre Verwendung bei der Behandlung von Krebs, Transplantationen und Autoimmunerkrankungen
US20070218116A1 (en) *	2006-03-14	2007-09-20	Schwendener Reto A	Compositions and methods for the treatment of tumors and tumor metastases
US9119782B2 (en) *	2006-03-20	2015-09-01	Mary P. McCourt	Drug delivery means
US20090220504A1 (en)	2006-03-21	2009-09-03	Anan Chuntharapai	Combinatorial therapy
EP2389947A1 (de)	2006-03-23	2011-11-30	Novartis AG	Antitumorzellenantigen-Antikörper-Therapeutika
KR101547579B1 (ko)	2006-03-31	2015-08-27	알닐람 파마슈티칼스 인코포레이티드	Ｅｇ5 유전자의 발현을 억제하는 이본쇄 리보핵산
WO2007126455A2 (en)	2006-04-05	2007-11-08	Genentech, Inc.	Method for using boc/cdo to modulate hedgehog signaling
US8758723B2 (en)	2006-04-19	2014-06-24	The Board Of Regents Of The University Of Texas System	Compositions and methods for cellular imaging and therapy
US20090288176A1 (en)	2006-04-19	2009-11-19	Genentech, Inc.	Novel Gene Disruptions, Compositions and Methods Relating Thereto
WO2007124361A2 (en) *	2006-04-20	2007-11-01	Mayo Foundation For Medical Education And Research	Soluble b7-h1
WO2007121522A1 (en)	2006-04-21	2007-11-01	Minister for Primary Industries For And On Behalf Of The State Of New South Wales	Pestivirus species
US7691824B2 (en)	2006-04-28	2010-04-06	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of a gene from the JC virus
EP2051585A4 (de) *	2006-04-28	2010-06-02	Univ South Florida	Materialien und verfahren zur unterdrückung von entzündungen durch hemmung des vorhof-rezeptors für natriuretische peptide
WO2007127428A2 (en) *	2006-04-28	2007-11-08	University Of Florida Research Foundation, Inc.	Double-stranded/self-complementary vectors with a truncated cba promoter and methods of gene delivery
WO2008018932A2 (en) *	2006-05-01	2008-02-14	The Board Of Trustees Of The Leland Stanford Junior University	Method and use of nano-scale devices for reduction of tissue injury in ischemic and reperfusion injury
CA2651031A1 (en) *	2006-05-03	2007-11-08	Baltic Technology Development, Ltd.	Antisense agents combining strongly bound base - modified oligonucleotide and artificial nuclease
WO2007133627A2 (en) *	2006-05-10	2007-11-22	Alza Corporation	Method for making liposomes conjugated with temperature-sensitive ligands
CA2652452C (en)	2006-05-15	2018-07-31	Sea Lane Biotechnologies, Llc	Neutralizing antibodies to influenza viruses
JP5282031B2 (ja) *	2006-05-15	2013-09-04	ドミトリィビーカーポティン	有機物を含む磁性微粒子
CN101489566B (zh)	2006-05-19	2012-04-18	阿尔尼拉姆医药品有限公司	Aha基因的RNAi调控及其治疗性应用
EP2029157A4 (de) *	2006-05-19	2009-11-18	Georgia Tech Res Inst	Abc-transporterligand
CA2653451C (en)	2006-05-22	2015-12-29	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of ikk-b gene
WO2007137301A2 (en) *	2006-05-23	2007-11-29	Isis Pharmaceuticals, Inc.	Modulation of chrebp expression
US8598333B2 (en) *	2006-05-26	2013-12-03	Alnylam Pharmaceuticals, Inc.	SiRNA silencing of genes expressed in cancer
US7862812B2 (en)	2006-05-31	2011-01-04	Lpath, Inc.	Methods for decreasing immune response and treating immune conditions
US7915399B2 (en) *	2006-06-09	2011-03-29	Protiva Biotherapeutics, Inc.	Modified siRNA molecules and uses thereof
CN101489593B (zh)	2006-06-19	2015-11-25	约翰·霍普金斯大学	通过脂质体酶的治疗剂肿瘤特异性递送
US7981425B2 (en)	2006-06-19	2011-07-19	Amgen Inc.	Thrombopoietic compounds
CA2654661C (en)	2006-06-26	2012-10-23	Amgen Inc.	Compositions comprising modified lcat and use thereof for treating atherosclerosis
EP2505209A1 (de)	2006-06-26	2012-10-03	MacroGenics, Inc.	Fcgamma-RIIB-spezifische Antikörper und Verfahren zu ihrer Anwendung
JP5072275B2 (ja)	2006-07-03	2012-11-14	テルモ株式会社	閉鎖小胞の分離方法、製剤の製造方法および評価方法
EP2471815B1 (de)	2006-07-11	2016-03-30	University Of Medicine And Dentistry Of New Jersey	Proteine, Nukleinsäuren zu deren Kodierung und entsprechende Verwendungsverfahren
US8343539B2 (en)	2006-07-14	2013-01-01	Regents Of The University Of Minnesota	Compounds that bind α5β1 integrin and methods of use
WO2008008873A2 (en) *	2006-07-14	2008-01-17	Georgia Tech Research Corporation	Clc channel ligand
AU2007275654A1 (en)	2006-07-19	2008-01-24	The Trustees Of The University Of Pennsylvania	WSX-1/p28 as a target for anti-inflammatory responses
US8198253B2 (en)	2006-07-19	2012-06-12	Isis Pharmaceuticals, Inc.	Compositions and their uses directed to HBXIP
JP4936312B2 (ja) *	2006-07-20	2012-05-23	株式会社島津製作所	新規な両親媒性物質、それを用いた薬剤搬送システム及び分子イメージングシステム
WO2008013918A2 (en) *	2006-07-26	2008-01-31	Myelin Repair Foundation, Inc.	Cell cycle regulation and differentiation
CN101626783A (zh) *	2006-08-04	2010-01-13	诺华有限公司	Ephb3-特异性抗体和其应用
JP5244103B2 (ja)	2006-08-09	2013-07-24	ホームステッドクリニカルコーポレイション	器官特異的蛋白質およびその使用方法
ES2457072T3 (es)	2006-08-14	2014-04-24	Xencor, Inc.	Anticuerpos optimizados que seleccionan como diana CD19
EP3415532A1 (de)	2006-08-18	2018-12-19	XOMA Technology Ltd.	Prlr-spezifischer antikörper und verwendungen davon
EP2423332A1 (de)	2006-08-25	2012-02-29	Oncotherapy Science, Inc.	Prognosemarker und therapeutische Targets für Lungenkrebs
BRPI0716088B8 (pt)	2006-08-28	2021-05-25	Kyowa Hakko Kirin Co Ltd	anticorpo isolado, composição, molécula de ácido nucléico isolada, vetor, método para produzir um anticorpo, hibridoma, e, kit
SG10201501498VA (en)	2006-08-29	2015-04-29	Genentech Inc	Use of tenecteplase for treating acute ischemic stroke
ES2519375T3 (es)	2006-09-01	2014-11-06	Zymogenetics, Inc.	Anticuerpos monoclonales IL-31 y procedimientos de uso
CA2600220C (en) *	2006-09-07	2014-12-09	Canadian Blood Services	Surface cross-linked lipidic particles, methods of production and uses therefor
CA2664738C (en)	2006-09-29	2017-03-07	Oncomed Pharmaceuticals, Inc.	Compositions and methods for diagnosing and treating cancer
EP2099467B1 (de)	2006-10-03	2017-05-10	University Of Medicine And Dentistry Of New Jersey	Atap-proteine, für diese kodierende nukleinsäuren und entsprechende verwendungsverfahren
US10925977B2 (en) *	2006-10-05	2021-02-23	Ceil>Point, LLC	Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications
US7803769B2 (en) *	2006-10-25	2010-09-28	Amgen Inc.	OSK1 peptide analogs and pharmaceutical compositions
JP5732182B2 (ja)	2006-10-27	2015-06-10	エルパス・インコーポレイテッドＬｐａｔｈ，Ｉｎｃ．	眼疾患と症状を処置するための組成物および方法
AU2007329759B2 (en)	2006-10-27	2013-05-30	Lpath, Inc.	Compositions and methods for binding sphingosine-1-phosphate
WO2008058291A2 (en)	2006-11-09	2008-05-15	California Institute Of Technology	Modular aptamer-regulated ribozymes
CA2669185A1 (en) *	2006-11-10	2008-05-15	Dimerix Bioscience Pty Ltd	Thyrotropin releasing hormone receptor-orexin receptor hetero-dimers/-oligomers
JP5313909B2 (ja) *	2006-11-13	2013-10-09	アイコスコーポレイション	炎症性疾患および癌の処置のためのチエノピリミジノン
AU2007325283B2 (en)	2006-11-27	2012-08-30	Diadexus, Inc.	Ovr110 antibody compositions and methods of use
WO2008070780A1 (en)	2006-12-07	2008-06-12	Novartis Ag	Antagonist antibodies against ephb3
EP1932517A3 (de) *	2006-12-11	2008-07-16	Universiteit Utrecht Holding B.V.	Liposomen beinhaltend Polyphenolderivaten und deren Verfahren zur Nachbeladung
WO2008076964A1 (en) *	2006-12-18	2008-06-26	The Johns Hopkins University	Therapeutics for cancer using 3-bromopyruvate and other selective inhibitors of atp production
US8536113B2 (en) *	2006-12-21	2013-09-17	Janssen Biotech, Inc.	EGFR binding peptides and uses thereof
US8834920B2 (en)	2006-12-21	2014-09-16	Alza Corporation	Liposome composition for targeting egfr receptor
WO2008079976A2 (en)	2006-12-21	2008-07-03	Centocor, Inc.	Dimeric high affinity egfr constructs and uses thereof
US20100129358A1 (en)	2006-12-22	2010-05-27	University Of Utah Research Foundation	Method of detecting ocular diseases and pathologic conditions and treatment of same
US8440185B2 (en) *	2006-12-26	2013-05-14	The Johns Hopkins University	Compositions and methods for the treatment of immunologic disorders
US7989173B2 (en)	2006-12-27	2011-08-02	The Johns Hopkins University	Detection and diagnosis of inflammatory disorders
AU2007339762B2 (en)	2006-12-27	2011-03-31	The Johns Hopkins University	Compositions and methods for treating inflammation and auto-immune diseases
US20090142342A1 (en) *	2006-12-27	2009-06-04	Johns Hopkins University	B7-h4 receptor agonist compositions and methods for treating inflammation and auto-immune diseases
US7638541B2 (en)	2006-12-28	2009-12-29	Metabolex Inc.	5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
US8048998B2 (en) *	2007-01-19	2011-11-01	Exiqon A/S	Mediated cellular delivery of LNA oligonucleotides
US20100329664A1 (en) *	2007-01-23	2010-12-30	Lim Dae-Soon	Shutter device for camera
WO2008094945A2 (en)	2007-01-29	2008-08-07	Isis Pharmaceuticals, Inc.	Compounds and methods for modulating protein expression
US8389482B2 (en)	2007-01-30	2013-03-05	New York University	Short peptides useful for treatment of ischemia/reperfusion injury and other tissue damage conditions associated with nitric oxide and its reactive species
KR101508397B1 (ko)	2007-02-22	2015-04-08	제넨테크, 인크.	염증성 장 질환의 검출 방법
WO2008109440A2 (en)	2007-03-02	2008-09-12	Genentech, Inc.	Predicting response to a her dimerisation inhibitor based on low her3 expression
CA2681302C (en) *	2007-03-19	2013-07-23	Dhiraj Khattar	Proliposomal and liposomal compositions of poorly water-soluble compounds
JP4510842B2 (ja) *	2007-03-26	2010-07-28	キヤノン株式会社	ポリヒドロキシアルカノエート被覆リポソーム
JP5350360B2 (ja)	2007-03-29	2013-11-27	アルナイラムファーマシューティカルズ，インコーポレイテッド	エボラ由来の遺伝子の発現を阻害するための組成物および方法
SG194368A1 (en)	2007-05-04	2013-11-29	Technophage Investigacao E Desenvolvimento Em Biotecnologia Sa	Engineered rabbit antibody variable domains and uses thereof
EP2703011A3 (de)	2007-05-07	2014-03-26	MedImmune, LLC	Anti-Icos-Antikörper und ihre Verwendung bei der Behandlung von Krebs, Transplantationen und Autoimmunerkrankungen
WO2008141276A1 (en) *	2007-05-11	2008-11-20	Centocor, Inc.	Anti-alpha-v immunoliposome composition, methods and uses
WO2008141274A1 (en)	2007-05-11	2008-11-20	Centocor, Inc.	Anti-alpha v immunoliposome composition, methods and uses
WO2008141278A1 (en) *	2007-05-11	2008-11-20	Centocor, Inc.	Method for preparing antibody conjugates
ES2441189T3 (es)	2007-05-14	2014-02-03	Novimmune Sa	Polipéptidos de unión al receptor de Fc con funciones efectoras modificadas
EP2160200B1 (de)	2007-05-14	2013-07-10	The University of Chicago	Antikörper-LIGHT-Fusionsprodukte als Krebstherapeutika
WO2008153745A2 (en)	2007-05-22	2008-12-18	Amgen Inc.	Compositions and methods for producing bioactive fusion proteins
WO2008148023A2 (en) *	2007-05-23	2008-12-04	Medical College Of Georgia Research Institute, Inc.	Compositions and methods for treating neurological disorders
AU2008256644B2 (en)	2007-05-24	2014-07-03	The United States Government As Represented By The Department Of Veterans Affairs	Intranuclear protein transduction through a nucleoside salvage pathway
DK2176298T3 (en) *	2007-05-30	2018-02-12	Xencor Inc	Methods and compositions for inhibiting CD32B-expressing cells
US9163091B2 (en) *	2007-05-30	2015-10-20	Lpath, Inc.	Compositions and methods for binding lysophosphatidic acid
JP5989299B2 (ja)	2007-05-30	2016-09-07	エルパス・インコーポレイテッドＬｐａｔｈ，Ｉｎｃ．	リゾホスファチジン酸結合のための組成物と方法
AR066984A1 (es)	2007-06-15	2009-09-23	Novartis Ag	Inhibicion de la expresion de la subunidad alfa del canal epitelial de sodio (enac) por medio de arni (arn de interferencia)
TW200916094A (en) *	2007-06-27	2009-04-16	Poniard Pharmaceuticals Inc	Stabilized picoplatin dosage form
CN101784564B (zh)	2007-07-13	2014-07-02	约翰霍普金斯大学	B7-dc变体
WO2009011855A2 (en) *	2007-07-16	2009-01-22	California Institute Of Technology	Selection of nucleic acid-based sensor domains within nucleic acid switch platform
PL2474557T3 (pl)	2007-07-16	2015-02-27	Genentech Inc	Przeciwciała anty- CD79b i immunokoniugaty i sposoby stosowania
US9845355B2 (en)	2007-07-16	2017-12-19	Genentech, Inc.	Humanized anti-CD79b antibodies and immunoconjugates and methods of use
CA2693169C (en) *	2007-07-19	2016-01-12	Metabolex, Inc.	N-linked heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders
EP2489730B1 (de)	2007-07-26	2015-12-30	Amgen, Inc	Modifizierte Lecithin-Cholesterin-Acyltransferase-Enzyme
CN101765616A (zh) *	2007-07-26	2010-06-30	巴斯夫欧洲公司	制备通过接枝聚合在溶液中获得的并基于固体聚醚的共聚物的方法
US7666973B2 (en)	2007-07-30	2010-02-23	Tyco Healthcare Group Lp	Carbonate copolymers
US8461303B2 (en)	2007-08-02	2013-06-11	Gilead Biologics, Inc.	LOX and LOXL2 inhibitors and uses thereof
KR20100046185A (ko) *	2007-08-09	2010-05-06	다이이찌 산쿄 가부시키가이샤	데스 도메인 함유 수용체 발현 세포에 아포토시스를 유도하는 이뮤노리포솜
US20090048423A1 (en) *	2007-08-15	2009-02-19	Tyco Healthcare Group Lp	Phospholipid Copolymers
US8268958B2 (en)	2007-08-15	2012-09-18	Tyco Healthcare Group Ip	Phospholipid copolymers
US8367815B2 (en) *	2007-08-28	2013-02-05	California Institute Of Technology	Modular polynucleotides for ligand-controlled regulatory systems
US20120165387A1 (en)	2007-08-28	2012-06-28	Smolke Christina D	General composition framework for ligand-controlled RNA regulatory systems
AU2008296012A1 (en) *	2007-09-07	2009-03-12	Gencia Corporation	Mitochondrial compositions and uses thereof
US8865667B2 (en) *	2007-09-12	2014-10-21	California Institute Of Technology	Higher-order cellular information processing devices
US20110014118A1 (en) *	2007-09-21	2011-01-20	Lawrence Tamarkin	Nanotherapeutic colloidal metal compositions and methods
KR20100123674A (ko) *	2007-09-21	2010-11-24	싸이티뮨 사이언스, 인크.	나노치료제 콜로이드성 금속 조성물 및 방법
CN101827613A (zh) *	2007-09-27	2010-09-08	免疫疫苗技术有限公司	在包括连续疏水相的载体中的脂质体在体内输送多核苷酸中的应用
CN101878229A (zh) *	2007-09-28	2010-11-03	巴塞尔大学医院	用于治疗癌症的免疫脂质体
CA2700953A1 (en)	2007-10-02	2009-04-09	Amgen Inc.	Increasing erythropoietin using nucleic acids hybridizable to micro-rna and precursors thereof
US20100209452A1 (en) *	2007-10-03	2010-08-19	Immunovaccine Technologies, Inc	Compositions comprising an antigen, an amphipathic compound and a hydrophobic carrier, and uses thereof
WO2009050738A2 (en) *	2007-10-16	2009-04-23	Biocon Limited	An orally administerable solid pharmaceutical composition and a process thereof
US8361465B2 (en) *	2007-10-26	2013-01-29	Lpath, Inc.	Use of anti-sphingosine-1-phosphate antibodies in combination with chemotherapeutic agents
BRPI0819193A2 (pt) *	2007-11-05	2017-05-23	Baltic Tech Dev Ltd	uso de oligonucleotídeos com bases modificadas na hibridização de ácidos nucleicos.
JP5767475B2 (ja)	2007-11-05	2015-08-19	メディミューン，エルエルシー	強皮症の治療方法
CN104888193A (zh)	2007-11-07	2015-09-09	健泰科生物技术公司	用于治疗微生物病症的组合物和方法
US20110033476A1 (en) *	2007-11-12	2011-02-10	Theraclone Sciences Inc.	Compositions and methods for the therapy and diagnosis of influenza
MX2010005244A (es)	2007-11-12	2010-10-25	Theraclone Sciences Inc	Composiciones y métodos para la terapia y el diagnóstico de influenza.
US8598165B2 (en) *	2007-11-26	2013-12-03	University Of Kansas	Morpholines as selective inhibitors of cytochrome P450 2A13
EP2222701B1 (de)	2007-12-06	2017-11-01	Dana-Farber Cancer Institute, Inc.	Antikörper gegen influenza-virus und deren verwendung
BRPI0820099A2 (pt)	2007-12-07	2020-11-24	Zymogenetics, Inc	anticorpo isolado ou fragmento de anticorpo, composição farmacêutica, e, uso de um anticorpo ou fragmento de anticorpo
JP5530933B2 (ja)	2007-12-10	2014-06-25	アルナイラムファーマシューティカルズ，インコーポレイテッド	第ｖｉｉ因子遺伝子発現阻害のための組成物及び方法
US9029524B2 (en) *	2007-12-10	2015-05-12	California Institute Of Technology	Signal activated RNA interference
JP5737944B2 (ja)	2007-12-17	2015-06-17	ファイザー・リミテッドＰｆｉｚｅｒＬｉｍｉｔｅｄ	間質性膀胱炎の治療
US8962806B2 (en)	2007-12-28	2015-02-24	Dana-Farber Cancer Institute, Inc.	Humanized monoclonal antibodies and methods of use
EP2224912B1 (de)	2008-01-02	2016-05-11	TEKMIRA Pharmaceuticals Corporation	Verbesserte zusammensetzungen und verfahren zur freisetzung von nukleinsäuren
US20090181094A1 (en) *	2008-01-15	2009-07-16	Eric Yueh-Lang Sheu	Molecular Cage for Sustained Release Control of Pharmaceutical and Cosmetic Agents
AR070141A1 (es) *	2008-01-23	2010-03-17	Glenmark Pharmaceuticals Sa	Anticuerpos humanizados especificos para el factor von willebrand
TWI472339B (zh)	2008-01-30	2015-02-11	Genentech Inc	包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
RU2553566C2 (ru)	2008-01-31	2015-06-20	Дженентек, Инк.	АНТИ-CD79b АНТИТЕЛА И ИММУНОКОНЪЮГАТЫ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
WO2009111315A2 (en) *	2008-02-29	2009-09-11	Mayo Foundation For Medical Education And Research	Methods for reducing granulomatous inflammation
JP2011518117A (ja) *	2008-03-05	2011-06-23	アルナイラムファーマシューティカルズ，インコーポレイテッド	Ｅｇ５およびＶＥＧＦ遺伝子の発現を阻害するための組成物および方法
ES2542308T3 (es) *	2008-03-10	2015-08-04	Theraclone Sciences, Inc.	Composiciones y métodos para la terapia y diagnóstico de infecciones por citomegalovirus
EP2105145A1 (de) *	2008-03-27	2009-09-30	ETH Zürich	Verfahren zur muskelspezifischen Abgabe lipidkonjugierter Oligonukleotide
JP2011516423A (ja)	2008-03-28	2011-05-26	シーレーンバイオテクノロジーズ，エルエルシー	ウイルス抗原に対する中和分子
AU2009231906A1 (en) *	2008-03-31	2009-10-08	Metabolex, Inc.	Oxymethylene aryl compounds and uses thereof
CA2720473A1 (en)	2008-04-04	2009-10-08	Calando Pharmaceuticals, Inc.	Compositions and use of epas1 inhibitors
CN104655854A (zh)	2008-04-09	2015-05-27	健泰科生物技术公司	用于免疫相关疾病的治疗的新组合物和方法
CA2718975A1 (en)	2008-04-10	2009-10-15	Cell Signaling Technology, Inc.	Compositions and methods for detecting egfr mutations in cancer
NZ588583A (en)	2008-04-15	2012-08-31	Protiva Biotherapeutics Inc	Novel lipid formulations for nucleic acid delivery
US8324366B2 (en)	2008-04-29	2012-12-04	Alnylam Pharmaceuticals, Inc.	Compositions and methods for delivering RNAI using lipoproteins
EP2280995A2 (de) *	2008-04-29	2011-02-09	Wyeth LLC	Verfahren zur behandlung von entzündungen
US20090280104A1 (en) *	2008-05-09	2009-11-12	Recopharma Ab	Compositions and methods for inhibiting shiga toxin and shiga-like toxin
US20090280134A1 (en) *	2008-05-09	2009-11-12	Recopharma Ab	Compositions and methods for inhibiting toxin a from clostridium difficile
AU2009246071B2 (en)	2008-05-16	2013-10-03	Genentech, Inc.	Use of biomarkers for assessing treatment of gastrointestinal inflammatory disorders with beta7integrin antagonists
US8093018B2 (en)	2008-05-20	2012-01-10	Otsuka Pharmaceutical Co., Ltd.	Antibody identifying an antigen-bound antibody and an antigen-unbound antibody, and method for preparing the same
CN102036658A (zh) *	2008-05-23	2011-04-27	香港大学	治疗流感的联合疗法
WO2009148121A1 (ja)	2008-06-05	2009-12-10	株式会社島津製作所	新規な分子集合体、それを用いた分子イメージング用分子プローブ及び薬剤搬送システム用分子プローブ、並びに分子イメージングシステム及び薬剤搬送システム
EP2296696B1 (de) *	2008-06-05	2014-08-27	ImmunoVaccine Technologies Inc.	Zusammensetzungen mit liposomen, einem antigen, einem polynucleotid und einem träger mit einer kontinuierlichen phase einer hydrophoben substanz
US8173621B2 (en)	2008-06-11	2012-05-08	Gilead Pharmasset Llc	Nucleoside cyclicphosphates
WO2009150623A1 (en)	2008-06-13	2009-12-17	Pfizer Inc	Treatment of chronic prostatitis
US20110104074A1 (en) *	2008-06-18	2011-05-05	University Of Louisville Research Foundation, Inc.	Methods for targeted cancer treatment and detection
US20100003315A1 (en) *	2008-07-02	2010-01-07	Willeford Kenneth L	Method and Composition for the Treatment of Skin Conditions
SG192467A1 (en)	2008-07-08	2013-08-30	Oncomed Pharm Inc	Notch1 receptor binding agents and methods of use thereof
CN102149749B (zh) *	2008-07-10	2014-06-25	塞瑞纳治疗公司	具有惰性端基的聚噁唑啉、由被保护的引发基团制备的聚噁唑啉以及相关化合物
US20100008900A1 (en) *	2008-07-14	2010-01-14	The University Of Hong Kong	Annexin ii compositions for treating or monitoring inflammation or immune-mediated disorders
WO2010008582A2 (en)	2008-07-18	2010-01-21	Rxi Pharmaceuticals Corporation	Phagocytic cell drug delivery system
WO2010017509A1 (en) *	2008-08-07	2010-02-11	Isis Pharmaceuticals, Inc.	Modulation of transthyretin expression for the treatment of cns related disorders
WO2010019702A2 (en)	2008-08-12	2010-02-18	Oncomed Pharmaceuticals, Inc.	Ddr1-binding agents and methods of use thereof
CN102186820B (zh)	2008-08-15	2013-08-28	乔治城大学	Rassf1a表达和人癌细胞增殖的荧光调节剂
WO2010021750A2 (en)	2008-08-21	2010-02-25	The Johns Hopkins University	Methods and compositions for administration of 3-halopyruvate and related compounds for the treatment of cancer
SI2367812T1 (sl) *	2008-08-22	2016-01-29	Sanofi	(4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il)-(7-fluoro-1-(2-metoksi- etil)-4trifluorometoksi-1H-indol-3-il)metanon kot inhibitor mastocitne triptaze
DK2350129T3 (en)	2008-08-25	2015-08-31	Amplimmune Inc	PREPARATIONS WITH PD-1 ANTAGONISTS AND PROCEDURES FOR USE THEREOF
EP3081648A1 (de)	2008-08-25	2016-10-19	Excaliard Pharmaceuticals, Inc.	Gegen den bindegewebe-wachstumsfaktor gerichtete antisense-oligonukleotide und verwendungen davon
CA2736799A1 (en)	2008-08-25	2010-03-11	Burnham Institute For Medical Research	Conserved hemagglutinin epitope, antibodies to the epitope, and methods of use
KR20110074850A (ko) *	2008-08-25	2011-07-04	앰플리뮨, 인크.	Ｐｄ-１ 길항제 및 그의 사용 방법
WO2010028054A1 (en)	2008-09-02	2010-03-11	Alnylam Europe Ag.	Compositions and methods for inhibiting expression of mutant egfr gene
CN102149728B (zh)	2008-09-10	2014-10-15	霍夫曼-拉罗奇有限公司	抑制眼部血管生成的方法
TWI516501B (zh)	2008-09-12	2016-01-11	禮納特神經系統科學公司	Ｐｃｓｋ９拮抗劑類
AR073295A1 (es)	2008-09-16	2010-10-28	Genentech Inc	Metodos para tratar la esclerosis multiple progresiva. articulo de fabricacion.
JP2012502991A (ja)	2008-09-22	2012-02-02	アールエックスアイファーマシューティカルズコーポレーション	皮膚適用におけるｒｎａ干渉
EP2334793B1 (de)	2008-09-25	2016-04-06	Alnylam Pharmaceuticals, Inc.	Zusammensetzungen und verfahren zur hemmung der expression des serumamyloid-a-gens
WO2010042823A1 (en)	2008-10-09	2010-04-15	Northeastern Universtiy	Multifunctional self-assembling polymeric nanosystems
WO2010042877A1 (en)	2008-10-09	2010-04-15	Tekmira Pharmaceuticals Corporation	Improved amino lipids and methods for the delivery of nucleic acids
EA029762B1 (ru)	2008-10-20	2018-05-31	Элнилэм Фармасьютикалз, Инк.	Композиции и способы для ингибирования экспрессии транстиретина
JP5382380B2 (ja) *	2008-10-21	2014-01-08	インターナショナルワクチンインスティテュート	新規のシゲラタンパク質抗原及び方法
MX2011004125A (es)	2008-10-21	2011-05-19	Metabolex Inc	Agonistas del receptor gpr120 de arilo y usos de los mismos.
US8871202B2 (en)	2008-10-24	2014-10-28	Lpath, Inc.	Prevention and treatment of pain using antibodies to sphingosine-1-phosphate
AU2009312532B2 (en) *	2008-11-06	2013-05-16	Ichnos Sciences SA	Treatment with anti-alpha2 integrin antibodies
KR20220150995A (ko)	2008-11-10	2022-11-11	알닐람 파마슈티칼스 인코포레이티드	치료제 운반용 신규 지질 및 조성물
US9492449B2 (en)	2008-11-13	2016-11-15	Gilead Calistoga Llc	Therapies for hematologic malignancies
CN102271683B (zh)	2008-11-13	2014-07-09	吉里德卡利斯托加公司	恶性血液病的治疗
HUE032693T2 (en)	2008-11-22	2017-10-30	Hoffmann La Roche	Use of anti-vegf antibody in combination with chemotherapy to treat breast cancer
US20110230399A1 (en) *	2008-11-25	2011-09-22	Bowen Richard L	Methods for Treating Obesity Related Disease
US20110160222A1 (en) *	2008-11-26	2011-06-30	Metabolex, Inc.	Modulators of glucose homeostasis for the treatment of diabetes and metabolic disorders
ES2637063T3 (es)	2008-12-04	2017-10-10	Curna, Inc.	Tratamiento de enfermedades relacionadas con genes supresores de tumor mediante inhibición del transcrito antisentido natural al gen
WO2010065792A2 (en)	2008-12-04	2010-06-10	Curna, Inc.	Treatment of erythropoietin (epo) related diseases by inhibition of natural antisense transcript to epo
MX366774B (es)	2008-12-04	2019-07-24	Curna Inc	Uso de oligonucleótidos antisentido en la inhibición de transcrito antisentido natural para sirtuina 1.
US8628762B2 (en)	2008-12-10	2014-01-14	Icahn School Of Medicine At Mount Sinai	T-helper cell type 17 lineage-specific adjuvants, compositions and methods
WO2010068816A1 (en)	2008-12-10	2010-06-17	Alnylam Pharmaceuticals, Inc.	Gnaq targeted dsrna compositions and methods for inhibiting expression
AR074760A1 (es) *	2008-12-18	2011-02-09	Metabolex Inc	Agonistas del receptor gpr120 y usos de los mismos en medicamentos para el tratamiento de diabetes y el sindrome metabolico.
TW201034675A (en)	2008-12-18	2010-10-01	Sanofi Aventis	Method for treating macular degeneration
EP2381964B1 (de)	2008-12-22	2014-06-25	Creabilis S.a.	Synthese von polymerkonjugaten von indolocarbazol-verbindungen
WO2010075249A2 (en)	2008-12-22	2010-07-01	Genentech, Inc.	A method for treating rheumatoid arthritis with b-cell antagonists
CN102753563A (zh)	2008-12-23	2012-10-24	吉利德制药有限责任公司	核苷类似物
AR074977A1 (es)	2008-12-23	2011-03-02	Pharmasset Inc	Sintesis de nucleosidos de purina
PT2376088T (pt)	2008-12-23	2017-05-02	Gilead Pharmasset Llc	Fosforamidatos de nucleósidos de 2-amino-purina 6-osubstituída
US9493774B2 (en)	2009-01-05	2016-11-15	Rxi Pharmaceuticals Corporation	Inhibition of PCSK9 through RNAi
CA2751342C (en)	2009-01-29	2019-05-07	Alnylam Pharmaceuticals, Inc.	Lipid formulations comprising cationic lipid and a targeting lipid comprising n-acetyl galactosamine for delivery of nucleic acid
WO2010086828A2 (en)	2009-02-02	2010-08-05	Rinat Neuroscience Corporation	Agonist anti-trkb monoclonal antibodies
WO2010090762A1 (en)	2009-02-04	2010-08-12	Rxi Pharmaceuticals Corporation	Rna duplexes with single stranded phosphorothioate nucleotide regions for additional functionality
PL2396038T3 (pl)	2009-02-12	2016-05-31	Curna Inc	Leczenie chorób związanych z neurotropowym czynnikiem pochodzenia mózgowego (bdnf) poprzez zahamowanie naturalnego antysensownego transkryptu bdnf
US20110319476A1 (en)	2009-02-12	2011-12-29	Opko Curna, Llc	Treatment of glial cell derived neurotrophic factor (gdnf) related diseases by inhibition of natural antisense transcript to gdnf
US8329882B2 (en)	2009-02-18	2012-12-11	California Institute Of Technology	Genetic control of mammalian cells with synthetic RNA regulatory systems
WO2010099341A1 (en)	2009-02-26	2010-09-02	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of mig-12 gene
US8975389B2 (en)	2009-03-02	2015-03-10	Alnylam Pharmaceuticals, Inc.	Nucleic acid chemical modifications
EP2403946A4 (de)	2009-03-04	2012-11-14		Behandlung von sirtuin 1 (sirt1)-bedingten erkrankungen mittels hemmung des natürlichen antisense-transkripts gegen sirt 1
JP6032724B2 (ja)	2009-03-12	2016-11-30	アルナイラムファーマシューティカルズ，インコーポレイテッドＡｌｎｙｌａｍＰｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ．	脂質製剤組成物およびＥｇ５遺伝子とＶＥＧＦ遺伝子の発現を阻害する方法
EP2228059A1 (de)	2009-03-12	2010-09-15	Universitätsspital Basel	Chemotherapeutische Zusammensetzung für die Krebsbehandlung
US9464287B2 (en)	2009-03-16	2016-10-11	Curna, Inc.	Treatment of nuclear factor (erythroid-derived 2)-like 2 (NRF2) related diseases by inhibition of natural antisense transcript to NRF2
CA2755404C (en)	2009-03-17	2020-03-24	Joseph Collard	Treatment of delta-like 1 homolog (dlk1) related diseases by inhibition of natural antisense transcript to dlk1
SI3260136T1 (sl)	2009-03-17	2021-05-31	Theraclone Sciences, Inc.	Humani imunodeficientni virus (HIV)-nevtralizirajoča protitelesa
EA019499B1 (ru)	2009-03-24	2014-04-30	ГИЛИЭД КАЛИСТОГА ЭлЭлСи	Производные атропоизомеров 2-пуринил-3-толилхиназолинона и способы применения
US8124740B2 (en)	2009-03-25	2012-02-28	Genentech, Inc.	Anti- α5 β1 antibodies and uses thereof
CA2752908A1 (en)	2009-04-01	2010-10-07	Genentech, Inc.	Treatment of insulin-resistant disorders
NZ595574A (en)	2009-04-01	2013-11-29	Genentech Inc	Anti-fcrh5 antibodies and immunoconjugates and methods of use
US9145555B2 (en)	2009-04-02	2015-09-29	California Institute Of Technology	Integrated—ligand-responsive microRNAs
EP2421536B1 (de) *	2009-04-20	2015-08-26	Gilead Calistoga LLC	Verfahren zur behandlung von soliden tumoren
EP3248618A1 (de)	2009-04-22	2017-11-29	Massachusetts Institute Of Technology	Angeborene immununterdrückung mit ermöglichung der wiederholten verabreichung von langen rna-molekülen
CA2759506A1 (en)	2009-04-23	2010-10-28	Theraclone Sciences, Inc.	Granulocyte-macrophage colony-stimulating factor (gm-csf) neutralizing antibodies
JP2012525149A (ja)	2009-04-27	2012-10-22	オンコメッドファーマシューティカルズインコーポレイテッド	ヘテロ多量体分子を作製するための方法
EP2248903A1 (de)	2009-04-29	2010-11-10	Universitat Autònoma De Barcelona	Verfahren und Reagenzien zum effizienten und gezielten Gentransfer in Monozyten und Makrophagen
US8524783B2 (en)	2009-04-30	2013-09-03	Intezyne Technologies, Incorporated	Polymer micelles containing anthracylines for the treatment of cancer
US8524784B2 (en)	2009-04-30	2013-09-03	Intezyne Technologies, Incorporated	Polymer micelles containing anthracylines for the treatment of cancer
US8318690B2 (en)	2009-05-01	2012-11-27	Curna, Inc.	Treatment of hemoglobin (HBF/HBG) related diseases by inhibition of natural antisense transcript to HBF/HBG
SG10201402054UA (en)	2009-05-05	2014-09-26	Muthiah Manoharan	Lipid compositions
AU2010245933B2 (en)	2009-05-05	2016-06-16	Arbutus Biopharma Corporation	Methods of delivering oligonucleotides to immune cells
AU2010244142B2 (en)	2009-05-05	2016-07-21	Novimmune Sa	Anti-IL-17F antibodies and methods of use thereof
ES2609655T3 (es)	2009-05-06	2017-04-21	Curna, Inc.	Tratamiento de enfermedades relacionadas con tristetraprolina (TTP) mediante inhibición de transcrito antisentido natural para TTP
CN106237345A (zh)	2009-05-06	2016-12-21	库尔纳公司	通过针对脂质转运和代谢基因的天然反义转录物的抑制治疗脂质转运和代谢基因相关疾病
JP5922017B2 (ja)	2009-05-18	2016-05-24	クルナ・インコーポレーテッド	リプログラミング因子に対する天然アンチセンス転写物の抑制によるリプログラミング因子関連疾患の治療
US20120128673A1 (en)	2009-05-20	2012-05-24	Schering Corporation	Modulation of pilr receptors to treat microbial infections
TWI576352B (zh)	2009-05-20	2017-04-01	基利法瑪席特有限責任公司	核苷磷醯胺
EP2432803A2 (de)	2009-05-20	2012-03-28	Theraclone Sciences, Inc.	Zusammensetzungen und verfahren zur therapie und diagnose von grippe
WO2010135695A2 (en)	2009-05-22	2010-11-25	Curna, Inc.	TREATMENT OF TRANSCRIPTION FACTOR E3 (TFE3) and INSULIN RECEPTOR SUBSTRATE 2 (IRS2) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO TFE3
EP2435571B1 (de)	2009-05-28	2016-12-14	CuRNA, Inc.	Behandlung von durch antivirale gene bedingten erkrankungen mittels hemmung des natürlichen antisense-transkripts gegen ein antivirales gen
CN104873464B (zh)	2009-06-10	2018-06-22	阿布特斯生物制药公司	改进的脂质制剂
EP2440250A1 (de)	2009-06-11	2012-04-18	Yissum Research Development Company of the Hebrew University of Jerusalem, Ltd.	Gezielt ausgerichtete liposome mit n-haltigen bisphosphonaten und ihre verwendung
ES2629339T3 (es)	2009-06-16	2017-08-08	Curna, Inc.	Tratamiento de enfermedades relacionadas con la paraoxonasa 1 (pon1) por inhibición de transcrito antisentido natural a pon1
KR101801404B1 (ko)	2009-06-16	2017-12-20	큐알엔에이, 인크.	콜라겐 유전자에 대한 천연 안티센스 전사체의 억제에 의한 콜라겐 유전자 관련된 질환의 치료
WO2010146511A1 (en)	2009-06-17	2010-12-23	Pfizer Limited	Treatment of overactive bladder
CA2765889A1 (en)	2009-06-24	2010-12-29	Opko Curna, Llc	Treatment of tumor necrosis factor receptor 2 (tnfr2) related diseases by inhibition of natural antisense transcript to tnfr2
KR101807324B1 (ko)	2009-06-26	2017-12-08	큐알엔에이, 인크.	다운 증후군 유전자에 대한 천연 안티센스 전사체의 억제에 의한 다운 증후군 유전자 관련된 질환의 치료
TWI560271B (en)	2009-06-26	2016-12-01	Sealane Biotechnologies Llc	Expression of surrogate light chains
WO2011000384A1 (ru)	2009-06-30	2011-01-06	Общество С Ограниченной Ответсвенностью "Онкомакс"	Способ подавления роста опухоли путем блокирования рецептора фактора роста фибробластов, способ диагностики злокачественных новообразований
US9018187B2 (en)	2009-07-01	2015-04-28	Protiva Biotherapeutics, Inc.	Cationic lipids and methods for the delivery of therapeutic agents
US8283333B2 (en)	2009-07-01	2012-10-09	Protiva Biotherapeutics, Inc.	Lipid formulations for nucleic acid delivery
WO2011000106A1 (en)	2009-07-01	2011-01-06	Protiva Biotherapeutics, Inc.	Improved cationic lipids and methods for the delivery of therapeutic agents
CN102471381A (zh)	2009-07-07	2012-05-23	霍夫曼-拉罗奇有限公司	自身免疫性脱髓鞘疾病的诊断和治疗
US8920775B2 (en)	2009-07-17	2014-12-30	Technical University Of Denmark	Loading technique for preparing radionuclide containing nanoparticles
WO2011011550A1 (en)	2009-07-21	2011-01-27	Calistoga Pharmaceuticals Inc.	Treatment of liver disorders with pi3k inhibitors
WO2011017297A2 (en)	2009-08-03	2011-02-10	The University Of North Carolina At Chapel Hill	Biodegradable delivery system complexes for the delivery of bioactive compounds
CA2769665A1 (en)	2009-08-05	2011-02-10	Opko Curna, Llc	Treatment of insulin gene (ins) related diseases by inhibition of natural antisense transcript to an insulin gene (ins)
AP2015008874A0 (en)	2009-08-14	2015-11-30	Alnylam Pharmaceuticals Inc	Lipid formulated compositions and methods for inhibiting expression of a gene from the ebola virus
TW201431558A (zh)	2009-08-15	2014-08-16	建南德克公司	用於治療先前治療過之乳癌之抗-血管新生療法
FR2955324A1 (fr)	2010-01-15	2011-07-22	Sanofi Aventis	[4-(5-aminomethyl-phenyl)-piperidin-1-yl]-1h-indol-3-yl]-methanones disubstituees
KR101892760B1 (ko)	2009-08-25	2018-08-28	큐알엔에이, 인크.	ＩＱＧＡＰ에 대한 천연 안티센스 전사체의 억제에 의한 ＧＴＰａｓｅ 활성화 단백질을 함유하는 ＩＱ 모티프(ＩＱＧＡＰ)와 관련된 질환의 치료
JP2013503205A (ja)	2009-08-31	2013-01-31	アンプリミューン，インコーポレイテッド	移植拒絶反応を阻害するための方法および組成物
US20110059111A1 (en)	2009-09-01	2011-03-10	Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center	Mammalian receptors as targets for antibody and active vaccination therapy against mold infections
DK2473522T3 (en)	2009-09-02	2016-11-28	Genentech Inc	Smoothened MUTANT AND METHODS OF USING THE SAME
WO2011041154A1 (en)	2009-10-01	2011-04-07	Metabolex, Inc.	Substituted tetrazol-1-yl-phenoxymethyl-thiazol-2-yl-piperidinyl-pyrimidine salts
EP2488210A4 (de)	2009-10-12	2014-04-30	Smith Holdings Llc	Verfahren und zusammensetzungen zur modulation der genexpression mit in-vivo oder in-vitro verabreichten arzneistoffen auf oligonukleotidbasis
CN102656266B (zh) *	2009-10-15	2016-08-03	霍夫曼-拉罗奇有限公司	具有改变的受体特异性的嵌合成纤维细胞生长因子
ES2575152T3 (es)	2009-10-16	2016-06-24	Oncomed Pharmaceuticals, Inc.	Combinación terapéutica y uso de anticuerpos antagonistas de DLL4 y agentes antihipertensores
WO2011049625A1 (en)	2009-10-20	2011-04-28	Mansour Samadpour	Method for aflatoxin screening of products
RU2539772C2 (ru)	2009-10-22	2015-01-27	Дженентек, Инк.	Способы и композиции для модуляции гепсином стимулирующего макрофаги белка
AU2010316780B2 (en)	2009-11-05	2015-07-16	Rhizen Pharmaceuticals Sa	Novel benzopyran kinase modulators
US20120244169A1 (en)	2009-11-06	2012-09-27	Fibrogen, Inc.	Treatment for Radiation-Induced Disorders
EP3037435B1 (de)	2009-11-17	2019-08-07	MUSC Foundation for Research Development	Humane monoklonale antikörper gegen menschliches nukleolin
PE20121584A1 (es)	2009-11-30	2012-11-29	Genentech Inc	Composiciones y metodos para el diagnostico y el tratamiento de tumores
WO2011071957A1 (en)	2009-12-07	2011-06-16	Sea Lane Biotechnologies, Llc	Conjugates comprising an antibody surrogate scaffold with improved pharmacokinetic properties
CA3044884A1 (en)	2009-12-07	2011-06-16	Arbutus Biopharma Corporation	Compositions for nucleic acid delivery
JP2013513588A (ja)	2009-12-11	2013-04-22	ジーンコードエーエス	Ｇｄｎｆファミリーリガンド（ｇｆｌ）のミメティックまたはｒｅｔシグナル経路活性化因子を用いた、神経系細胞の生存を容易にするための方法
WO2011081904A1 (en)	2009-12-14	2011-07-07	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Delivery of transthyretin across the blood-brain barrier as a treatment for alzheimer's disease
ES2661813T3 (es)	2009-12-16	2018-04-04	Curna, Inc.	Tratamiento de enfermedades relacionadas con la peptidasa del factor de transcripción de membrana, sitio 1 (mbtps1) mediante inhibición del transcrito antisentido natural al gen mbtps1
US8691227B2 (en)	2009-12-17	2014-04-08	Merck Sharp & Dohme Corp.	Methods of treating multiple sclerosis, rheumatoid arthritis and inflammatory bowel disease using agonists antibodies to PILR-α
US20130017223A1 (en)	2009-12-18	2013-01-17	The University Of British Columbia	Methods and compositions for delivery of nucleic acids
PT2516418E (pt)	2009-12-23	2014-07-18	Sanofi Sa	Profármacos de [4[4-(5-aminometil-2-fluoro-fenil)-piperidin-1- il]-(1h-pirrolo-piridin-il)-metanonas e sua síntese
WO2011079261A2 (en)	2009-12-23	2011-06-30	Curna, Inc.	Treatment of hepatocyte growth factor (hgf) related diseases by inhibition of natural antisense transcript to hgf
WO2011078984A1 (en)	2009-12-23	2011-06-30	Sanofi	[4[4-(5-aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-(1h-pyrrolo-pyridin-yl)-methanones and synthesis thereof
EP2515947B1 (de)	2009-12-23	2021-10-06	CuRNA, Inc.	Behandlung von durch das uncoupling protein 2 (ucp2) bedingten erkrankungen mittels hemmung des natürlichen antisense-transkripts für ucp2
HUE028629T2 (en)	2009-12-23	2016-12-28	Synimmune Gmbh	Anti-FLT3 antibodies and ways of their use
ES2701626T3 (es)	2009-12-28	2019-02-25	Oncotherapy Science Inc	Anticuerpos anti-CDH3 y sus usos
RU2615450C2 (ru)	2009-12-29	2017-04-04	Курна, Инк.	Лечение заболеваний, связанных с ядерным респираторным фактором 1(nrf1), путем ингибирования природного антисмыслового транскрипта к nrf1
JP5982288B2 (ja)	2009-12-29	2016-08-31	カッパーアールエヌエー，インコーポレイテッド	腫瘍タンパク質６３（ｐ６３）に対する天然アンチセンス転写物の阻害による腫瘍タンパク質６３関連疾患の治療
US20110159588A1 (en)	2009-12-30	2011-06-30	Kui Lin	Methods for Modulating a PDGF-AA Mediated Biological Response
DK2521784T3 (en)	2010-01-04	2018-03-12	Curna Inc	TREATMENT OF INTERFERON REGULATORY FACTOR 8- (IRF8) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENCE TRANSCRIPT TO IRF8
JP5963680B2 (ja)	2010-01-06	2016-08-03	カッパーアールエヌエー，インコーポレイテッド	膵臓発生遺伝子に対する天然アンチセンス転写物の阻害による膵臓発生遺伝子疾患の治療
US8961929B2 (en)	2010-01-08	2015-02-24	Fujifilm Corporation	Targeting agent for tumor site
WO2011085347A2 (en)	2010-01-11	2011-07-14	Opko Curna, Llc	Treatment of sex hormone binding globulin (shbg) related diseases by inhibition of natural antisense transcript to shbg
TWI535445B (zh)	2010-01-12	2016-06-01	安可美德藥物股份有限公司	Ｗｎｔ拮抗劑及治療和篩選方法
ES2561102T3 (es)	2010-01-13	2016-02-24	Oncomed Pharmaceuticals, Inc.	Agentes de unión a Notch1 y procedimientos de uso de los mismos
WO2011090971A2 (en)	2010-01-19	2011-07-28	The Trustees Of Columbia University In The City Of New York	Osteocalcin as a treatment for male reproductive disorders
WO2011089211A1 (en)	2010-01-22	2011-07-28	Synimmune Gmbh	Anti-cd133 antibodies and methods of using the same
ES2671877T3 (es)	2010-01-25	2018-06-11	Curna, Inc.	Tratamiento de enfermedades relacionadas con la RNASA (H1) mediante inhibición del transcrito antisentido natural a RNASA H1
US8198337B2 (en) *	2010-01-27	2012-06-12	Momentive Performance Materials Inc.	Demulsifier compositions and methods for separating emulsions using the same
US20130052259A1 (en)	2010-02-01	2013-02-28	Yechezkel Barenholz	Liposomes comprising amphipathic drugs and method for their preparation
CN102844435B (zh)	2010-02-22	2017-05-10	库尔纳公司	通过抑制吡咯啉‑5‑羧酸还原酶1(pycr1)的天然反义转录物而治疗pycr1相关疾病
EP3590966A1 (de)	2010-02-23	2020-01-08	Sanofi	Anti-alpha2-integrin-antikörper und deren verwendungen
KR20130004579A (ko)	2010-02-23	2013-01-11	제넨테크, 인크.	종양의 진단 및 치료를 위한 조성물 및 방법
KR20180028561A (ko)	2010-02-23	2018-03-16	제넨테크, 인크.	난소암의 치료를 위한 항혈관신생 요법
US8298535B2 (en)	2010-02-24	2012-10-30	Rinat Neuroscience Corp.	Anti-IL-7 receptor antibodies
US8889193B2 (en)	2010-02-25	2014-11-18	The Johns Hopkins University	Sustained delivery of therapeutic agents to an eye compartment
JP5932670B2 (ja)	2010-03-11	2016-06-08	ライナットニューロサイエンスコーポレイション	ｐＨ依存性の抗原結合を有する抗体
KR20180000342A (ko)	2010-03-22	2018-01-02	제넨테크, 인크.	단백질-함유 제제의 안정화에 유용한 조성물 및 방법
WO2011119852A1 (en)	2010-03-24	2011-09-29	Rxi Pharmaceuticals Corporation	Reduced size self-delivering rnai compounds
CA2793959C (en)	2010-03-25	2019-06-04	Oregon Health & Science University	Cmv glycoproteins and recombinant vectors
CA2794745A1 (en)	2010-03-29	2011-10-06	Zymeworks, Inc.	Antibodies with enhanced or suppressed effector function
AU2011235276B2 (en)	2010-03-29	2015-09-03	Alnylam Pharmaceuticals, Inc.	SiRNA therapy for transthyretin (TTR) related ocular amyloidosis
US8563530B2 (en)	2010-03-31	2013-10-22	Gilead Pharmassel LLC	Purine nucleoside phosphoramidate
CN102858790A (zh)	2010-03-31	2013-01-02	吉利德制药有限责任公司	核苷氨基磷酸酯
WO2011123672A1 (en)	2010-03-31	2011-10-06	Pharmasset, Inc.	Purine nucleoside phosphoramidate
MY187990A (en)	2010-03-31	2021-11-07	Boehringer Ingelheim Int	Anti-cd40 antibodies
WO2011123621A2 (en)	2010-04-01	2011-10-06	Alnylam Pharmaceuticals Inc.	2' and 5' modified monomers and oligonucleotides
US9073990B2 (en)	2010-04-05	2015-07-07	Bar-Llan University	Protease-activatable pore-forming polypeptides
EP2556160A4 (de)	2010-04-09	2013-08-21	Curna Inc	Behandlung von erkrankungen im zusammenhang mit dem fibroblastenwachstumsfaktor 21 (fgf21) mittels hemmung des natürlichen antisense-transkripts gegen fgf21
US10913767B2 (en)	2010-04-22	2021-02-09	Alnylam Pharmaceuticals, Inc.	Oligonucleotides comprising acyclic and abasic nucleosides and analogs
WO2011133868A2 (en)	2010-04-22	2011-10-27	Alnylam Pharmaceuticals, Inc.	Conformationally restricted dinucleotide monomers and oligonucleotides
US9725479B2 (en)	2010-04-22	2017-08-08	Ionis Pharmaceuticals, Inc.	5′-end derivatives
EP3085387A1 (de)	2010-04-26	2016-10-26	Abraxis BioScience, LLC	Sparc-bindende antikörper und verwendungen davon
US20130195962A1 (en) *	2010-04-28	2013-08-01	National University Corporation Hokkaido University	Lipid membrane structure
ES2625689T3 (es)	2010-04-29	2017-07-20	Ionis Pharmaceuticals, Inc.	Modulación de la expresión de transtiretina
WO2011139911A2 (en)	2010-04-29	2011-11-10	Isis Pharmaceuticals, Inc.	Lipid formulated single stranded rna
PL2563813T3 (pl)	2010-04-30	2016-01-29	Alexion Pharma Inc	Przeciwciała anty-C5a i sposoby stosowania przeciwciał
WO2011139387A1 (en)	2010-05-03	2011-11-10	Opko Curna, Llc	Treatment of sirtuin (sirt) related diseases by inhibition of natural antisense transcript to a sirtuin (sirt)
MX2012012743A (es)	2010-05-03	2012-11-23	Genentech Inc	Composiciones y metodos utiles para reducir la viscosidad de formulaciones que contienen proteina.
CN107090045A (zh)	2010-05-03	2017-08-25	霍夫曼-拉罗奇有限公司	用于肿瘤诊断和治疗的组合物和方法
US9457079B2 (en)	2010-05-12	2016-10-04	The Trustees Of Columbia University In The City Of New York	Methods for producing enteroendocrine cells that make and secrete insulin
TWI586356B (zh)	2010-05-14	2017-06-11	可娜公司	藉由抑制ｐａｒ４天然反股轉錄本治療ｐａｒ４相關疾病
EP3450432A1 (de)	2010-05-17	2019-03-06	Incozen Therapeutics Pvt. Ltd.	Neuartige 3,5-disubstituierte-3h-imidazo[4,5-b]pyridin- und 3,5- disubstituierte-3h-[1,2,3]triazol[4,5-b]pyridin-verbindungen als modulatoren der proteinkinase
EP2571516B1 (de)	2010-05-18	2017-11-15	Neumedicines, Inc	Formulierungen enthaltend il-12 zur erhöhung der hematopoese
WO2011146568A1 (en)	2010-05-19	2011-11-24	Genentech, Inc.	Predicting response to a her inhibitor
KR20180053419A (ko)	2010-05-26	2018-05-21	큐알엔에이, 인크.	무조(無調)의 동소체 1 (atoh1)에 대한 자연 안티센스 전사체의 저해에 의한 atoh1 관련된 질환의 치료
WO2011153243A2 (en)	2010-06-02	2011-12-08	Genentech, Inc.	Anti-angiogenesis therapy for treating gastric cancer
EP2576579B1 (de)	2010-06-02	2018-08-08	Alnylam Pharmaceuticals, Inc.	Zusammensetzungen und verfahren zur behandlung von leberfibrose
EP2575882B1 (de)	2010-06-02	2017-11-01	Dana-Farber Cancer Institute, Inc.	Humanisierte monoklonale antikörper und verfahren zu ihrer verwendung
US9012498B2 (en)	2010-06-03	2015-04-21	Alnylam Pharmaceuticals, Inc.	Biodegradable lipids for the delivery of active agents
ES2526124T3 (es)	2010-06-16	2015-01-07	Cymabay Therapeutics, Inc.	Agonistas del receptor GPR120 y sus usos
US8299117B2 (en)	2010-06-16	2012-10-30	Metabolex Inc.	GPR120 receptor agonists and uses thereof
WO2011160110A1 (en) *	2010-06-19	2011-12-22	Western University Of Health Sciences	Novel formulation of pegylated-liposome encapsulated glycopeptide antibiotics
CN103037843A (zh)	2010-06-23	2013-04-10	麦它波莱克斯股份有限公司	5-乙基-2-{4-[4-(4-四唑-1-基-苯氧甲基)-噻唑-2-基]-哌啶-1-基}-嘧啶的组合物
MY161390A (en)	2010-06-24	2017-04-14	Genentech Inc	Compositions and methods containing alkylglycosides for stabilizing protein-containing formulations
CN102309448B (zh) *	2010-06-29	2014-07-09	中国人民解放军军事医学科学院毒物药物研究所	一种肺部给药的环丙沙星药用组合物及其制备方法
WO2012000104A1 (en)	2010-06-30	2012-01-05	Protiva Biotherapeutics, Inc.	Non-liposomal systems for nucleic acid delivery
BR112013000392B8 (pt)	2010-07-06	2022-10-04	Novartis Ag	Composição farmacêutica contendo partícula de distribuição semelhante a vírion para moléculas de rna autorreplicantes e seu uso
HUE047796T2 (hu)	2010-07-06	2020-05-28	Glaxosmithkline Biologicals Sa	RNS bevitele több immunútvonal bekapcsolására
PT2591114T (pt)	2010-07-06	2016-08-02	Glaxosmithkline Biologicals Sa	Imunização de mamíferos de grande porte com doses baixas de arn
US20130171241A1 (en)	2010-07-06	2013-07-04	Novartis Ag	Liposomes with lipids having an advantageous pka-value for rna delivery
US20120208855A1 (en)	2010-07-12	2012-08-16	Sanofi	Amino-benzoic acid derivatives for use in the treatment of dihydrogenase-related disorders
CA2804185C (en)	2010-07-12	2017-03-21	Covx Technologies Ireland Limited	Multifunctional antibody conjugates
WO2012009402A2 (en)	2010-07-14	2012-01-19	Opko Curna Llc	Treatment of discs large homolog (dlg) related diseases by inhibition of natural antisense transcript to dlg
JP2013538191A (ja)	2010-07-23	2013-10-10	トラスティーズオブボストンユニバーシティ	病的血管新生および腫瘍細胞侵襲性の阻害のための治療法としてならびに分子イメージングおよび標的化送達のための抗ＤＥｓｕｐＲ阻害剤
WO2012016184A2 (en)	2010-07-30	2012-02-02	Alnylam Pharmaceuticals, Inc.	Methods and compositions for delivery of active agents
WO2012016188A2 (en)	2010-07-30	2012-02-02	Alnylam Pharmaceuticals, Inc.	Methods and compositions for delivery of active agents
WO2012019093A1 (en)	2010-08-05	2012-02-09	Human Biomolecular Research Institute	Synthetic compounds and methods to decrease nicotine self-administration
AU2011289275A1 (en)	2010-08-12	2013-02-21	Theraclone Sciences, Inc.	Anti-hemagglutinin antibody compositions and methods of use thereof
EP2420250A1 (de)	2010-08-13	2012-02-22	Universitätsklinikum Münster	Anti-Syndecan-4-Antikörper
ES2935009T3 (es)	2010-08-31	2023-03-01	Glaxosmithkline Biologicals Sa	Liposomas pegilados para la administración de ARN que codifica para inmunógeno
DK4066819T3 (da)	2010-08-31	2023-04-24	Glaxosmithkline Biologicals Sa	Små liposomer til levering af RNA, der koder for immunogen
ES2774369T3 (es)	2010-08-31	2020-07-20	Theraclone Science Int	Anticuerpo de neutralización del virus de la inmunodeficiencia humana
US8551479B2 (en)	2010-09-10	2013-10-08	Oncomed Pharmaceuticals, Inc.	Methods for treating melanoma
AU2011312205B2 (en)	2010-10-05	2015-08-13	Curis, Inc.	Mutant smoothened and methods of using the same
CA2813901C (en)	2010-10-06	2019-11-12	Curna, Inc.	Treatment of sialidase 4 (neu4) related diseases by inhibition of natural antisense transcript to neu4
AU2011316707A1 (en)	2010-10-11	2013-05-09	Novartis Ag	Antigen delivery platforms
EP2630241B1 (de)	2010-10-22	2018-10-17	CuRNA, Inc.	Behandlung von alpha-l-iduronidase (idua)-bedingten erkrankungen mittels hemmung des natürlichen antisense-transkripts gegen idua
EP3214442A1 (de)	2010-10-25	2017-09-06	F. Hoffmann-La Roche AG	Behandlung von gastrointestinalen entzündungen und psoriasis und asthmaentzündung und psoriasis a
ES2677070T3 (es)	2010-10-27	2018-07-27	Curna, Inc.	Tratamiento de enfermedades relacionadas con el regulador del desarrollo 1 asociado a interferón (ifrd1) mediante inhibición del transcrito antisentido natural al gen ifrd1
US8778346B2 (en)	2010-11-04	2014-07-15	Boehringer Ingelheim International Gmbh	Anti-IL-23 antibodies
US20140134181A1 (en)	2010-11-05	2014-05-15	Kenneth E. Lipson	Treatment Method For Lung Remodeling Diseases
CN110123830A (zh)	2010-11-09	2019-08-16	阿尔尼拉姆医药品有限公司	用于抑制Eg5和VEGF基因的表达的脂质配制的组合物和方法
WO2012065044A2 (en)	2010-11-12	2012-05-18	Purdue Research Foundation	Treating bladder tumor cells using fibronectin attachment protein as a target
EP2640831A1 (de)	2010-11-17	2013-09-25	Sea Lane Biotechnologies,llc.	Die bindungsstelle eines influenzaneutralisierenden antikörpers nachahmende influenzavirusneutralisierungsmittel
JP2014505666A (ja)	2010-11-18	2014-03-06	ザジェネラルホスピタルコーポレイション	癌治療のための降圧剤の組成物および使用
ES2657590T3 (es)	2010-11-23	2018-03-06	Curna, Inc.	Tratamiento de enfermedades relacionadas con nanog mediante inhibición del transcrito antisentido natural a nanog
TW201242974A (en)	2010-11-30	2012-11-01	Gilead Pharmasset Llc	Compounds
WO2012078967A2 (en)	2010-12-10	2012-06-14	Alnylam Pharmaceuticals, Inc.	Compositions and methods for increasing erythropoietin (epo) production
EP2648763A4 (de)	2010-12-10	2014-05-14	Alnylam Pharmaceuticals Inc	Zusammensetzungen und verfahren zur expressionshemmung der gene klf-1 und bcl11a
AU2011344865B2 (en)	2010-12-14	2017-03-09	Rigshospitalet	Entrapment of radionuclides in nanoparticle compositions
EP2468259A1 (de) *	2010-12-23	2012-06-27	Traslational Cancer Drugs Pharma, S.L.	Pharmazeutische Zusammensetzungen aus Pyridinium- und Chinoliniumderivaten
WO2012094033A1 (en)	2011-01-05	2012-07-12	Livon Laboratories	Methods of making liposomes, liposome compositions made by the methods, and methods of using the same
WO2012099755A1 (en)	2011-01-11	2012-07-26	Alnylam Pharmaceuticals, Inc.	Pegylated lipids and their use for drug delivery
EP3586844A1 (de)	2011-01-11	2020-01-01	Dimerix Bioscience Pty Ltd	Kombinationstherapie
TWI593416B (zh)	2011-02-02	2017-08-01	艾克厘德製藥公司	利用針對結締組織生長因子（ｃｔｇｆ）目標之反義化合物治療瘢痕或肥厚性疤痕之方法
RU2440142C1 (ru)	2011-02-07	2012-01-20	Общество С Ограниченной Ответственностью "Онкомакс"	Антитело, останавливающее или замедляющее рост опухоли (варианты), способ подавления роста опухоли, способ диагностики злокачественных образований
WO2012109495A1 (en)	2011-02-09	2012-08-16	Metabolic Solutions Development Company, Llc	Cellular targets of thiazolidinediones
EP2675478A4 (de)	2011-02-14	2015-06-10	Theraclone Sciences Inc	Zusammensetzungen und verfahren zur therapie und diagnose von grippe
PL226015B1 (pl) *	2011-03-03	2017-06-30	Wrocławskie Centrum Badań Eit + Spółka Z Ograniczoną	Liposomowy preparat zawierajacy przeciwnowotworowa substancje aktywna, sposob jego wytwarzania i zawierajaca go kompozycja farmaceutyczna
DK2683736T3 (en)	2011-03-09	2018-04-23	Cell Signaling Technology Inc	METHODS AND REAGENTS FOR CREATING MONOCLONAL ANTIBODIES
SG193402A1 (en)	2011-03-15	2013-10-30	Theraclone Sciences Inc	Compositions and methods for the therapy and diagnosis of influenza
PE20140593A1 (es)	2011-03-16	2014-05-10	Amgen Inc	Inhibidores potentes y selectivos de nav1.3 y nav1.7
US10184942B2 (en)	2011-03-17	2019-01-22	University Of South Florida	Natriuretic peptide receptor as a biomarker for diagnosis and prognosis of cancer
WO2012134975A1 (en)	2011-03-28	2012-10-04	St. Jude Children's Research Hospital	Methods and compositions employing immunogenic fusion proteins
JP6108628B2 (ja)	2011-03-29	2017-04-05	アルナイラムファーマシューティカルズ，インコーポレイテッドＡｌｎｙｌａｍＰｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ．	Ｔｍｐｒｓｓ６遺伝子の発現を阻害する組成物および方法
CA2831732C (en)	2011-03-31	2019-12-31	Genentech, Inc.	Use of a monoclonal anti-beta7 antibody for treating gastrointestinal inflammatory disorders
EP2508176A1 (de)	2011-04-08	2012-10-10	Lipotarg Gmbh	Neues Kombinatonsbehandlung für Krebs
CN105886506A (zh)	2011-04-13	2016-08-24	Isis制药公司	Ptp1b 表达的反义调节
KR101589135B1 (ko)	2011-04-20	2016-01-29	주식회사 셀앤바이오	인간화 항-ｅｍａｐｉｉ 항체 및 이의 용도
HUE037651T2 (hu)	2011-04-20	2018-09-28	Medimmune Llc	B7-Hl-et és PD-l-et kötõ ellenanyagok és más molekulák
MY168757A (en)	2011-05-04	2018-12-04	Rhizen Pharmaceuticals S A	Novel compounds as modulators of protein kinases
CN107903325B (zh)	2011-05-16	2021-10-29	埃泰美德(香港)有限公司	多特异性fab融合蛋白及其使用方法
SG10201805199RA (en)	2011-06-02	2018-07-30	Harvard College	Methods and Uses for Ex Vivo Tissue Culture Systems
RU2620980C2 (ru)	2011-06-09	2017-05-30	Курна, Инк.	Лечение заболеваний, связанных с фратаксином (fxn), путем ингибирования природного антисмыслового транскрипта fxn
CA2832109C (en)	2011-06-10	2021-07-06	Oregon Health & Science University	Cmv glycoproteins and recombinant vectors
CA2839437A1 (en)	2011-06-16	2012-12-20	Isis Pharmaceuticals, Inc.	Antisense modulation of fibroblast growth factor receptor 4 expression
CA2839896A1 (en)	2011-06-21	2012-12-27	Alnylam Pharmaceuticals, Inc.	Assays and methods for determining activity of a therapeutic agent in a subject
RU2631805C2 (ru)	2011-06-21	2017-09-26	Элнилэм Фармасьютикалз, Инк.	Композиции и способы ингибирования экспрессии генов аполипопротеина с-iii (арос3)
EP3388068A1 (de)	2011-06-21	2018-10-17	Alnylam Pharmaceuticals, Inc.	Zusammensetzung und verfahren zur hemmung der expression von protein-c (proc)-genen
EP2537532A1 (de)	2011-06-22	2012-12-26	J. Stefan Institute	Cathepsinbindende Verbindungen, die an ein Nanogerät gebunden sind, und deren diagnostische und therapeutische Verwendung
EP3366312A1 (de)	2011-06-23	2018-08-29	Alnylam Pharmaceuticals, Inc.	Serpina 1 sirnas: materialzusammensetzungen und verfahren zur behandlung
EP2724156B1 (de)	2011-06-27	2017-08-16	The Jackson Laboratory	Verfahren und zusammensetzungen zur behandlung von krebs und autoimmunerkrankungen
WO2013003652A1 (en)	2011-06-28	2013-01-03	Sea Lane Biotechnologies, Llc	Multispecific stacked variable domain binding proteins
US11896636B2 (en)	2011-07-06	2024-02-13	Glaxosmithkline Biologicals Sa	Immunogenic combination compositions and uses thereof
LT2731591T (lt)	2011-07-13	2020-12-28	Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.	Liposomos, kuriose kartu inkapsuliuotas bisfosfonatas ir amfipatinis agentas
EP2731623A1 (de)	2011-07-14	2014-05-21	Pfizer Inc	Behandlung mit anti-pcsk9- antikörpern
US9120858B2 (en)	2011-07-22	2015-09-01	The Research Foundation Of State University Of New York	Antibodies to the B12-transcobalamin receptor
US20130022551A1 (en)	2011-07-22	2013-01-24	Trustees Of Boston University	DEspR ANTAGONISTS AND AGONISTS AS THERAPEUTICS
WO2013015821A1 (en)	2011-07-22	2013-01-31	The Research Foundation Of State University Of New York	Antibodies to the b12-transcobalamin receptor
US20140328811A1 (en)	2011-08-01	2014-11-06	Alnylam Pharmaceuticals, Inc.	Method for improving the success rate of hematopoietic stem cell transplants
JP6120848B2 (ja)	2011-08-15	2017-04-26	メディミューン，エルエルシー	抗ｂ７−ｈ４抗体およびその使用
FR2979239A1 (fr) *	2011-08-25	2013-03-01	Trophos	Liposome comprenant au moins un derive de cholesterol
US8822651B2 (en)	2011-08-30	2014-09-02	Theraclone Sciences, Inc.	Human rhinovirus (HRV) antibodies
US9399791B2 (en)	2011-08-31	2016-07-26	St. Jude Children's Research Hospital	Methods of treating alzheimer's disease by administration of protective protein/cathepsin A
WO2013035345A2 (en)	2011-09-09	2013-03-14	Osaka University	Dengue-virus serotype neutralizing antibodies
EP2568289A3 (de)	2011-09-12	2013-04-03	International AIDS Vaccine Initiative	Immunselektion von rekombinantem vesikulärem Stomatitisvirus mit Expression von HIV-1-Proteinen durch Breitbandneutralisierungs-Antikörper
WO2013043580A2 (en)	2011-09-19	2013-03-28	Gencia Corporation	Modified creatine compounds
EP3401401B1 (de)	2011-09-20	2020-04-15	Ionis Pharmaceuticals, Inc.	Antisense-modulation der gcgr-expression
WO2013041687A1 (en)	2011-09-23	2013-03-28	Amgen Research (Munich) Gmbh	Bispecific binding molecules for 5t4 and cd3
BR112014006929A2 (pt)	2011-09-23	2017-04-04	Technophage Investigação E Desenvolvimento Em Biotecnologia Sa	agentes anti-fator de necrose tumoral-alfa e seus usos
MX361712B (es)	2011-09-23	2018-12-14	Oncomed Pharm Inc	Agentes de ligacion al factor de crecimiento endotelial vascular/ligando 4 similar a delta (vegf/dell4) y usos de los mismos.
WO2013049328A1 (en)	2011-09-27	2013-04-04	Alnylam Pharmaceuticals, Inc.	Di-aliphatic substituted pegylated lipids
AU2012315545B2 (en)	2011-09-29	2017-03-09	Plx Opco Inc.	pH dependent carriers for targeted release of pharmaceuticals along the gastrointestinal tract, compositions therefrom, and making and using same
US20130085139A1 (en)	2011-10-04	2013-04-04	Royal Holloway And Bedford New College	Oligomers
ES2855474T3 (es)	2011-10-06	2021-09-23	Immunovaccine Technologies Inc	Composiciones de liposomas que comprenden un adyuvante que activa o incrementa la actividad de TLR2 y usos del mismo
US9738727B2 (en)	2011-10-14	2017-08-22	Genentech, Inc.	Anti-HtrA1 antibodies and methods of use
US8883989B2 (en)	2011-10-18	2014-11-11	Regents Of The University Of Minnesota	Fractalkine binding polynucleotides and methods of use
RU2014119787A (ru)	2011-10-25	2015-12-10	Айсис Фармасьютикалс, Инк.	Антисмысловая регуляция экспрессии gccr
US9402894B2 (en)	2011-10-27	2016-08-02	International Aids Vaccine Initiative	Viral particles derived from an enveloped virus
SG11201401815XA (en)	2011-10-28	2014-05-29	Genentech Inc	Therapeutic combinations and methods of treating melanoma
CN109078182B (zh)	2011-10-31	2022-08-12	弗·哈夫曼-拉罗切有限公司	抗体制剂
US10980798B2 (en)	2011-11-03	2021-04-20	Taiwan Liposome Company, Ltd.	Pharmaceutical compositions of hydrophobic camptothecin derivatives
CN103957912B (zh) *	2011-11-03	2019-04-05	台湾微脂体股份有限公司	疏水性喜树碱衍生物的药物组合物
CA2854720C (en)	2011-11-11	2018-12-18	Rinat Neuroscience Corp.	Antibodies specific for trop-2 and their uses
TWI679212B (zh)	2011-11-15	2019-12-11	美商安進股份有限公司	針對ｂｃｍａ之e3以及ｃｄ３的結合分子
AU2012339734B2 (en)	2011-11-16	2017-02-16	Boehringer Ingelheim International Gmbh	Anti IL-36R antibodies
JP2015501839A (ja)	2011-12-15	2015-01-19	ザ・ユニバーシティ・オブ・シカゴＴｈｅＵｎｉｖｅｒｓｉｔｙＯｆＣｈｉｃａｇｏ	受容体に対する親和性が増大した変異型ｌｉｇｈｔ分子を使用する癌療法のための方法および組成物
CA2859472A1 (en)	2011-12-22	2013-06-27	Rinat Neuroscience Corp.	Human growth hormone receptor antagonist antibodies and methods of use thereof
WO2013093693A1 (en)	2011-12-22	2013-06-27	Rinat Neuroscience Corp.	Staphylococcus aureus specific antibodies and uses thereof
EP3539982A3 (de)	2011-12-23	2020-01-15	Pfizer Inc	Konstante regionen gentechnisch hergestellter antikörper für stellenspezifische konjugation sowie verfahren und verwendungen dafür
WO2013101771A2 (en)	2011-12-30	2013-07-04	Genentech, Inc.	Compositions and method for treating autoimmune diseases
ES2700398T3 (es)	2012-01-09	2019-02-15	Pfizer Healthcare Ireland	Anticuerpos mutantes y conjugación de los mismos
EP2804620A4 (de)	2012-01-18	2016-04-13	Neumedicines Inc	Il-12 für strahlenschutz und strahlungsbedingte toxizitätsabschwächung
JP2015505537A (ja)	2012-01-20	2015-02-23	シーレーンバイオテクノロジーズ，エルエルシー	結合分子コンジュゲート
WO2013114377A1 (en)	2012-02-02	2013-08-08	Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd	Stable liposomes for drug delivery
CN111533804A (zh)	2012-02-06	2020-08-14	印希彼有限公司	Cd47抗体及其使用方法
KR102161271B1 (ko) *	2012-02-17	2020-09-29	셀젼 코퍼레이션	감열성 나노입자 제제 및 그의 제조 방법
US9138492B2 (en) *	2012-02-23	2015-09-22	Canon Kabushiki Kaisha	Particle containing hydrophobic dye having cyanine structure, and contrast agent containing the particle
JP6407726B2 (ja)	2012-03-01	2018-10-24	アムゲンリサーチ（ミュンヘン）ゲーエムベーハーＡＭＧＥＮＲｅｓｅａｒｃｈ（Ｍｕｎｉｃｈ）ＧｍｂＨ	長寿命ポリペプチド結合分子
WO2013134288A1 (en)	2012-03-05	2013-09-12	Gilead Calistoga Llc	Polymorphic forms of (s)-2-(1-(9h-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3h)-one
US20150031750A1 (en)	2012-03-15	2015-01-29	The Scripps Research Institute	Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf
DK2831117T3 (en)	2012-03-29	2017-12-18	Novimmune Sa	ANTI-TLR4 ANTIBODIES AND APPLICATIONS THEREOF
US9815831B2 (en)	2012-03-30	2017-11-14	Rhizen Pharmaceuticals Sa	3,5-disubstituted-3H-imidazo[4,5-B]pyridine and 3,5-disubstituted-3H-[1,2,3]triazolo[4,5-B] pyridine compounds as modulators of c-Met protein kinases
WO2013151649A1 (en)	2012-04-04	2013-10-10	Sialix Inc	Glycan-interacting compounds
US9133461B2 (en)	2012-04-10	2015-09-15	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of the ALAS1 gene
US20160054299A9 (en)	2012-04-24	2016-02-25	University Of Miami	Perforin 2 defense against invasive and multidrug resistant pathogens
AU2013256724A1 (en)	2012-05-03	2014-10-30	Boehringer Ingelheim International Gmbh	Anti-IL-23p19 antibodies
CA2871751C (en)	2012-05-04	2021-08-24	Dana-Farber Cancer Institute, Inc.	Affinity matured anti-ccr4 humanized monoclonal antibodies and methods of use
US9889208B2 (en)	2012-05-04	2018-02-13	The Johns Hopkins University	Lipid-based drug carriers for rapid penetration through mucus linings
AU2013202947B2 (en)	2012-06-13	2016-06-02	Ipsen Biopharm Ltd.	Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
US9717724B2 (en)	2012-06-13	2017-08-01	Ipsen Biopharm Ltd.	Methods for treating pancreatic cancer using combination therapies
AU2013274101B2 (en)	2012-06-15	2017-09-07	The Brigham And Women's Hospital, Inc.	Compositions for treating cancer and methods for making the same
US9856314B2 (en)	2012-06-22	2018-01-02	Cytomx Therapeutics, Inc.	Activatable antibodies having non-binding steric moieties and methods of using the same
ES2631608T3 (es)	2012-06-27	2017-09-01	International Aids Vaccine Initiative	Variante de la glicoproteína Env del VIH-1
AU2013292636A1 (en) *	2012-07-18	2015-02-05	Onyx Therapeutics, Inc.	Liposomal compositions of epoxyketone-based proteasome inhibitors
US8603470B1 (en)	2012-08-07	2013-12-10	National Cheng Kung University	Use of IL-20 antagonists for treating liver diseases
CN103565745A (zh)	2012-08-10	2014-02-12	德克萨斯州大学系统董事会	用于治疗中风的神经保护性脂质体组合物和方法
CN104768972B (zh)	2012-08-14	2019-12-06	南洋理工大学	血管生成素样4抗体及其用在癌症治疗中的方法
JP2015530387A (ja)	2012-09-04	2015-10-15	エライゾンファーマシューティカルズ，エルエルシー	脂質複合体化シスプラチンによる肺癌の再発防止
EP2943194A1 (de)	2012-09-17	2015-11-18	Chemedest Ltd.	Behandlung peripherer neuropathie mit gfr (alpha)-typ-3 -rezeptoragonisten
CA3139031A1 (en)	2012-10-04	2014-04-10	Dana-Farber Cancer Institute, Inc.	Human monoclonal anti-pd-l1 antibodies and methods of use
ES2738305T3 (es)	2012-10-05	2020-01-21	Hoffmann La Roche	Procedimientos para diagnosticar y tratar enfermedades inflamatorias intestinales
AU2013334790A1 (en)	2012-10-23	2015-04-30	Oncomed Pharmaceuticals, Inc.	Methods of treating neuroendocrine tumors using Wnt pathway-binding agents
JP6371294B2 (ja)	2012-10-31	2018-08-08	オンコメッドファーマシューティカルズインコーポレイテッド	Ｄｌｌ４アンタゴニストによる処置の方法およびモニタリング
ES2784631T3 (es)	2012-12-03	2020-09-29	Novimmune Sa	Anticuerpos anti-CD47 y métodos de uso de los mismos
CA2894846A1 (en)	2012-12-12	2014-06-19	Temple University - Of The Commonwealth System Of Higher Education	Compositions and methods for treatment of cancer
BR112015014063A2 (pt)	2012-12-19	2018-10-30	Amplimmune Inc	anticorpos anti-b7-h4 humano e seus usos.
US10086074B2 (en)	2012-12-19	2018-10-02	The Research Foundation For The State University Of New York	Compositions and method for light triggered release of materials from nanovesicles
GB201223053D0 (en)	2012-12-20	2013-02-06	Medical Res Council	Receptor
EP2935311B1 (de)	2012-12-20	2021-03-31	Amgen Inc.	Apj-rezeptoragonisten und verwendungen davon
EP2935332B1 (de)	2012-12-21	2021-11-10	MedImmune, LLC	Anti-h7cr antikörpern
ES2847930T3 (es)	2013-01-07	2021-08-04	Mucosal Vaccine Tech Llc	Vacunas terapéuticas para el tratamiento de las infecciones por el virus del herpes simple de tipo 2
WO2014114801A1 (en)	2013-01-25	2014-07-31	Amgen Inc.	Antibodies targeting cdh19 for melanoma
JO3519B1 (ar)	2013-01-25	2020-07-05	Amgen Inc	تركيبات أجسام مضادة لأجل cdh19 و cd3
WO2014124006A1 (en)	2013-02-05	2014-08-14	The Johns Hopkins University	Nanoparticles for magnetic resonance imaging tracking and methods of making and using thereof
MX2015010115A (es)	2013-02-06	2016-05-31	Inhibrx Llc	Anticuerpos cd47 de no agotamiento de plaquetas y no agotamiento de globulos rojos y metodos de uso de los mismos.
US9534041B2 (en)	2013-02-12	2017-01-03	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Monoclonal antibodies that neutralize a norovirus
US10344060B2 (en)	2013-03-12	2019-07-09	Amgen Inc.	Potent and selective inhibitors of Nav1.7
US9302005B2 (en)	2013-03-14	2016-04-05	Mayo Foundation For Medical Education And Research	Methods and materials for treating cancer
MX2015011462A (es)	2013-03-14	2016-05-31	Jerome J Schentag	Vesiculas colestosomicas para incorporacion de moleculas en quilomicrones.
CA2906697A1 (en)	2013-03-15	2014-09-18	Gencia Corporation	Compositions and methods for treating conditions that affect epidermis
CA2907175C (en) *	2013-03-15	2022-11-08	M. Alphabet 3, L.L.C.	Methods and compositions for enhancing oxygen levels in tissues
US11156608B2 (en)	2013-03-15	2021-10-26	The Trustees Of The University Of Pennsylvania	Method for the site-specific covalent cross-linking of antibodies to surfaces
AR095374A1 (es)	2013-03-15	2015-10-14	Amgen Res (Munich) Gmbh	Moléculas de unión para bcma y cd3
US20140283157A1 (en)	2013-03-15	2014-09-18	Diadexus, Inc.	Lipoprotein-associated phospholipase a2 antibody compositions and methods of use
US9505849B2 (en)	2013-03-15	2016-11-29	Amgen Research (Munich) Gmbh	Antibody constructs for influenza M2 and CD3
HUE045859T2 (hu)	2013-03-15	2020-01-28	Amgen Res Munich Gmbh	N-terminális ABP-t tartalmazó, egyláncú kötõmolekulák
WO2014152497A2 (en)	2013-03-15	2014-09-25	The Trustees Of Columbia University In The City Of New York	Osteocalcin as a treatment for cognitive disorders
US9822166B2 (en)	2013-03-15	2017-11-21	Dana-Farber Cancer Institute, Inc.	Flavivirus neutralizing antibodies and methods of use thereof
CN105051068A (zh)	2013-03-15	2015-11-11	戴埃克斯有限公司	抗血浆激肽释放酶抗体
CA2904095A1 (en)	2013-03-27	2014-10-02	Genentech, Inc.	Use of biomarkers for assessing treatment of gastrointestinal inflammatory disorders with beta7 integrin antagonists
CA2918194C (en)	2013-03-27	2022-12-06	The General Hospital Corporation	Methods and agents for treating alzheimer's disease
CA2909357C (en)	2013-04-12	2022-02-22	Icahn School Of Medicine At Mount Sinai	Use of ketamine to treat post-traumatic stress disorder
WO2014179760A1 (en)	2013-05-03	2014-11-06	The Regents Of The University Of California	Cyclic di-nucleotide induction of type i interferon
AR096203A1 (es)	2013-05-06	2015-12-16	Alnylam Pharmaceuticals Inc	Dosificaciones y métodos para administrar moléculas de ácido nucleico formuladas en lípidos
LT2981822T (lt)	2013-05-06	2020-12-28	Scholar Rock, Inc.	Kompozicijos ir būdai, skirti augimo faktoriaus moduliacijai
AU2014264295A1 (en)	2013-05-07	2015-10-29	Rinat Neuroscience Corp.	Anti-glucagon receptor antibodies and methods of use thereof
EP2994163B1 (de)	2013-05-09	2019-08-28	The United States of America, as represented by The Secretary, Department of Health and Human Services	Single-domain-vhh-antikörper gegen norovirus gi.1 und gii.4 und deren verwendung
CN106414489A (zh)	2013-05-24	2017-02-15	米迪缪尼有限公司	抗-b7-h5抗体及其用途
WO2014193722A1 (en)	2013-05-31	2014-12-04	Genentech, Inc.	Anti-wall teichoic antibodies and conjugates
JP6469094B2 (ja)	2013-05-31	2019-02-13	ジェネンテック，インコーポレイテッド	抗細胞壁タイコ酸抗体及びコンジュゲート
CA2914369C (en)	2013-06-06	2023-02-14	Igenica Biotherapeutics, Inc.	Anti-c10orf54 antibodies and uses thereof
US20160129089A1 (en)	2013-06-13	2016-05-12	Antisense Therapeutics Ltd	Combination therapy
US10208125B2 (en)	2013-07-15	2019-02-19	University of Pittsburgh—of the Commonwealth System of Higher Education	Anti-mucin 1 binding agents and uses thereof
RS63152B1 (sr)	2013-07-25	2022-05-31	Cytomx Therapeutics Inc	Multispecifična antitela, multispecifična antitela koja mogu da se aktiviraju i postupci za njihovu upotrebu
US20160193148A1 (en) *	2013-08-01	2016-07-07	University Of Georgia Research Foundation, Inc.	Liposomal formulations for the treatment of bacterial infections
MY190252A (en)	2013-08-02	2022-04-08	Pfizer	Anti-cxcr4 antibodies and antibody-drug conjugates
EA201690213A1 (ru)	2013-08-12	2016-07-29	Дженентек, Инк.	Композиции и способ лечения связанных с комплементом состояний
EP3033356B1 (de)	2013-08-14	2020-01-15	Sachdev Sidhu	Antikörper gegen frizzled proteine und verwendung davon
JP2016529284A (ja) *	2013-08-27	2016-09-23	ノースイースタンユニバーシティ	ナノ粒子薬物デリバリシステムおよび、癌および神経外傷の治療方法
US10647983B2 (en)	2013-09-04	2020-05-12	Cold Spring Harbor Laboratory	Reducing nonsense-mediated mRNA decay
WO2015035231A1 (en)	2013-09-05	2015-03-12	Sarepta Therapeutics, Inc.	Antisense-induced exon2 inclusion in acid alpha-glucosidase
US20150065381A1 (en)	2013-09-05	2015-03-05	International Aids Vaccine Initiative	Methods of identifying novel hiv-1 immunogens
AR097648A1 (es)	2013-09-13	2016-04-06	Amgen Inc	Combinación de factores epigenéticos y compuestos biespecíficos que tienen como diana cd33 y cd3 en el tratamiento de leucemia mieloide
LT3046537T (lt) *	2013-09-16	2021-12-10	Glycomine, Inc.	Farmacinis angliavandenių preparatas, skirtas terapiniam panaudojimui
DE102013015334A1 (de) *	2013-09-17	2015-03-19	Fresenius Medical Care Deutschland Gmbh	Magnesium-Liposomen-Komplexe
EP3047023B1 (de)	2013-09-19	2019-09-04	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Zusammensetzungen und methoden zur inhibierung des jc virus (jcv)
JP6915987B2 (ja)	2013-09-25	2021-08-11	シトムクスセラピューティクス，インコーポレイティド	マトリックスメタロプロテイナーゼ基質及び他の切断可能部分並びにそれらの使用方法
EP3470081A1 (de)	2013-10-01	2019-04-17	Mayo Foundation for Medical Education and Research	Verfahren zur behandlung von krebs bei patienten mit erhöhten bim-werten
EP3052626A1 (de)	2013-10-02	2016-08-10	Alnylam Pharmaceuticals, Inc.	Zusammensetzungen und verfahren zur hemmung der lect2-genexpression
UA124961C2 (uk)	2013-10-04	2021-12-22	Елнілем Фармасьютикалз, Інк.	ДВОНИТКОВА РИБОНУКЛЕЇНОВА КИСЛОТА (dsRNA) ДЛЯ ІНГІБУВАННЯ ЕКСПРЕСІЇ ALAS1
EP2873423B1 (de)	2013-10-07	2017-05-31	International Aids Vaccine Initiative	Lösliche hiv-1-hüllglykoproteintrimere
JPWO2015068781A1 (ja)	2013-11-06	2017-03-09	国立大学法人大阪大学	インフルエンザウイルスａ型のグループ１に対して広域な中和活性を有する抗体
WO2015087187A1 (en)	2013-12-10	2015-06-18	Rinat Neuroscience Corp.	Anti-sclerostin antibodies
US20160333063A1 (en)	2013-12-13	2016-11-17	The General Hospital Corporation	Soluble high molecular weight (hmw) tau species and applications thereof
WO2015095605A1 (en)	2013-12-20	2015-06-25	Gilead Calistoga Llc	Polymorphic forms of a hydrochloride salt of (s) -2-(9h-purin-6-ylamino) propyl) -5-fluoro-3-phenylquinazolin-4 (3h) -one
ES2752552T3 (es)	2013-12-20	2020-04-06	Gilead Calistoga Llc	Métodos de proceso para inhibidores de fosfatidilinositol 3-quinasa
WO2015108933A1 (en)	2014-01-14	2015-07-23	The Johns Hopkins University	Cyclodextrin compositions encapsulating a selective atp inhibitor and uses thereof
EP3099715B1 (de)	2014-01-31	2020-11-18	Boehringer Ingelheim International GmbH	Neue anti-baff antikörper
WO2015116902A1 (en)	2014-01-31	2015-08-06	Genentech, Inc.	G-protein coupled receptors in hedgehog signaling
CN114106099A (zh)	2014-01-31	2022-03-01	西托姆克斯治疗公司	蛋白裂解酶和u型纤溶酶原激活物的底物和其它可裂解部分及其使用方法
CA2937539A1 (en)	2014-02-04	2015-08-13	Genentech, Inc.	Mutant smoothened and methods of using the same
EP3110974A4 (de)	2014-02-24	2018-01-24	Celgene Corporation	Verfahren zur verwendung eines aktivators von cereblon für neuronale zellexpansion und behandlung von erkrankungen des zentralnervensystems
GB201403775D0 (en)	2014-03-04	2014-04-16	Kymab Ltd	Antibodies, uses & methods
NZ631007A (en)	2014-03-07	2015-10-30	Alexion Pharma Inc	Anti-c5 antibodies having improved pharmacokinetics
CA2940196C (en)	2014-03-19	2023-03-07	Wayne Marasco	Immunogenetic restriction on elicitation of antibodies
IL247853B (en)	2014-03-21	2022-08-01	Teva Pharmaceuticals Int Gmbh	Antibodies which are antagonists against a peptide relating to the calcitonin gene and methods of using them
AU2015235986B2 (en)	2014-03-27	2020-12-03	Genentech, Inc.	Methods for diagnosing and treating inflammatory bowel disease
US10426753B2 (en)	2014-04-03	2019-10-01	Invictus Oncology Pvt. Ltd.	Supramolecular combinatorial therapeutics
US10131704B2 (en)	2014-04-25	2018-11-20	Dana-Farber Cancer Institute, Inc.	Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof
PT3137114T (pt)	2014-04-30	2021-02-26	Pfizer	Conjugados anticorpo-fármaco anti-ptk7
US10308697B2 (en)	2014-04-30	2019-06-04	President And Fellows Of Harvard College	Fusion proteins for treating cancer and related methods
WO2015171918A2 (en)	2014-05-07	2015-11-12	Louisiana State University And Agricultural And Mechanical College	Compositions and uses for treatment thereof
US10392438B2 (en)	2014-05-16	2019-08-27	Pfizer Inc.	Bispecific antibodies
EA028614B1 (ru)	2014-05-22	2017-12-29	Общество С Ограниченной Ответственностью "Русские Фармацевтические Технологии"	Селективные ингибиторы, нарушающие взаимодействие рецептора фактора роста фибробластов и frs2, для профилактики и лечения рака
WO2015179654A1 (en)	2014-05-22	2015-11-26	Mayo Foundation For Medical Education And Research	Distinguishing antagonistic and agonistic anti b7-h1 antibodies
ES2905777T3 (es)	2014-05-30	2022-04-12	Shanghai Henlius Biotech Inc	Anticuerpos anti-receptor del factor de crecimiento epidérmico (EGFR)
CA2951391C (en)	2014-06-10	2021-11-02	Amgen Inc.	Apelin polypeptides
EA201692202A1 (ru)	2014-06-11	2017-06-30	Джилид Сайэнс, Инк.	Способы лечения сердечно-сосудистых заболеваний
US11021467B2 (en)	2014-06-13	2021-06-01	Gilead Sciences, Inc.	Phosphatidylinositol 3-kinase inhibitors
TWI695011B (zh)	2014-06-18	2020-06-01	美商梅爾莎納醫療公司	抗ｈｅｒ２表位之單株抗體及其使用之方法
CN114057857A (zh)	2014-06-20	2022-02-18	豪夫迈·罗氏有限公司	基于chagasin的支架组合物、方法和应用
US10487314B2 (en)	2014-06-26	2019-11-26	The Trustees Of Columbia University In The City Of New York	Inhibition of serotonin expression in gut enteroendocrine cells results in conversion to insulin-positive cells
EP3171896A4 (de)	2014-07-23	2018-03-21	Mayo Foundation for Medical Education and Research	Abzielung auf dna-pkcs und b7-h1 zur behandlung von krebs
BR112017001579A2 (pt)	2014-07-25	2017-11-21	Cytomx Therapeutics Inc	anticorpos anti-cd3, anticorpos anti-cd3 ativáveis, anticorpos anti-cd3 multiespecíficos, anticorpos anti-cd3 ativáveis multiespecíficos e métodos de uso dos mesmos
TW201609812A (zh)	2014-07-31	2016-03-16	安美基研究（慕尼黑）公司	最佳化之跨物種特異性雙特異性單鏈抗體構築體
AR101669A1 (es)	2014-07-31	2017-01-04	Amgen Res (Munich) Gmbh	Constructos de anticuerpos para cdh19 y cd3
WO2016020798A1 (en)	2014-08-06	2016-02-11	Rinat Neuroscience Corp.	Methods for reducing ldl-cholesterol
WO2016020799A1 (en)	2014-08-06	2016-02-11	Rinat Neuroscience Corp.	Methods for reducing ldl-cholesterol
WO2016033424A1 (en)	2014-08-29	2016-03-03	Genzyme Corporation	Methods for the prevention and treatment of major adverse cardiovascular events using compounds that modulate apolipoprotein b
WO2016034968A1 (en)	2014-09-02	2016-03-10	Pfizer Inc.	Therapeutic antibody
EP3197492A1 (de)	2014-09-23	2017-08-02	Pfizer Inc	Behandlung mit anti-pcsk9- antikörpern
JP2017531427A (ja)	2014-10-03	2017-10-26	デイナファーバーキャンサーインスティチュート，インコーポレイテッド	グルココルチコイド誘導腫瘍壊死因子受容体（ｇｉｔｒ）抗体およびその使用法
CN107250160B (zh)	2014-10-06	2022-01-11	达纳－法伯癌症研究所公司	人源化cc趋化因子受体4 (ccr4)抗体及其使用方法
GB201417589D0 (en)	2014-10-06	2014-11-19	Cantab Biopharmaceuticals Patents Ltd	Pharmaceutical Formulations
PT3212233T (pt)	2014-10-31	2020-07-16	Oncomed Pharm Inc	Terapia combinada para o tratamento de doenças
HUE061672T2 (hu)	2014-11-12	2023-08-28	Seagen Inc	Glikán-interakcióban lévõ vegyületek és felhasználási módszerek
WO2016077566A1 (en)	2014-11-12	2016-05-19	Research Institute At Nationwide Children's Hospital	Modulation of alternative mdm2 splicing
US9879087B2 (en)	2014-11-12	2018-01-30	Siamab Therapeutics, Inc.	Glycan-interacting compounds and methods of use
WO2016081728A1 (en)	2014-11-19	2016-05-26	The Trustees Of Columbia University In The City Of New York	Osteocalcin as a treatment for frailty associated with aging
WO2016090040A1 (en)	2014-12-03	2016-06-09	Genentech, Inc.	Anti-staphylococcus aureus antibody rifamycin conjugates and uses thereof
BR112017011325A2 (pt)	2014-12-03	2020-07-21	Genentech, Inc.	?composto de conjugado anticorpo?antibiótico, composição, método de tratamento de uma infecção, método para matar staph aureus, processo para produzir o conjugado, kit para o tratamento de uma infecção, intermediários antibiótico-ligante e ligante-droga?
WO2016090170A1 (en)	2014-12-05	2016-06-09	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	A potent anti-influenza a neuraminidase subtype n1 antibody
TWI595006B (zh)	2014-12-09	2017-08-11	禮納特神經系統科學公司	抗ｐｄ－１抗體類和使用彼等之方法
KR20170087500A (ko)	2014-12-11	2017-07-28	피에르 파브르 메디카먼트	항-c10orf54 항체들 및 그들의 용도들
TW201702218A (zh)	2014-12-12	2017-01-16	美國杰克森實驗室	關於治療癌症、自體免疫疾病及神經退化性疾病之組合物及方法
NZ733130A (en)	2014-12-15	2018-09-28	Univ Johns Hopkins	Sunitinib formulations and methods for use thereof in treatment of ocular disorders
WO2016100716A1 (en)	2014-12-18	2016-06-23	Vasant Jadhav	Reversirtm compounds
MA41374A (fr)	2015-01-20	2017-11-28	Cytomx Therapeutics Inc	Substrats clivables par métalloprotéase matricielle et clivables par sérine protéase et procédés d'utilisation de ceux-ci
US11400139B2 (en)	2015-01-20	2022-08-02	The Children's Medical Center Corporation	Anti-NET compounds for treating and preventing fibrosis and for facilitating wound healing
WO2016123125A1 (en)	2015-01-27	2016-08-04	The Johns Hopkins University	Hypotonic hydrogel formulations for enhanced transport of active agents at mucosal surfaces
JP2018506275A (ja)	2015-01-28	2018-03-08	ジェネンテック，インコーポレイテッド	多発性硬化症の遺伝子発現マーカー及び治療
CN107428818A (zh)	2015-01-29	2017-12-01	密西根州立大学校董会	隐藏多肽及其用途
US20160250177A1 (en) *	2015-02-17	2016-09-01	Mallinckrodt Llc	Modified docetaxel liposome formulations and uses thereof
EP3259597B1 (de)	2015-02-19	2022-04-06	Compugen Ltd.	Pvrig-polypeptide und verfahren zur behandlung
US10227408B2 (en)	2015-02-19	2019-03-12	Compugen Ltd.	Anti-PVRIG antibodies and methods of use
CN113209289A (zh)	2015-02-26	2021-08-06	豪夫迈·罗氏有限公司	治疗Crohn病的整联蛋白β7拮抗剂和方法
EP3265063A4 (de) *	2015-03-03	2018-11-07	Cureport, Inc.	Doppelt beladene liposomale pharmazeutische formulierungen
AU2016227493B2 (en)	2015-03-03	2022-01-20	Kymab Limited	Antibodies, uses & methods
CN107530283A (zh)	2015-03-03	2018-01-02	奎尔波特股份有限公司	组合脂质体药物制剂
KR20170135860A (ko)	2015-03-13	2017-12-08	싸이톰스 테라퓨틱스, 인크.	항-pdl1 항체, 활성화 가능한 항-pdl1 항체, 및 이들의 사용 방법
EP3270898B1 (de)	2015-03-17	2021-05-05	Lipomedix Pharmaceuticals Ltd.	Verfahren zur behandlung von blasenkrebs
MA41795A (fr)	2015-03-18	2018-01-23	Sarepta Therapeutics Inc	Exclusion d'un exon induite par des composés antisens dans la myostatine
US10174292B2 (en)	2015-03-20	2019-01-08	International Aids Vaccine Initiative	Soluble HIV-1 envelope glycoprotein trimers
US9931394B2 (en)	2015-03-23	2018-04-03	International Aids Vaccine Initiative	Soluble HIV-1 envelope glycoprotein trimers
US9758575B2 (en)	2015-04-06	2017-09-12	Yung Shin Pharmaceutical Industrial Co. Ltd.	Antibodies which specifically bind to canine vascular endothelial growth factor and uses thereof
CN107750253B (zh)	2015-04-08	2022-10-04	达纳－法伯癌症研究所公司	人源化流感单克隆抗体及其使用方法
DK3283106T3 (da)	2015-04-13	2022-01-10	Pfizer	Terapeutiske antistoffer og anvendelser deraf
CN116063541A (zh)	2015-04-17	2023-05-05	安进研发（慕尼黑）股份有限公司	用于cdh3和cd3的双特异性抗体构建体
EP3288977B1 (de)	2015-05-01	2021-11-17	Dana-Farber Cancer Institute, Inc.	Verfahren zur vermittlung der cytokinexpression mit anti-ccr4-antikörpern
PT3292150T (pt)	2015-05-04	2020-06-01	Cytomx Therapeutics Inc	Anticorpos anti-cd166 ativáveis e os seus métodos de utilização
EP4029880A1 (de)	2015-05-04	2022-07-20	CytomX Therapeutics, Inc.	Aktivierbare anti-cd71-antikörper und verfahren zur verwendung davon
BR112017023868A2 (pt)	2015-05-04	2018-07-24	Cytomx Therapeutics Inc	anticorpos anti-itga3, anticorpos anti-itga3 ativáveis, e métodos de uso dos mesmos
US20180104331A1 (en)	2015-05-11	2018-04-19	The Johns Hopkins University	Autoimmune antibodies for use in inhibiting cancer cell growth
WO2016180986A1 (en)	2015-05-14	2016-11-17	Fundación Centro Nacional De Investigaciones Cardiovasculares Carlos Iii (Cnic)	Mirna compositions for the treatment of mature b-cell neoplasms
US11318131B2 (en)	2015-05-18	2022-05-03	Ipsen Biopharm Ltd.	Nanoliposomal irinotecan for use in treating small cell lung cancer
EP3303619B1 (de)	2015-05-29	2020-06-10	H. Hoffnabb-La Roche Ag	Pd-l1-promotormethylierung bei krebs
US10849917B2 (en)	2015-06-01	2020-12-01	Sarepta Therapeutics, Inc.	Antisense-induced exon exclusion in type VII collagen
EP3307754B1 (de)	2015-06-10	2022-09-14	Elysium Health, Inc.	Nicotinamidribosid- und pterostilbenzusammensetzungen und verfahren zur behandlung von hauterkrankungen
BR112018000054A2 (pt)	2015-07-02	2018-09-04	Otsuka Pharmaceutical Co., Ltd.	composições farmacêuticas liofilizadas
WO2017009712A1 (en)	2015-07-13	2017-01-19	Compugen Ltd.	Hide1 compositions and methods
BR112018000768A2 (pt)	2015-07-13	2018-09-25	Cytomx Therapeutics Inc	anticorpos anti-pd-1, anticorpos anti-pd-1 ativáveis e métodos de uso dos mesmos
AU2016295168B2 (en)	2015-07-17	2021-08-19	Alnylam Pharmaceuticals, Inc.	Multi-targeted single entity conjugates
NZ739088A (en)	2015-07-21	2024-01-26	Takeda Pharmaceuticals Co	A monoclonal antibody inhibitor of factor xiia
WO2017020001A2 (en)	2015-07-29	2017-02-02	Allergan, Inc.	Heavy chain only antibodies to ang-2
TWI717375B (zh)	2015-07-31	2021-02-01	德商安美基研究（慕尼黑）公司	Ｃｄ７０及ｃｄ３抗體構築體
TWI829617B (zh)	2015-07-31	2024-01-21	德商安美基研究（慕尼黑）公司	Ｆｌｔ３及ｃｄ３抗體構築體
TWI744242B (zh)	2015-07-31	2021-11-01	德商安美基研究（慕尼黑）公司	Egfrviii及cd3抗體構築體
TWI796283B (zh)	2015-07-31	2023-03-21	德商安美基研究（慕尼黑）公司	Ｍｓｌｎ及ｃｄ３抗體構築體
TW202346349A (zh)	2015-07-31	2023-12-01	德商安美基研究（慕尼黑）公司	Dll3及cd3抗體構築體
CA2992788A1 (en)	2015-08-14	2017-02-23	Allergan, Inc.	Heavy chain only antibodies to pdgf
TWI724018B (zh)	2015-08-20	2021-04-11	英商益普生生物製藥有限公司	用於癌症治療之組合療法
JP2018528185A (ja)	2015-08-21	2018-09-27	イプセンバイオファームリミティド	リポソーム型イリノテカン及びオキサリプラチンを含む組み合わせ療法を使用して転移性膵臓癌を治療するための方法
US20170058038A1 (en)	2015-09-01	2017-03-02	Boehringer Ingelheim International Gmbh	Use of anti-cd40 antibodies for treatment of lupus nephritis
TW201718857A (zh)	2015-09-14	2017-06-01	艾爾妮蘭製藥公司	用於抑制alas1基因表現之組合物及方法
EP3922645A1 (de)	2015-09-15	2021-12-15	Scholar Rock, Inc.	Anti-pro/latentes-myostatin-antikörper und verwendungen davon
TWI799366B (zh)	2015-09-15	2023-04-21	美商建南德克公司	胱胺酸結骨架平臺
CA2999160A1 (en)	2015-09-23	2017-03-30	Oncomed Pharmaceuticals, Inc.	Methods and compositions for treatment of cancer
US10954300B2 (en)	2015-09-28	2021-03-23	The Trustees Of Columbia University In The City Of New York	Use of pentoxifylline with immune checkpoint-blockade therapies for the treatment of melanoma
WO2017055966A1 (en)	2015-10-01	2017-04-06	Pfizer Inc.	Low viscosity antibody compositions
JP2018529747A (ja)	2015-10-06	2018-10-11	ジェネンテック，インコーポレイテッド	多発性硬化症を治療するための方法
EP3858993A1 (de)	2015-10-09	2021-08-04	Sarepta Therapeutics, Inc.	Zusammensetzungen und verfahren zur behandlung von duchenne-muskeldystrophie und damit assoziierten erkrankungen
GB201518170D0 (en)	2015-10-14	2015-11-25	Cantab Biopharmaceuticals Patents Ltd	Colloidal particles for subcutaneous administration with intravenous administration of therapeutic agent
GB201518171D0 (en)	2015-10-14	2015-11-25	Cantab Biopharmaceuticals Patents Ltd	Colloidal particles for topical administration with therapeutic agent
GB201518172D0 (en)	2015-10-14	2015-11-25	Cantab Biopharmaceuticals Patents Ltd	Colloidal particles for use in medicine
WO2017066714A1 (en)	2015-10-16	2017-04-20	Compugen Ltd.	Anti-vsig1 antibodies and drug conjugates
RU2732567C2 (ru)	2015-10-16	2020-09-21	Ипсен Биофарм Лтд.	Стабилизированные фармацевтические композиции камптотецина
WO2017075037A1 (en)	2015-10-27	2017-05-04	Scholar Rock, Inc.	Primed growth factors and uses thereof
US10875923B2 (en)	2015-10-30	2020-12-29	Mayo Foundation For Medical Education And Research	Antibodies to B7-H1
KR102440160B1 (ko)	2015-10-30	2022-09-02	제넨테크, 인크.	항-HtrA1 항체 및 이의 사용 방법
ES2938883T3 (es)	2015-11-05	2023-04-17	Los Angeles Childrens Hospital	Oligo antisentido para su uso en el tratamiento de la leucemia mieloide aguda
US10751306B2 (en)	2015-11-06	2020-08-25	The Johns Hopkins University	Methods of treating liver fibrosis by administering 3-bromopyruvate
SG11201803915UA (en)	2015-11-10	2018-06-28	Childrens Research Institute Childrens National Medical Center	Echinomycin formulation, method of making and method of use thereof
CN116217729A (zh)	2015-11-12	2023-06-06	思进公司	聚糖相互作用化合物及使用方法
CN108367079B (zh)	2015-11-12	2022-11-22	灰色视觉公司	用于治疗的聚集性微粒
US10689458B2 (en)	2015-11-30	2020-06-23	Pfizer Inc.	Site specific HER2 antibody drug conjugates
CA2949033A1 (en)	2015-11-30	2017-05-30	Pfizer Inc.	Antibodies and antibody fragments for site-specific conjugation
US10875920B2 (en)	2015-12-02	2020-12-29	Stcube & Co., Inc.	Antibodies and molecules that immunospecifically bind to BTN1A1 and the therapeutic uses thereof
EP3383908A1 (de)	2015-12-02	2018-10-10	Stsciences, Inc.	Spezifische antikörper gegen glykosylierten btla (b- und t-lymphozyt-attenuator)
MA43415A (fr)	2015-12-09	2018-10-17	Modernatx Inc	Arnm modifié codant pour une uridine diphosphate glucuronosyltransférase et utilisations associées
US10548844B2 (en)	2015-12-14	2020-02-04	Massachusetts Institute Of Technology	pH-responsive mucoadhesive polymeric encapsulated microorganisms
WO2017106630A1 (en)	2015-12-18	2017-06-22	The General Hospital Corporation	Polyacetal polymers, conjugates, particles and uses thereof
EP3395370B1 (de)	2015-12-21	2021-01-20	FUJIFILM Corporation	Liposom und liposomzusammensetzung
EP4310503A3 (de)	2015-12-30	2024-03-20	Momenta Pharmaceuticals, Inc.	Verfahren im zusammenhang mit biologika
US10287345B2 (en)	2016-01-08	2019-05-14	Scholar Rock, Inc.	Methods for inhibiting myostatin activation by administering anti-pro/latent myostatin antibodies
US20210206818A1 (en)	2016-01-22	2021-07-08	Modernatx, Inc.	Messenger ribonucleic acids for the production of intracellular binding polypeptides and methods of use thereof
JOP20170017B1 (ar)	2016-01-25	2021-08-17	Amgen Res Munich Gmbh	تركيب صيدلي يتضمن تركيبات جسم مضاد ثنائي الاختصاص
EA039859B1 (ru)	2016-02-03	2022-03-21	Эмджен Рисерч (Мюник) Гмбх	Биспецифические конструкты антител, связывающие egfrviii и cd3
DK3411402T3 (da)	2016-02-03	2022-02-07	Amgen Res Munich Gmbh	Bcma- og cd3-bispecifikke t-celle-engagerende antistofkonstruktioner
WO2017134158A1 (en)	2016-02-03	2017-08-10	Amgen Research (Munich) Gmbh	Psma and cd3 bispecific t cell engaging antibody constructs
CN109071625A (zh)	2016-02-04	2018-12-21	柯瑞斯公司	平滑化突变体和其使用方法
JP2019512484A (ja) *	2016-03-07	2019-05-16	メモリアルスローンケタリングキャンサーセンター	骨髄、細網内皮系、および／またはリンパ節を標的にする放射標識リポソームならびにその診断用および治療用使用の方法
WO2017156032A1 (en)	2016-03-07	2017-09-14	Charlestonpharma, Llc	Anti-nucleolin antibodies
BR112018068340A2 (pt)	2016-03-11	2019-01-15	Scholar Rock Inc	imunoglobulinas de ligação ao tgfss1 e usos destas
CN109476756B (zh)	2016-03-15	2022-05-31	埃泰美德(香港)有限公司	一种多特异性Fab融合蛋白及其用途
SG11201808964PA (en)	2016-04-18	2018-11-29	Sarepta Therapeutics Inc	Antisense oligomers and methods of using the same for treating diseases associated with the acid alpha-glucosidase gene
CN109069473B (zh)	2016-04-21	2022-09-16	港大科桥有限公司	用于亮肤和减少色素沉着过度的组合物和方法
JP7148504B2 (ja)	2016-06-08	2022-10-05	ゼンコー，インコーポレイティド	ＣＤ３２Ｂに交差結合した抗ＣＤ１９抗体を用いたＩｇＧ４関連疾患の治療
ITUA20164630A1 (it)	2016-06-23	2017-12-23	Paolo Blasi	Adiuvanti farmacologici per la termoablazione tumorale
EP3474886B1 (de)	2016-06-27	2021-08-04	Alexion Pharmaceuticals, Inc.	Verfahren zur behandlung von hypophosphatasie bei kindern und jugendlichen
WO2018005657A1 (en)	2016-06-28	2018-01-04	Verily Life Sciences Llc	Serial filtration to generate small cholesterol-containing liposomes
WO2018018039A2 (en)	2016-07-22	2018-01-25	Dana-Farber Cancer Institute, Inc.	Glucocorticoid-induced tumor necrosis factor receptor (gitr) antibodies and methods of use thereof
US10292983B2 (en)	2016-08-03	2019-05-21	Cymabay Therapeutics, Inc.	Oxymethylene aryl compounds for treating inflammatory gastrointestinal diseases or gastrointestinal conditions
TWI754659B (zh)	2016-08-08	2022-02-11	台灣微脂體股份有限公司	用於製備含有弱酸性劑之微脂體組合物的傳輸載體、方法及套組
WO2018045379A1 (en)	2016-09-02	2018-03-08	Dana-Farber Cancer Institute, Inc.	Composition and methods of treating b cell disorders
MX2019002696A (es)	2016-09-06	2019-09-27	Dana Farber Cancer Inst Inc	Metodos para tratar o prevenir una infeccion del virus del zika.
TW201825674A (zh)	2016-09-09	2018-07-16	美商艾斯合顧問有限公司	表現雙特異性接合分子的溶瘤病毒
CN110198729A (zh)	2016-09-09	2019-09-03	豪夫迈·罗氏有限公司	卷曲蛋白的选择性肽抑制剂
CA3036829A1 (en)	2016-09-14	2018-03-22	The Trustees Of The University Of Pennsylvania	Proximity-based sortase-mediated protein purification and ligation
BR112019005129A2 (pt)	2016-09-16	2019-06-04	Shanghai Henlius Biotech Inc	anticorpos anti-pd-1
JP2019529463A (ja)	2016-09-23	2019-10-17	テバ・ファーマシューティカルズ・インターナショナル・ゲー・エム・ベー・ハー	群発頭痛の治療方法
CN109952314A (zh)	2016-09-23	2019-06-28	泰瓦制药国际有限公司	治疗难治性偏头痛
RU2765874C2 (ru)	2016-10-26	2022-02-04	МОДЕРНАТиЭкс, ИНК.	Матричные рибонуклеиновые кислоты для усиления иммунных ответов и способы их применения
JP2019533684A (ja)	2016-11-02	2019-11-21	イプセンバイオファームリミティド	リポソームイリノテカン、オキサリプラチン、５−フルオロウラシル（およびロイコボリン）を含む併用療法を用いる胃がんの処置
WO2018083248A1 (en)	2016-11-03	2018-05-11	Kymab Limited	Antibodies, combinations comprising antibodies, biomarkers, uses & methods
JP2020503256A (ja)	2016-11-04	2020-01-30	ノビミューンエスアー	抗ｃｄ１９抗体およびそれを使用する方法
US11339209B2 (en)	2016-11-14	2022-05-24	Novartis Ag	Compositions, methods, and therapeutic uses related to fusogenic protein minion
US11401330B2 (en)	2016-11-17	2022-08-02	Seagen Inc.	Glycan-interacting compounds and methods of use
WO2018106738A1 (en)	2016-12-05	2018-06-14	Massachusetts Institute Of Technology	Brush-arm star polymers, conjugates and particles, and uses thereof
KR102466418B1 (ko)	2016-12-16	2022-11-14	화이자 인코포레이티드	Glp-1 수용체 작용제 및 이의 용도
US10772926B2 (en)	2016-12-16	2020-09-15	Nutragen Health Innovations, Inc.	Natural drugs for the treatment of inflammation and melanoma
WO2018129395A1 (en)	2017-01-06	2018-07-12	Scholar Rock, Inc.	Methods for treating metabolic diseases by inhibiting myostatin activation
US11155611B2 (en)	2017-01-06	2021-10-26	Scholar Rock, Inc.	Compositions and methods for making and using anti-myostatin antibodies
CN110382530A (zh)	2017-01-06	2019-10-25	供石公司	亚型特异性、背景许可性TGFβ1抑制剂及其用途
CN117224710A (zh)	2017-02-01	2023-12-15	莫得纳特斯公司	编码活化致癌基因突变肽的免疫调节治疗性mrna组合物
JOP20190189A1 (ar)	2017-02-02	2019-08-01	Amgen Res Munich Gmbh	تركيبة صيدلانية ذات درجة حموضة منخفضة تتضمن بنيات جسم مضاد يستهدف الخلية t
WO2018152496A1 (en)	2017-02-17	2018-08-23	The Usa, As Represented By The Secretary, Dept. Of Health And Human Services	Compositions and methods for the diagnosis and treatment of zika virus infection
EP3589319A4 (de)	2017-03-03	2021-07-14	Seagen Inc.	Glycaninteragierende verbindungen und verfahren zur verwendung
EP3589657A1 (de)	2017-03-03	2020-01-08	Rinat Neuroscience Corp.	Anti-gitr-antikörper und verfahren zur verwendung davon
CA3055574A1 (en)	2017-03-09	2018-09-13	Cytomx Therapeutics, Inc.	Cd147 antibodies, activatable cd147 antibodies, and methods of making and use thereof
EP3601350A1 (de)	2017-03-27	2020-02-05	Boehringer Ingelheim International GmbH	Kombinationstherapie gegen il-36r-antikörper
WO2018191153A1 (en)	2017-04-09	2018-10-18	The Cleveland Clinic Foundation	Cancer treatment by malat1 inhibition
EP3609915A1 (de)	2017-04-12	2020-02-19	Pfizer Inc	Antikörper mit bedingter affinität und verfahren zur verwendung dafür
WO2018191548A2 (en)	2017-04-14	2018-10-18	Kodiak Sciences Inc.	Complement factor d antagonist antibodies and conjugates thereof
EP3612625A4 (de)	2017-04-21	2021-08-18	Mellitus, LLC	Verfahren und antikörper für mit diabetes assoziierte anwendungen
EP3615569A1 (de)	2017-04-25	2020-03-04	The U.S.A. As Represented By The Secretary, Department Of Health And Human Services	Antikörper und verfahren zur diagnose und behandlung von epstein-barr-virus-infektionen
US11318190B2 (en)	2017-05-05	2022-05-03	United States Government As Represented By The Department Of Veterans Affairs	Methods and compositions for treating liver disease
UY37726A (es)	2017-05-05	2018-11-30	Amgen Inc	Composición farmacéutica que comprende constructos de anticuerpos biespecíficos para almacenamiento y administración mejorados
CA3057875A1 (en)	2017-05-10	2018-11-15	Graybug Vision, Inc.	Extended release microparticles and suspensions thereof for medical therapy
WO2018209288A1 (en)	2017-05-12	2018-11-15	Massachusetts Institute Of Technology	Argonaute protein-double stranded rna complexes and uses related thereto
JP7169298B2 (ja)	2017-05-12	2022-11-10	オーガスタユニバーシティリサーチインスティテュート，インコーポレーテッド	ヒトアルファフェトタンパク質特異的ｔ細胞受容体およびその使用
JP7220161B2 (ja)	2017-05-26	2023-02-09	ノビミューンエスアー	抗ＣＤ４７ｘ抗メソテリン抗体およびそれを使用する方法
KR20200024158A (ko)	2017-05-31	2020-03-06	주식회사 에스티큐브앤컴퍼니	Btn1a1에 면역특이적으로 결합하는 항체 및 분자를 사용하여 암을 치료하는 방법
EP3630835A1 (de)	2017-05-31	2020-04-08	STCube & Co., Inc.	Antikörper und moleküle, die immunspezifisch an btn1a1 binden, und therapeutische verwendungen davon
US11168144B2 (en)	2017-06-01	2021-11-09	Cytomx Therapeutics, Inc.	Activatable anti-PDL1 antibodies, and methods of use thereof
KR20200026209A (ko)	2017-06-06	2020-03-10	주식회사 에스티큐브앤컴퍼니	Btn1a1 또는 btn1a1-리간드에 결합하는 항체 및 분자를 사용하여 암을 치료하는 방법
GB201710838D0 (en)	2017-07-05	2017-08-16	Ucl Business Plc	Bispecific antibodies
AU2018297262A1 (en)	2017-07-06	2020-02-27	Arrowhead Pharmaceuticals, Inc.	RNAi agents for inhibiting expression of alpha-ENaC and methods of use
BR112020000679A2 (pt)	2017-07-13	2020-07-14	Massachusetts Institute Of Technology	visando o complexo hdac2-sp3 para potencializar a função sináptica
EP3652210A1 (de)	2017-07-14	2020-05-20	CytomX Therapeutics, Inc.	Anti-cd166-antikörper und verwendungen davon
CN111094334A (zh)	2017-07-19	2020-05-01	美国卫生与公众服务部	用于诊断和治疗乙肝病毒感染的抗体和方法
US20210025877A1 (en)	2017-07-20	2021-01-28	CytomX Therapeutices, Inc.	Methods of qualitatively and/or quantitatively analyzing properties of activatable antibodies and uses thereof
WO2019016784A1 (en)	2017-07-21	2019-01-24	Universidade De Coimbra	ANTI-NUCLEOLIN ANTIBODIES
EP3655040A1 (de)	2017-07-21	2020-05-27	Modernatx, Inc.	Modifizierte mrna zur codierung einer propionyl-coa-carboxylase und verwendungen davon
MA49684A (fr)	2017-07-24	2020-06-03	Modernatx Inc	Arnm modifié codant une glucose-6-phosphatase et utilisations associées
SI3658184T1 (sl)	2017-07-27	2024-01-31	Alexion Pharmaceuticals, Inc.,	Formulacije z visoko koncentracijo protiteles proti-C5
EP3658583A1 (de)	2017-07-28	2020-06-03	Scholar Rock, Inc.	Ltbp-komplex-spezifische inhibitoren von tgf-beta 1 und verwendungen davon
SG11202000932XA (en)	2017-08-03	2020-02-27	Otsuka Pharma Co Ltd	Drug compound and purification methods thereof
US11135187B2 (en)	2017-08-22	2021-10-05	National Institutes Of Health (Nih)	Compositions and methods for treating diabetic retinopathy
BR112020004231A2 (pt)	2017-08-30	2020-09-08	Cytomx Therapeutics, Inc.	anticorpos anti-cd166 ativáveis e métodos de uso dos mesmos
MX2020002612A (es)	2017-09-07	2020-07-13	Univ Res Inst Inc Augusta	Anticuerpos de la proteina de muerte celular programada 1.
US11364303B2 (en)	2017-09-29	2022-06-21	Pfizer Inc.	Cysteine engineered antibody drug conjugates
WO2019075270A1 (en)	2017-10-12	2019-04-18	Amesino Llc	VEGFR ANTIBODY LIGHT CHAIN FUSION PROTEIN
BR112020007309A2 (pt)	2017-10-14	2020-09-29	Cytomx Therapeutics, Inc.	anticorpos, anticorpos ativáveis, anticorpos biespecíficos e anticorpos ativáveis biespecíficos e métodos de uso dos mesmos
CA3079141A1 (en)	2017-10-17	2019-04-25	Rhizen Pharmaceuticals Sa	Crac channel modulators for treating esophageal cancer
US11555189B2 (en)	2017-10-18	2023-01-17	Sarepta Therapeutics, Inc.	Antisense oligomer compounds
WO2019082124A1 (en)	2017-10-26	2019-05-02	Rhizen Pharmaceuticals Sa	COMPOSITION AND METHOD FOR THE TREATMENT OF LARGE B-CELL DIFFUSED LYMPHOMA
BR112020008127A2 (pt)	2017-10-27	2020-10-13	Pfizer Inc.	anticorpos e conjugados de anticorpo-fármaco específicos para cd123 e seus usos
US20200281918A1 (en)	2017-10-30	2020-09-10	Rhizen Pharmaceuticals Sa	Calcium release-activated calcium channel modulators for treating hematological and solid cancers
WO2019086626A1 (en)	2017-11-03	2019-05-09	Centro Nacional De Investigaciones Cardiovasculares Carlos Iii (F.S.P.)	MIRNAs AND COMBINATIONS THEREOF FOR USE IN THE TREATMENT OF HUMAN B CELL NEOPLASIAS
JP2021505571A (ja)	2017-12-06	2021-02-18	ルヒゼンファーマスティカルズエスエー	末梢ｔ細胞リンパ腫および皮膚ｔ細胞リンパ腫を治療するための組成物および方法
US11946094B2 (en)	2017-12-10	2024-04-02	Augusta University Research Institute, Inc.	Combination therapies and methods of use thereof
EP3724229A1 (de)	2017-12-11	2020-10-21	Amgen Inc.	Kontinuierliches herstellungsverfahren für bispezifische antikörperprodukte
UY38041A (es)	2017-12-29	2019-06-28	Amgen Inc	Construcción de anticuerpo biespecífico dirigida a muc17 y cd3
WO2019165101A1 (en)	2018-02-22	2019-08-29	Verily Life Sciences Llc	Combining orthogonal chemistries for preparation of multiplexed nanoparticles
SG11202007518RA (en)	2018-02-28	2020-09-29	Pfizer	Il-15 variants and uses thereof
EP3762420A1 (de)	2018-03-09	2021-01-13	CytomX Therapeutics, Inc.	Aktivierbare cd147-antikörper und verfahren zur herstellung und verwendung davon
RU2020128013A (ru)	2018-03-14	2022-04-15	Бейцзин Сюаньи Фармасайенсиз Ко., Лтд.	Антитела против клаудина 18.2
EP3765520A1 (de)	2018-03-14	2021-01-20	NovImmune SA	Anti-cd3-epsilon-antikörper und verfahren zur verwendung davon
CA3093723A1 (en)	2018-03-21	2019-09-26	Colorado State University Research Foundation	Cancer vaccine compositions and methods of use thereof
US10722528B2 (en)	2018-03-28	2020-07-28	Augusta University Research Institute, Inc.	Compositions and methods for inhibiting metastasis
CA3096274A1 (en)	2018-04-06	2019-10-10	Children's Medical Center Corporation	Compositions and methods for somatic cell reprogramming and modulating imprinting
WO2019195561A2 (en)	2018-04-06	2019-10-10	BioLegend, Inc.	Anti-tetraspanin 33 agents and compositions and methods for making and using the same
US20210115156A1 (en)	2018-04-13	2021-04-22	INSERM (Institut National de la Santé et de la Recherche Médicale)	Fc-engineered anti-human ige antibodies and methods of use
US20210171610A1 (en)	2018-05-02	2021-06-10	The U.S.A., As Represented By The Secretary, Department Of Health And Human Services	Antibodies and methods for the diagnosis, prevention, and treatment of epstein barr virus infection
KR102602329B1 (ko)	2018-05-23	2023-11-16	화이자 인코포레이티드	Cd3에 특이적인 항체 및 이의 용도
WO2019224716A2 (en)	2018-05-23	2019-11-28	Pfizer Inc.	Antibodies specific for gucy2c and uses thereof
CA3045370A1 (en)	2018-06-08	2019-12-08	Pfizer Inc.	Methods of treating metabolic disease
TWI707683B (zh)	2018-06-13	2020-10-21	美商輝瑞股份有限公司	Ｇｌｐ－１受體促效劑及其用途
FI3806855T3 (fi)	2018-06-15	2023-05-04	Pfizer	Glp-1 -reseptorin agonisteja ja niiden käyttöjä
WO2019245817A1 (en)	2018-06-19	2019-12-26	Armo Biosciences, Inc.	Compositions and methods of use of il-10 agents in conjunction with chimeric antigen receptor cell therapy
CA3104028A1 (en)	2018-06-28	2020-01-02	Crispr Therapeutics Ag	Compositions and methods for genomic editing by insertion of donor polynucleotides
EA202190094A1 (ru)	2018-06-29	2021-04-21	Бёрингер Ингельхайм Интернациональ Гмбх	Антитела против cd40 для применения в лечении аутоиммунного заболевания
KR102568464B1 (ko)	2018-07-06	2023-08-21	화이자 인코포레이티드	피롤로[2,3-d]피리미딘 화합물의 제조 방법, 이의 중간체, 및 이의 용도
MX2021000347A (es)	2018-07-11	2021-04-19	Scholar Rock Inc	Inhibidores de tgf?1 selectivos de isoforma, de alta afinidad y usos de los mismos.
EP3820896A1 (de)	2018-07-11	2021-05-19	Scholar Rock, Inc.	Tgfbeta1-inhibitoren und verwendung davon
MA52165A (fr)	2018-07-11	2021-06-02	Scholar Rock Inc	Inhibiteurs sélectifs de l'isoforme tgfbeta1 et utilisation associée
JP2021531007A (ja)	2018-07-20	2021-11-18	ピエール、ファーブル、メディカマン	Ｖｉｓｔａに対する受容体
TW202020157A (zh)	2018-08-16	2020-06-01	美商艾爾妮蘭製藥公司	用於抑制lect2基因表現之組合物及方法
EP3849515A1 (de) *	2018-09-11	2021-07-21	Memorial Sloan Kettering Cancer Center	Knochenmark-, retikuloendotheliale system- und/oder lymphknoten-gerichtete radioaktiv markierte liposomen sowie verfahren zu deren diagnostischer und therapeutischer verwendung
CN113365697A (zh)	2018-09-25	2021-09-07	百进生物科技公司	抗tlr9药剂和组合物及其制备方法和使用方法
SG11202103025PA (en)	2018-09-27	2021-04-29	Phosphogam Inc	Methods and compositions for the expansion and use of allogeneic gamma/delta-t cells
WO2020065409A2 (en)	2018-09-28	2020-04-02	Lyvgen Biopharma Co., Ltd.	Anti-cd40 binding molecules having engineered fc domains and therapeutic uses thereof
WO2020076776A1 (en)	2018-10-10	2020-04-16	Boehringer Ingelheim International Gmbh	Method for membrane gas transfer in high density bioreactor culture
AU2019356564A1 (en)	2018-10-11	2021-04-29	Amgen Inc.	Downstream processing of bispecific antibody constructs
WO2020079652A1 (en)	2018-10-17	2020-04-23	Insilico Medicine Hong Kong Limited	Kinase inhibitors
EA202191122A1 (ru)	2018-10-23	2021-07-19	Сколар Рок, Инк.	СЕЛЕКТИВНЫЕ К RGMc ИНГИБИТОРЫ И ИХ ПРИМЕНЕНИЕ
US20210379545A1 (en) *	2018-10-26	2021-12-09	University Of Connecticut	A Continuous Processing System And Methods For Internal And External Modifications To Nanoparticles
EP3873531A1 (de)	2018-11-02	2021-09-08	Cytomx Therapeutics Inc.	Aktivierbare anti-cd166-antikörper und verfahren zur verwendung davon
AU2019382642A1 (en)	2018-11-22	2021-06-10	Qilu Regor Therapeutics Inc.	GLP-1R agonists and uses thereof
US20220024999A1 (en)	2018-11-29	2022-01-27	Flagship Pioneering Innovations V, Inc.	Methods of modulating rna
MX2021006429A (es)	2018-12-06	2021-07-15	Cytomx Therapeutics Inc	Sustratos escindibles con matriz de metaloproteasa, serina o cisteína escindible con proteasa y métodos de uso de estos.
CA3177829A1 (en)	2018-12-12	2020-06-18	Kite Pharma, Inc.	Chimeric antigen and t cell receptors and methods of use
JP2022523051A (ja)	2019-01-22	2022-04-21	マサチューセッツインスティテュートオブテクノロジー	ＩｎＶｉｔｒｏのヒト血液脳関門
JP2020117502A (ja)	2019-01-28	2020-08-06	ファイザー・インク	変形性関節症の徴候および症状を処置する方法
EP3689905A3 (de)	2019-01-30	2021-02-24	Scholar Rock, Inc.	Ltbp-komplex-spezifische inhibitoren von tgf-beta und verwendungen davon
SG11202108863WA (en)	2019-02-15	2021-09-29	Pfizer	Crystalline pyrimidinyl-3,8-diazabicyclo[3.2.1]octanylmethanone compound and use thereof
US20220135663A1 (en)	2019-02-18	2022-05-05	Pfizer Inc.	Method of treatment of Chronic Low Back Pain
CN113874394B (zh)	2019-02-20	2024-01-19	和铂抗体有限公司	抗体
US11795160B2 (en)	2019-02-22	2023-10-24	Insilico Medicine Ip Limited	Kinase inhibitors
CN113677372A (zh)	2019-02-26	2021-11-19	西托姆克斯治疗公司	可活化免疫检查点抑制剂和经缀合可活化抗体的组合疗法
WO2020181058A1 (en)	2019-03-05	2020-09-10	Massachusetts Institute Of Technology	Dna launched rna replicon system (drep) and uses thereof
US11717548B2 (en)	2019-03-08	2023-08-08	Massachusetts Institute Of Technology	Synthetic oncolytic LNP-replicon RNA and uses for cancer immunotherapy
CA3131705A1 (en)	2019-03-27	2020-10-01	Umc Utrecht Holding B.V.	Engineered iga antibodies and methods of use
JP2022521840A (ja)	2019-04-01	2022-04-12	ジェネンテック，インコーポレイテッド	タンパク質含有製剤を安定化するための組成物および方法
AU2020251841A1 (en)	2019-04-02	2021-10-07	Array Biopharma Inc.	Protein tyrosine phosphatase inhibitors
TW202115086A (zh)	2019-06-28	2021-04-16	美商輝瑞大藥廠	Bckdk抑制劑
US20220363673A1 (en)	2019-06-28	2022-11-17	Pfizer Inc.	5-(Thiophen-2-YL)-1 H-Tetrazole Derivative as BCKDK Inhibitors Useful for Treating Various Diseases
LT6699B (lt)	2019-07-15	2020-02-10	UAB "Valentis"	Proliposomų gamybos būdas, naudojant ne daugiau kaip 5 % etanolio, ir jų panaudojimas lipofilinių medžiagų kapsuliavimui
CN112300279A (zh)	2019-07-26	2021-02-02	上海复宏汉霖生物技术股份有限公司	针对抗cd73抗体和变体的方法和组合物
US10758329B1 (en)	2019-08-20	2020-09-01	Raymond L. Wright, III	Hydrating mouth guard
US20220290152A1 (en)	2019-09-03	2022-09-15	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of the lect2 gene
CN114650844A (zh)	2019-09-23	2022-06-21	西托姆克斯治疗公司	抗cd47抗体、可活化抗cd47抗体及其使用方法
US11834659B2 (en)	2019-09-26	2023-12-05	Massachusetts Institute Of Technology	Trans-activated functional RNA by strand displacement and uses thereof
US11492622B2 (en)	2019-09-26	2022-11-08	Massachusetts Institute Of Technology	MicroRNA-based logic gates and uses thereof
WO2021062323A1 (en)	2019-09-26	2021-04-01	Stcube & Co.	Antibodies specific to glycosylated ctla-4 and methods of use thereof
US20220356234A1 (en)	2019-10-02	2022-11-10	Alexion Pharmaceuticals, Inc.	Complement inhibitors for treating drug-induced complement-mediated response
US20220389429A1 (en)	2019-10-04	2022-12-08	Alnylam Pharmaceuticals, Inc.	Compositions and methods for silencing ugt1a1 gene expression
TWI771766B (zh)	2019-10-04	2022-07-21	美商輝瑞股份有限公司	二醯基甘油醯基轉移酶２抑制劑
AU2020363372A1 (en)	2019-10-07	2022-05-19	University Of Virginia Patent Foundation	Modulating lymphatic vessels in neurological disease
WO2021072277A1 (en)	2019-10-09	2021-04-15	Stcube & Co.	Antibodies specific to glycosylated lag3 and methods of use thereof
AU2020364071A1 (en)	2019-10-10	2022-05-26	Kodiak Sciences Inc.	Methods of treating an eye disorder
WO2021072244A1 (en)	2019-10-11	2021-04-15	Beth Israel Deaconess Medical Center, Inc.	Anti-tn antibodies and uses thereof
CN114828842A (zh)	2019-10-21	2022-07-29	理森制药股份公司	用于治疗急性髓系白血病的包含dhodh抑制剂的组合物
EP4051796A1 (de)	2019-11-01	2022-09-07	Alnylam Pharmaceuticals, Inc.	Zusammensetzungen und verfahren zum unterdrücken der dnajb1-prkaca-fusionsgenexpression
JP2021091683A (ja)	2019-12-10	2021-06-17	ファイザー・インク	２−（（４−（（Ｓ）−２−（５−クロロピリジン−２−イル）−２−メチルベンゾ［ｄ］［１，３］ジオキソール−４−イル）ピペリジン−１−イル）メチル）−１−（（（Ｓ）−オキセタン−２−イル）メチル）−１Ｈ−ベンゾ［ｄ］イミダゾール−６−カルボン酸の１，３−ジヒドロキシ−２−（ヒドロキシメチル）プロパン−２−アミン塩の固体形態
CA3167427A1 (en)	2020-01-11	2021-07-15	Scholar Rock, Inc.	Tgfb inhibitors and use thereof
AU2021205440A1 (en)	2020-01-11	2022-09-01	Scholar Rock,Inc.	TGF-beta inhibitors and use thereof
KR20220141299A (ko)	2020-01-14	2022-10-19	신테카인, 인크.	Il2 오르토로그 및 사용 방법
EP4090681A1 (de)	2020-01-17	2022-11-23	Biolegend, Inc.	Anti-tlr7-mittel und zusammensetzungen sowie verfahren zu ihrer herstellung und verwendung
US20230067811A1 (en)	2020-01-24	2023-03-02	University Of Virginia Patent Foundation	Modulating lymphatic vessels in neurological disease
IL295445A (en)	2020-02-10	2022-10-01	Alnylam Pharmaceuticals Inc	Preparations and methods for silencing vegf-a expression
JP2022058085A (ja)	2020-02-24	2022-04-11	ファイザー・インク	ジアシルグリセロールアシルトランスフェラーゼ２阻害剤とアセチル－ＣｏＡカルボキシラーゼ阻害剤との組合せ
CA3170563A1 (en)	2020-03-06	2021-09-10	Raymond P. Goodrich	Production of vaccines comprising inactivated sars-cov-2 viral particles
WO2021181233A2 (en)	2020-03-09	2021-09-16	Pfizer Inc.	Fusion proteins and uses thereof
GB202003632D0 (en)	2020-03-12	2020-04-29	Harbour Antibodies Bv	SARS-Cov-2 (SARS2, COVID-19) antibodies
WO2021188096A1 (en)	2020-03-17	2021-09-23	Dst Pharma, Inc.	Methods and compositions for treating viral infections
JP2023518822A (ja)	2020-03-26	2023-05-08	ピーエルエックスオプコインコーポレイテッド	ｐＨ依存的再構築が可能な医薬キャリア、その製造方法及び使用方法
IL296694A (en)	2020-03-27	2022-11-01	Pfizer	Treatment of type 2 diabetes, obesity or excess weight using 2-[(4-{6-[(4-cyano-2-fluorobenzyl)oxy]pyridin-2-yl}piperidin-1-yl)methyl]-1-[( 2s)-oxetan-2-ylmethyl]-1h-benzimidazole-6-carboxylic acid or its pharmaceutical salts
EP4127171A2 (de)	2020-03-30	2023-02-08	Alnylam Pharmaceuticals, Inc.	Zusammensetzungen und verfahren zur ausschaltung der dnajc15-genexpression
CA3179411A1 (en)	2020-04-06	2021-10-14	Alnylam Pharmaceuticals, Inc.	Compositions and methods for silencing myoc expression
CN116134135A (zh)	2020-04-07	2023-05-16	阿尔尼拉姆医药品有限公司	用于沉默scn9a表达的组合物和方法
EP4132931A1 (de)	2020-04-08	2023-02-15	Pfizer Inc.	Kristalline formen von 3-cyano-1-[4-[(6-(1-methyl-1h-pyrazol-4-yl)pyrazolo[1,5-a!pyrazin-4-yl!-1h-pyrazol-1-yl!cyclobutanacetonitril und verwendung davon
BR112022021450A2 (pt)	2020-04-24	2022-12-27	Millennium Pharm Inc	O cd19 ou fragmento de ligação, método de tratamento de um câncer, composição farmacêutica, ácido nucleico, vetor, e, célula isolada
US20230181750A1 (en)	2020-05-06	2023-06-15	Crispr Therapeutics Ag	Mask peptides and masked anti-ptk7 antibodies comprising such
US20210355463A1 (en)	2020-05-15	2021-11-18	Crispr Therapeutics Ag	Messenger rna encoding cas9 for use in genome-editing systems
EP4153746A1 (de)	2020-05-21	2023-03-29	Alnylam Pharmaceuticals, Inc.	Zusammensetzungen und verfahren zur hemmung der marc1-genexpression
US20230203023A1 (en)	2020-05-27	2023-06-29	Qilu Regor Therapeutics Inc.	Salt and crystal forms of glp-1r agonists and uses thereof
WO2021250541A1 (en)	2020-06-09	2021-12-16	Pfizer Inc.	Spiro compounds as melanocortin 4 receptor antagonists and uses thereof
US20230235070A1 (en)	2020-06-26	2023-07-27	Pfizer Inc.	Method of treatment of inflammatory bowel disease using anti-tl1a antibodies
WO2022006562A1 (en)	2020-07-03	2022-01-06	Dana-Farber Cancer Institute, Inc.	Multispecific coronavirus antibodies
CN116323668A (zh)	2020-07-17	2023-06-23	辉瑞公司	治疗性抗体及其用途
WO2022020811A1 (en)	2020-07-24	2022-01-27	Strand Therapeutics, Inc.	Lipidnanoparticle comprising modified nucleotides
IL300110A (en)	2020-07-28	2023-03-01	Jazz Pharmaceuticals Ireland Ltd	Chiral synthesis of RAF inhibitors in compressed cyclics
BR112023001557A2 (pt)	2020-07-28	2023-04-04	Jazz Pharmaceuticals Ireland Ltd	Inibidores de raf bicíclicos fundidos e métodos para uso dos mesmos
US20230272094A1 (en)	2020-08-05	2023-08-31	Synthekine, Inc.	Il2rb/il2rg synthetic cytokines
US20230295314A1 (en)	2020-08-05	2023-09-21	Synthekine, Inc.	IL27RAlpha Binding Molecules and Methods of Use
WO2022032006A2 (en)	2020-08-05	2022-02-10	Synthekine, Inc.	Il2rb binding molecules and methods of use
WO2022031885A2 (en)	2020-08-05	2022-02-10	Synthekine, Inc.	Il10ra binding molecules and methods of use
WO2022031994A1 (en)	2020-08-06	2022-02-10	Qilu Regor Therapeutics Inc.	Glp-1r agonists and uses thereof
WO2022036041A1 (en)	2020-08-14	2022-02-17	Kite Pharma, Inc	Improving immune cell function
CN116615443A (zh)	2020-09-14	2023-08-18	Vor生物制药股份有限公司	针对cd33的单结构域抗体
WO2022061061A1 (en)	2020-09-21	2022-03-24	Boehringer Ingelheim International Gmbh	Use of anti-cd40 antibodies for treatment of inflammatory conditions
KR20230104152A (ko)	2020-10-06	2023-07-07	젠코어 인코포레이티드	전신 홍반성 루푸스(sle)를 포함하는 자가면역 질환을 치료하기 위한 바이오마커, 방법 및 조성물
TW202227421A (zh)	2020-10-14	2022-07-16	大陸商上海齊魯銳格醫藥研發有限公司	Ｇｌｐ－１ｒ促效劑的晶型及其用途
WO2022093641A1 (en)	2020-10-30	2022-05-05	BioLegend, Inc.	Anti-nkg2a agents and compositions and methods for making and using the same
WO2022093640A1 (en)	2020-10-30	2022-05-05	BioLegend, Inc.	Anti-nkg2c agents and compositions and methods for making and using the same
US11058637B1 (en) *	2020-11-25	2021-07-13	King Abdulaziz University	Surface-modified emulsomes for intranasal delivery of drugs
IL303195A (en)	2020-11-25	2023-07-01	Akagera Medicines Inc	Lipid nanoparticles for delivery of nucleic acids and related methods of use
JP2024505790A (ja)	2020-12-18	2024-02-08	モメンタファーマシューティカルズインコーポレイテッド	インテグリンアルファ１１ベータ１に対する抗体
AR124599A1 (es)	2021-01-08	2023-04-12	Strand Therapeutics Inc	Constructos de expresión y usos de estos
US11278494B1 (en)	2021-01-22	2022-03-22	Pacira Pharmaceuticals, Inc.	Manufacturing of bupivacaine multivesicular liposomes
US11033495B1 (en)	2021-01-22	2021-06-15	Pacira Pharmaceuticals, Inc.	Manufacturing of bupivacaine multivesicular liposomes
US11357727B1 (en)	2021-01-22	2022-06-14	Pacira Pharmaceuticals, Inc.	Manufacturing of bupivacaine multivesicular liposomes
WO2022170008A2 (en)	2021-02-05	2022-08-11	Boehringer Ingelheim International Gmbh	Anti-il1rap antibodies
AU2022225035A1 (en)	2021-02-24	2023-08-31	Insilico Medicine Ip Limited	Analogs for the treatment of disease
WO2022192439A1 (en)	2021-03-11	2022-09-15	Kite Pharma, Inc.	Improving immune cell function
WO2022195504A1 (en)	2021-03-19	2022-09-22	Pfizer Inc.	Method of treating osteoarthritis pain with an anti ngf antibody
IL305827A (en)	2021-03-22	2023-11-01	Novimmune Sa	Bispecific antibodies targeting CD47 and PD-L1 and methods of using them
CA3212599A1 (en)	2021-03-22	2022-09-29	Novimmune S.A.	Bispecific antibodies targeting cd47 and pd-l1 and methods of use thereof
US11952461B2 (en)	2021-03-22	2024-04-09	Sunbio, Inc.	Siloxy polyethylene glycol and derivatives thereof
WO2022204581A2 (en)	2021-03-26	2022-09-29	Scholar Rock, Inc.	Tgf-beta inhibitors and use thereof
CN117425673A (zh)	2021-04-09	2024-01-19	武田药品工业株式会社	靶向补体因子d的抗体和其用途
JP2024516168A (ja)	2021-04-22	2024-04-12	デイナファーバーキャンサーインスティチュート，インコーポレイテッド	がんを治療するための組成物および方法
CN117580860A (zh)	2021-04-26	2024-02-20	米伦纽姆医药公司	抗adgre2抗体及其用途
CA3216770A1 (en)	2021-04-26	2022-11-03	Tomoki Yoshihara	Anti-clec12a antibodies and uses thereof
WO2022235940A1 (en)	2021-05-06	2022-11-10	Dana-Farber Cancer Institute, Inc.	Antibodies against alk and methods of use thereof
US20230115257A1 (en)	2021-05-17	2023-04-13	Curia Ip Holdings, Llc	Sars-cov-2 spike protein antibodies
US20220372114A1 (en)	2021-05-17	2022-11-24	Curia Ip Holdings, Llc	Sars-cov-2 spike protein antibodies
EP4348260A2 (de)	2021-06-03	2024-04-10	Scholar Rock, Inc.	Tgf-beta inhibitoren und deren therapeutische verwendung
AU2022299185A1 (en)	2021-06-23	2024-01-25	Scholar Rock, Inc.	A myostatin pathway inhibitor in combination with a glp-1 pathway activator for use in treating metabolic disorders
WO2023283403A2 (en)	2021-07-09	2023-01-12	Alnylam Pharmaceuticals, Inc.	Bis-rnai compounds for cns delivery
WO2023288182A1 (en)	2021-07-12	2023-01-19	Genentech, Inc.	Structures for reducing antibody-lipase binding
WO2023288277A1 (en)	2021-07-14	2023-01-19	Scholar Rock, Inc.	Ltbp complex-specific inhibitors of tgfb1 and uses thereof
WO2023007374A1 (en)	2021-07-27	2023-02-02	Pfizer Inc.	Method of treatment of cancer pain with tanezumab
GB202111757D0 (en)	2021-08-17	2021-09-29	Cantab Biopharmaceuticals Patents Ltd	Modified colloidal particles for use in the treatment of haemophilia A
GB202111759D0 (en)	2021-08-17	2021-09-29	Cantab Biopharmaceuticals Patents Ltd	Modified colloidal particles
GB202111758D0 (en)	2021-08-17	2021-09-29	Cantab Biopharmaceuticals Patents Ltd	Modified colloidal particles for use in the treatment of haemophilia A
WO2023031741A1 (en)	2021-08-31	2023-03-09	Pfizer Inc.	Solid forms of 2-[(4-{6-[(4-cyano-2-fluorobenzyl)oxy]pyridin-2-yl}piperidin-1-yl)methyl]-1-[(2s)-oxetan-2-ylmethyl]-1h-benzimidazole-6-carboxylic acid, 1,3-dihydroxy-2-(hydroxymethyl)propan-2-amine salt
WO2023034901A1 (en)	2021-09-01	2023-03-09	The Broad Institute, Inc.	Tumor avatar vaccine compositions and uses thereof
GB202112935D0 (en)	2021-09-10	2021-10-27	Harbour Antibodies Bv	Sars-cov-2 (sars2, covid-19) heavy chain only antibodies
WO2023036982A1 (en)	2021-09-10	2023-03-16	Harbour Antibodies Bv	Anti-sars2-s antibodies
WO2023068382A2 (en)	2021-10-20	2023-04-27	Takeda Pharmaceutical Company Limited	Compositions targeting bcma and methods of use thereof
WO2023077148A1 (en)	2021-11-01	2023-05-04	Tome Biosciences, Inc.	Single construct platform for simultaneous delivery of gene editing machinery and nucleic acid cargo
WO2023081471A1 (en)	2021-11-05	2023-05-11	Dana-Farber Cancer Institute, Inc.	Human broadly crossreactive influenza monoclonal antibodies and methods of use thereof
WO2023097024A1 (en)	2021-11-24	2023-06-01	Dana-Farber Cancer Institute, Inc.	Antibodies against ctla-4 and methods of use thereof
WO2023100061A1 (en)	2021-12-01	2023-06-08	Pfizer Inc.	3-phenyl-1-benzothiophene-2-carboxylic acid derivatives as branched-chain alpha keto acid dehydrogenase kinase inhibitors for the treatment of diabetes, kidney diseases, nash and heart failure
WO2023105387A1 (en)	2021-12-06	2023-06-15	Pfizer Inc.	Melanocortin 4 receptor antagonists and uses thereof
WO2023105371A1 (en)	2021-12-08	2023-06-15	Array Biopharma Inc.	Crystalline form of n-(2-chloro-3-((5-chloro-3-methyl-4-oxo-3,4-dihydroquinazolin-6-yl)amino)-4-fluorophenyl)-3-fluoroazetidine-1-sulfonamide
WO2023114544A1 (en)	2021-12-17	2023-06-22	Dana-Farber Cancer Institute, Inc.	Antibodies and uses thereof
WO2023114543A2 (en)	2021-12-17	2023-06-22	Dana-Farber Cancer Institute, Inc.	Platform for antibody discovery
WO2023111817A1 (en)	2021-12-17	2023-06-22	Pfizer Inc.	Crystalline forms of [(1r,5s,6r)-3-{2-[(2s)-2-methylazetidin-1-yl]-6-(trifluoromethyl) pyrimidin-4-yl}-3-azabicyclo[3.1.0]hex-6-yl]acetic acid
WO2023122764A1 (en)	2021-12-22	2023-06-29	Tome Biosciences, Inc.	Co-delivery of a gene editor construct and a donor template
WO2023178357A1 (en)	2022-03-18	2023-09-21	Evolveimmune Therapeutics, Inc.	Bispecific antibody fusion molecules and methods of use thereof
WO2023201238A1 (en)	2022-04-11	2023-10-19	Vor Biopharma Inc.	Binding agents and methods of use thereof
WO2023205744A1 (en)	2022-04-20	2023-10-26	Tome Biosciences, Inc.	Programmable gene insertion compositions
WO2023212618A1 (en)	2022-04-26	2023-11-02	Strand Therapeutics Inc.	Lipid nanoparticles comprising venezuelan equine encephalitis (vee) replicon and uses thereof
WO2023215831A1 (en)	2022-05-04	2023-11-09	Tome Biosciences, Inc.	Guide rna compositions for programmable gene insertion
WO2023220641A2 (en)	2022-05-11	2023-11-16	Juno Therapeutics, Inc.	Methods and uses related to t cell therapy and production of same
WO2023225670A2 (en)	2022-05-20	2023-11-23	Tome Biosciences, Inc.	Ex vivo programmable gene insertion
WO2023228023A1 (en)	2022-05-23	2023-11-30	Pfizer Inc.	Treatment of type 2 diabetes or weight management control with 2-((4-((s)-2-(5-chloropyridin-2-yl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((s)-oxetan-2-yl)methyl)-1h-benzo[d]imidazole-6-carboxylic acid or a pharmaceutically salt thereof
WO2023235852A1 (en)	2022-06-03	2023-12-07	Zenas Biopharma, Inc.	Methods and compositions for treating igg4- related diseases
WO2024020051A1 (en)	2022-07-19	2024-01-25	BioLegend, Inc.	Anti-cd157 antibodies, antigen-binding fragments thereof and compositions and methods for making and using the same
WO2024030850A1 (en)	2022-08-01	2024-02-08	Cytomx Therapeutics, Inc.	Protease-cleavable substrates and methods of use thereof
WO2024030858A1 (en)	2022-08-01	2024-02-08	Cytomx Therapeutics, Inc.	Protease-cleavable substrates and methods of use thereof
WO2024030847A1 (en)	2022-08-01	2024-02-08	Cytomx Therapeutics, Inc.	Protease-cleavable moieties and methods of use thereof
WO2024030843A1 (en)	2022-08-01	2024-02-08	Cytomx Therapeutics, Inc.	Protease-cleavable moieties and methods of use thereof
WO2024030845A1 (en)	2022-08-01	2024-02-08	Cytomx Therapeutics, Inc.	Protease-cleavable moieties and methods of use thereof
WO2024030829A1 (en)	2022-08-01	2024-02-08	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Monoclonal antibodies that bind to the underside of influenza viral neuraminidase
WO2024039670A1 (en)	2022-08-15	2024-02-22	Dana-Farber Cancer Institute, Inc.	Antibodies against cldn4 and methods of use thereof
WO2024039672A2 (en)	2022-08-15	2024-02-22	Dana-Farber Cancer Institute, Inc.	Antibodies against msln and methods of use thereof
WO2024040114A2 (en)	2022-08-18	2024-02-22	BioLegend, Inc.	Anti-axl antibodies, antigen-binding fragments thereof and methods for making and using the same
WO2024059165A1 (en)	2022-09-15	2024-03-21	Alnylam Pharmaceuticals, Inc.	17b-hydroxysteroid dehydrogenase type 13 (hsd17b13) irna compositions and methods of use thereof
WO2024075051A1 (en)	2022-10-07	2024-04-11	Pfizer Inc.	Hsd17b13 inhibitors and/or degraders

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3993754A (en) *	1974-10-09	1976-11-23	The United States Of America As Represented By The United States Energy Research And Development Administration	Liposome-encapsulated actinomycin for cancer chemotherapy
US4426330A (en) *	1981-07-20	1984-01-17	Lipid Specialties, Inc.	Synthetic phospholipid compounds
US4534899A (en) *	1981-07-20	1985-08-13	Lipid Specialties, Inc.	Synthetic phospholipid compounds
US4501728A (en) *	1983-01-06	1985-02-26	Technology Unlimited, Inc.	Masking of liposomes from RES recognition
JPS60100516A (ja) *	1983-11-04	1985-06-04	Takeda Chem Ind Ltd	徐放型マイクロカプセルの製造法
US4885172A (en) *	1985-06-26	1989-12-05	The Liposome Company, Inc.	Composition for targeting, storing and loading of liposomes
IE58981B1 (en) *	1985-10-15	1993-12-15	Vestar Inc	Anthracycline antineoplastic agents encapsulated in phospholipid micellular particles
US4797285A (en) *	1985-12-06	1989-01-10	Yissum Research And Development Company Of The Hebrew University Of Jerusalem	Lipsome/anthraquinone drug composition and method
GB8601100D0 (en) *	1986-01-17	1986-02-19	Cosmas Damian Ltd	Drug delivery system
US4837028A (en) *	1986-12-24	1989-06-06	Liposome Technology, Inc.	Liposomes with enhanced circulation time
US4920016A (en) *	1986-12-24	1990-04-24	Linear Technology, Inc.	Liposomes with enhanced circulation time
US4863739A (en) *	1987-05-19	1989-09-05	Board Of Regents, The University Of Texas System	Liposome compositions of anthracycline derivatives
JPH0696636B2 (ja) *	1988-03-30	1994-11-30	富士写真フイルム株式会社	２，４―ビス（ｏ―メトキシポリエチレングリコール）―６―コレステリル―Ｓ―トリアジン化合物
JPH0720857B2 (ja) *	1988-08-11	1995-03-08	テルモ株式会社	リポソームおよびその製法
AU616040B2 (en) *	1988-08-11	1991-10-17	Terumo Kabushiki Kaisha	Agents for inhibiting adsorption of proteins on the liposome surface
GB8824593D0 (en) *	1988-10-20	1988-11-23	Royal Free Hosp School Med	Liposomes
US5013556A (en) *	1989-10-20	1991-05-07	Liposome Technology, Inc.	Liposomes with enhanced circulation time

1989
- 1989-10-20 US US07/425,224 patent/US5013556A/en not_active Expired - Lifetime
1990
- 1990-10-19 KR KR1019920700918A patent/KR0134982B1/ko not_active IP Right Cessation
- 1990-10-19 WO PCT/US1990/006034 patent/WO1991005545A1/en not_active Application Discontinuation
- 1990-10-19 AT AT91900513T patent/ATE122229T1/de active
- 1990-10-19 WO PCT/US1990/006211 patent/WO1991005546A1/en active IP Right Grant
- 1990-10-19 DE DE19675048C patent/DE19675048I2/de active Active
- 1990-10-19 AU AU66374/90A patent/AU642679B2/en not_active Expired
- 1990-10-19 KR KR1019920700919A patent/KR920703013A/ko not_active Application Discontinuation
- 1990-10-19 ES ES91900513T patent/ES2071976T3/es not_active Expired - Lifetime
- 1990-10-19 AU AU68982/91A patent/AU654120B2/en not_active Expired
- 1990-10-19 DE DE69019366T patent/DE69019366T2/de not_active Expired - Lifetime
- 1990-10-19 AT AT90916409T patent/ATE115401T1/de not_active IP Right Cessation
- 1990-10-19 DE DE69015207T patent/DE69015207T2/de not_active Revoked
- 1990-10-19 CA CA002067133A patent/CA2067133C/en not_active Expired - Lifetime
- 1990-10-19 EP EP91900513A patent/EP0496835B1/de not_active Expired - Lifetime
- 1990-10-19 CA CA002067178A patent/CA2067178C/en not_active Expired - Lifetime
- 1990-10-19 EP EP90916409A patent/EP0496813B1/de not_active Revoked
- 1990-10-19 JP JP3501034A patent/JP2667051B2/ja not_active Expired - Lifetime
- 1990-10-19 DK DK91900513.2T patent/DK0496835T3/da active
- 1990-10-19 JP JP51523890A patent/JP3571335B2/ja not_active Expired - Fee Related
- 1990-10-21 IL IL9606990A patent/IL96069A/en not_active IP Right Cessation
- 1990-10-21 IL IL9607090A patent/IL96070A/en not_active IP Right Cessation
1991
- 1991-01-15 US US07/642,321 patent/US5213804A/en not_active Expired - Lifetime
1992
- 1992-03-27 NO NO92921213A patent/NO921213L/no unknown
- 1992-03-27 NO NO920996A patent/NO304637B1/no not_active IP Right Cessation
- 1992-04-21 FI FI921764A patent/FI105151B/fi active Protection Beyond IP Right Term
- 1992-04-21 FI FI921763A patent/FI921763A/fi not_active Application Discontinuation
1995
- 1995-08-09 GR GR950402186T patent/GR3017060T3/el unknown
1996
- 1996-12-13 LU LU88854C patent/LU88854I2/fr unknown
- 1996-12-18 NL NL960031C patent/NL960031I2/nl unknown
1997
- 1997-02-05 HK HK14097A patent/HK14097A/xx not_active IP Right Cessation
- 1997-03-17 JP JP9063661A patent/JP2889549B2/ja not_active Expired - Lifetime
1999
- 1999-02-23 NO NO1999003C patent/NO1999003I1/no unknown
2001
- 2001-01-11 JP JP2001004291A patent/JP3921050B2/ja not_active Expired - Fee Related

Also Published As

Publication number	Publication date
JP3571335B2 (ja)	2004-09-29
JP2001181214A (ja)	2001-07-03
KR0134982B1 (ko)	1998-04-22
JP2667051B2 (ja)	1997-10-22
KR920703012A (ko)	1992-12-17
NO921213D0 (no)	1992-03-27
WO1991005546A1 (en)	1991-05-02
NO921214L (no)	1992-06-01
KR920703013A (ko)	1992-12-17
AU642679B2 (en)	1993-10-28
ES2071976T3 (es)	1995-07-01
JP3921050B2 (ja)	2007-05-30
ATE122229T1 (de)	1995-05-15
AU6637490A (en)	1991-05-16
DE69015207T2 (de)	1995-05-04
GR3017060T3 (en)	1995-11-30
IL96070A0 (en)	1991-07-18
DE69019366T2 (de)	1995-10-05
AU6898291A (en)	1991-05-16
DK0496835T3 (da)	1995-07-17
WO1991005545A1 (en)	1991-05-02
JPH05501264A (ja)	1993-03-11
JPH05505173A (ja)	1993-08-05
IL96069A (en)	1995-12-08
DE69019366D1 (de)	1995-06-14
FI105151B (fi)	2000-06-30
US5213804A (en)	1993-05-25
JP2889549B2 (ja)	1999-05-10
NO921213L (no)	1992-06-04
IL96070A (en)	1995-03-30
FI921763A0 (fi)	1992-04-21
JPH101431A (ja)	1998-01-06
CA2067178C (en)	1997-03-25
ATE115401T1 (de)	1994-12-15
FI921764A0 (fi)	1992-04-21
EP0496813B1 (de)	1994-12-14
NO921214D0 (no)	1992-03-27
US5013556A (en)	1991-05-07
AU654120B2 (en)	1994-10-27
NL960031I2 (nl)	2005-04-01
HK14097A (en)	1997-02-14
FI921763A (fi)	1992-04-21
CA2067133A1 (en)	1991-04-21
CA2067133C (en)	1998-07-21
IL96069A0 (en)	1991-07-18
NL960031I1 (nl)	1997-03-03
NO1999003I1 (no)	1999-02-23
EP0496835A1 (de)	1992-08-05
EP0496813A1 (de)	1992-08-05
EP0496835B1 (de)	1995-05-10
FI921764A (fi)	1992-04-21
NO304637B1 (no)	1999-01-25
DE19675048I2 (de)	2009-05-28
LU88854I2 (fr)	1997-03-11
CA2067178A1 (en)	1991-04-21

Legal Events

Date	Code	Title	Description
1995-12-14	8363	Opposition against the patent
2002-01-03	8331	Complete revocation

Publication	Publication Date	Title
DE69015207T2 (de)	1995-05-04	Liposomenmikroreservoirzusammensetzung und -verfahren.
EP0632719A1 (de)	1995-01-11	Verfahren zur behandlung infizierter gewebe.
ES2104184T3 (es)	1997-10-01	Composiciones para el tratamiento de los tejidos inflamados.
FI102724B1 (fi)	1999-02-15	Menetelmä bioaktiivisesta aineesta ja lipidistä koostuvan kompleksin valmistamiseksi
CN1088582C (zh)	2002-08-07	能治疗多种疾病具有层状类脂组分的类脂基载体、其组合物及其应用
Boman	1975	Tissue Distribution of 14C‐Rifampicin I. Whole Body Autoradiography of Albino Mice
Mizuno et al.	1993	Prognostic Comparison of Hepatic Resection of Liver Metastases and Chemotherapy via the Portal Vein with Liposome-Entrapped Adriamycin for Unresectable Liver Metastases on Gastric Cancer